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Abstract 
Japanese encephalitis virus is the leading cause of viral encephalitis in Asia. In spite of 
this, the immunological correlates for recovery from primary Japanese encephalitis 
virus (JEV) infection remain poorly defined. In this work, I have first established a 
mouse model for Japanese encephalitis in which a low-dose virus inoculum was 
administered subcutaneously into adult C57BL/6 mice. In this model, ,.___,60% of the 
mice developed fatal encephalitis, concomitant with virus burden in the central nervous 
system (CNS). JEV infection induced a peak natural killer (NK) cell response on day 4 
post-infection (pi), a peak CD8+ T cell response on day 7 pi, a peak anti-JEV IgM 
response on day 8 pi, and an increasing anti-JEV IgG responses from day 8 pi onwards. 
Second, to investigate the relative importance of immune effector cell populations, 
splenocyte transfer experiments, and JEV-challenge of mice with acquired or induced 
cellular deficiency were performed. Using mice lacking B cells (µMT-/- mice) and 
immune B cell transfer to wild-type mice, I find a critically important role for humoral 
immunity in preventing virus spread to the CNS. T cell help played an essential part in 
the maintenance of an effective antibody response necessary to combat the infection, 
since mice lacking major histocompatibility complex class II showed truncated IgM and 
blunted IgG responses, and the infection was uniformly lethal. On the other hand, NK 
_ cells were dispensable for protection against lethal Japanese encephalitis, while CD8+ T 
cells, by itself, have no significant effect on the survival of JEV-infected mice. 
V 
Third, cytolytic effector pathways and interferon gamma (IFN-y) help protect against 
lethal JE. Granule exocytosis and Fas-Fas ligand pathways of cytotoxicity act within the 
CNS to reduce disease severity, and show a redundancy in control of JEV infection. 
Only mice defective in both cell contact-dependent cytotoxic effector mechanisms 
display increased susceptibility to subcutaneous challenge with a low dose of JEV. 
Also, I demonstrate that IFN-y is critical in recovery from primary infection with JEV 
by a mechanism involving suppression of virus growth in the CNS, but not in 
extraneural tissues, and that T cells are the main source of the cytokine that promotes 
viral clearance from the brain. 
Fourth, the chemokine receptor, CCR5, serves as a host antiviral factor important 
against lethal JE. CCR5 deficiency resulted in increased mortality, and viral burden in 
the CNS. Absence of CCR5 did not only result in impaired trafficking of leucocytes into 
the brain, but also resulted in a multifaceted deficiency of cellular immune responses 
characterized by reduced NK cell activity, reduced CD8+ T cell activity, and low splenic 
cellularity. This result is consistent with a mechanism by which CCR5 expression 
enhances lymphocyte activation and thereby promotes host survival after JEV infection. 
Fifth, a novel immunodeficient mouse strain, Tuara , was established. Tuara mice 
displayed enhanced susceptibility to flavivirus infections, due to a loss-of-function 
mutation that was originally derived from an inbred knockout mouse strain , MHCII-Aa-
1-. The gene of interest was segregated from the MHCII defect, and after customized 
sequence capture and re-sequencing, was localized within -50 Mb region of 
Chromosome 1. Among the candidate list, a G>T trans ersion on mouse genome 
reference position 52,179,547 bp of ST AT 1 gene as identified as the most likely 
causal mutation. 
Vl 
Finally, towards application of the insights gained on the basic immunobiology of JE, 
vaccination experiments using 'new generation' JE vaccines were performed. They 
revealed a dominant role of humoral immunity in vaccine-mediated protection of mice 
from lethal challenge with JEV, and in cross-protection against related viruses 
belonging to the JE serocomplex. CD8+ T cells were not required for protection, while 
CD4+ T cells provided substantial helper function for the protective humoral immune 
responses induced by vaccination. These immune correlates for homologous and 
heterologous protection against JE serocomplex viruses were observed in vaccination 
with either a live attenuated vaccine (ChimeriVax-JE), or a candidate inactivated Vero 
cell culture-derived JE vaccine ( ccJE) formulated with Advax™, a novel 
immunologically active polysaccharide adjuvant. 
. . 
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Chapter 1 
Introduction 
Japanese encephalitis (JE) is an acute central nervous system inflammatory disease 
caused by an infection with Japanese encephalitis virus (JEV), a small, enveloped, plus-
strand RNA virus belonging to the family Flaviviridae. It is the leading cause of viral 
encephalitis in South-East Asia, India and China, where 3 billion people are at risk of 
contracting the disease (Erlanger et al., 2009). Annually, about 35,000 - 50,000 cases of 
JE are reported, resulting in about 10,000 deaths and a high incidence of 
neuropsychiatric deficits among survivors (Solomon, 2004; Tsai, 2000). Treatment of 
JE patients is supportive and in the absence of availability of antiviral compounds the 
mainstay of protection against JE is vaccination (Halstead & Thomas, 2011 ). In the past 
decades there has been an expansion of the geographic distribution of the virus in Asia 
and the Asia-Pacific region (van den Hurk et al., 2009) and there is an urgent 
requirement for improved human and veterinary JE vaccines. An understanding of the 
immunological responses that lead to recovery from infection with JEV and account for 
vaccine-mediated protection is important in the design of rational approaches to new 
treatments and vaccines against the disease, and will be the focus of this introduction. 
1.1 Classification, Epidemiology, and Biology of JEV 
1.1.1 Taxonomy of flaviviruses 
The Flaviviridae are a large family of positive-sense single-stranded RNA viruses. The 
name is derived from the Latin word "flavus" (meaning yellow), named after the first 
described human virus, the jaundice-causing Yellow Fever virus (YFV) discovered by 
Walter Reed in 1901. The family Flaviviridae is classified into 3 genera: Flavivirus, 
Hepacivirus, and Pestivirus (Heinz et al., 2000; Lindenbach et al., 2007). The 
Flavivirus genus comprise of at least 70 viruses, and is further subdivided, based on 
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molecular phylogenetics, into clusters, clades, and species, or based on serological 
criteria, into antigenic complexes or subcomplexes (Billoir et al, 1997; Kuno et al, 
1998; Kuno et al., 2001; Lindenbach et al., 2007; Westaway and Blok, 1997; Zanotto et 
al., 1996). The genus mostly consists of arthropod-borne viruses causing major human 
diseases, including flu-like illness, hepatitis, hemorrhagic fevers, and encephalitis. The 
principal vectors of one group are Ixodes ticks, transmitting tick-borne viruses such as 
Powassan virus, TBEV-European subtype, and TBEV-Far Eastern subtype. Another 
group are transmitted by mosquitoes, which include Aedes-borne flaviviruses such as 
YFV and dengue viruses (DENY), and Culex-borne encephalitic flaviviruses such as 
JEV, West Nile virus (WNV), Murray Valley encephalitis virus (MVEV), and St Louis 
encephalitis virus (SLEV) (Fig 1.1 ). 
Virus Serocomplex Clade Cluster 
West Nile 
Japanese encephalitis XIV Japanese 
Murray Valley encephalitis encephalitis 
St Louis encephalitis XI Mosquito-
Dengue-1 borne 
Dengue-3 
Dengue IX 
Dengue-2 
Dengue-4 
Yellow fever None VII 
Central European encephalitis 
Far Eastern encephalitis Tick-borne IV Tick-borne 
encephalitis 
Powassan 
Dakar bat None 111 No vector 
Figure 1.1 Classification of Flavivirus genus. Flaviviruses are classified, 
based on serologic criteria, into serocomplexes, or based on phylogenetic studies, into 
clusters, clades, or species. Figure was adapted, with some modifications, from 
Mukhopadhyay et al. (2005). 
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1.1.2 Geographical distribution of Flaviviruses 
Encephalitic flaviviruses of the JE serocomplex have a widespread global distribution 
(Mackenzie et al., 2004) (Fig. 1.2). JEV is largely endemic in the Asia-Pacific region 
encompassing Japan, extreme south-eastern part of Russia, Korea, Taiwan, and China in 
the northeast, to Nepal, Bhutan, Bangladesh, India, Sri Lanka, and southern Pakistan in 
the west, and to Southeast Asia, Papua New Guinea, and Torres Strait Islands in the 
southeast (van de Hurk et al., 2009). In 1998, expansion of JEV towards the Australian 
mainland was documented with a single human case and seroconverted sentinel pigs on 
Cape York Peninsula (Hanna et al, 1999). MVEV, on the other hand, is locally endemic 
in Australia, Papua New Guinea, and eastern Indonesia (Knox et al, 2012; Marshall, 
1988). WNV has a widespread distribution throughout Africa, south and central Asia, 
the Middle East and southern Europe (Kramer et al., 2008). WNV strain Kunjin 
(WNVKUN), is endemic in the Australasian region, while another WNV strain started to 
appear in New York City on 1999 (WNVNY99), and rapidly spread throughout the 
Americas in a span of ~8 years (Kramer et al., 2008). Lastly, SLEV is endemic in North 
and South America (Day, 2001). Regions were two or more viruses of the JE 
serocomplex overlap in geographic distribution include India and the Indochinese 
peninsula for WNV and JEV, North America for WNV and SLEV, Australia for 
WNVKUN and MVEV, and eastern Indonesia and Papua New Guinea for WNVKUN, 
JEV, and MVEV. Flaviviruses belonging to the JE seroco1nplex that are of minor 
medical importance and of limited geographical distribution, include Calcipacore virus 
in South America, MVEV subtype Alfuy in Australia, and Usutu, Koutango, and 
Yaounde viruses in Africa (Mackenzie et al., 2004 ). 
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Figure 1.2 Geographic distribution of encephalitic flaviviruses of major 
medical importance. World map indicating the distribution of the most important 
encephalitic flaviviruses belonging to the JE serocomplex: SLEV, WNV, JEV, and 
MVEV. Figure was adapted from Mackenzie et al. (2004). 
1.1.3 Basic structure and genome organization of flaviviruses 
Flaviviruses are ~50 nm small enveloped viruses, with an electron dense core of ~30 nm 
(Murphy, 1980; Kuhn et al., 2002; Mukhopadhyay et al., 2003). The viral particles have 
an outer surface made up of two viral proteins, the envelope (E) and membrane (M) 
protein, while the core is an assembly .of viral capsid (C) proteins and a positive-sense, 
single-stranded RNA genome of ~ 11 ,000 nucleotides in length (Sumiyoshi et al. , 1987). 
The 5' terminus carries a type 1 cap structure (m7GpppAmpN2), while the 3' terminus 
is non-polyadenylated (Lindenbach., 2007). The genome serves as the messenger RNA 
(mRNA) that codes for a single polyprotein composed of (from the amino-terminus) 3 
structural proteins: C, E, and premembrane ·(prM), and 7 non-structural (NS) proteins: 
NSl, NS2A, NS2B, NS3, NS4A, NS4B, and NS5 (Figure 1.3). 
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Figure 1.3 Flavivirus genome organization and protein expression. (A) 
Flavivirus approximate genome size of 10.8 KB, with open reading frame flanked by 
non-coding regions of capped 5' and non-polyadenylated 3' ends. (B) Chronological list 
of expressed structural and nonstructural genes, with proportional representation of 
individual proteins based on amino acid length. (C) Putative topology of flavivirus 
protein cleavage products in relation to the endoplasmic reticulum membrane, with 
labelled enzymes responsible for various specific cleavages. Figures adapted, with some 
modifications from Lindenbach et al. (2007) and Murray et al. (2008). 
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The NS proteins are thought to play a role in the morphogenesis of flaviviruses (Murray 
et al., 2008) (summarized in Table 1. 1). Capsid protein subunits form the nucleocapsid 
containing the viral genomic RNA, while the prM protein serves as the precursor of the 
mature M protein (Dokland et al., 2004; Jones et al. 2003; Konishi and Mason, 1993). 
The latter forms a dimmer with E protein and prevents the premature fusion of the E 
protein during passage of immature virions through the secretory pathway (Elshuber et 
al., 2003; Wengler and Wengler, 1989). The cleavage of prM by the cellular enzyme 
furin into pr and M coincides with the formation of E protein homodimers, a process 
important for virus maturation (Stadler et al., 1997; Yu et al., 2008). 
Table 1.1 Functional description of flaviviral proteins. 
Viral protein Functional description 
E Receptor binding and membrane fusion 
Main target of neutralizing antibodies 
prM Precursor of M protein 
Prevents premature fusion of E protein during virus maturation 
C Structural component of the nucleocapsid, C-terminal hydrophobic anchor of 
nascent C protein is a signal peptide for ER translocation of prM 
NS1 RNA replication 
Interferon inhibition 
NS2A RNA replication 
Genome encapsidation 
NS2B RNA replication 
Capsid Cleavage 
Cofactor for the NS2B-NS3 serine protease that cleaves at the C/prM, 
NS2A/NS2B, NS2B/NS3, NS3/NS4A, NS4B/NS5 junctions 
NS3 RNA replication 
Capsid Cleavage 
Genome encapsidation 
Forms part of NS2B-NS3 serine protease that cleaves at the C/prM, 
NS2A/NS2B, NS2B/NS3, NS3/NS4A, NS4B/NS5 junctions 
Helicase and RNA triphosphatase activity 
NS4A RNA replication 
Interferon inhibition 
NS4B RNA replication 
NS5 RNA replication 
RNA-dependent RNA polymerase and Methytransferase activity 
Interferon inhibition 
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The E protein plays an essential role in the early entry steps of the viral replication cycle 
through its receptor-binding and fusion functions (Allison et al., 2001; Chu and Ng., 
2004; Davis et al., 2006b; Huang et al., 2010; Lee E. et al., 2006; Navarro-Sanchez et 
al., 2003). It has three ectodomains, domain 1 (DI), DII, and DIII (Luca et al., 2012). A 
single N-linked glycosylation site is located at amino acid position 154 in JEV, and is 
considered important for flavivirus particle release and infectivity, virulence, and 
stimulation of innate immune responses (Beasley et al., 2005; Davis et al., 2006a; 
Hanna et al., 2005, Lee and Lobigs, 2010). Given its surface-exposed position on the 
virion particle, the E glycoprotein is the principal immunologic protein of JEV and 
related flaviviruses (Lobigs and Diamond, 2012). Mapping of the neutralizing epitopes 
on the E glycoprotein revealed 4 important sites: DI lateral ridge, fusion loop, DIII 
lateral ridge, and DI-DII hinge (Luca et al., 2012) (Fig. 1.4). -
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Figure 1.4 Neutralizing epitopes on JEV E glycoprotein domains. 
Reconstructed virion indicating neutralizing epitopes mapped on fusion loop, DI-DII 
hinge, DI lateral ridge, and DIII lateral ridge of JEV glycoprotein. (A) Colored-green 
spheres represent side chains of residues for binding sites of previously established JEV 
neutralizing antibodies. JEV £-specific neutralizing antibodies (B) 4G2 (G 104, G 106, 
-and Ll07) was mapped to the fusion loop; (C) B2 (1126), NARMA3 (Q52), and 503 
(Q52, 1126, Kl 36, and S275) to the DI-DII hinge; (D) A3 (Kl 79) to the DI lateral ridge; 
(E) E3 (G302) and E3 .3 (133 7, F360, and R3 87) to the DIII lateral ridge ( colored-green 
spheres as side chains of residues for binding site). Figure was adapted from Luca et al. 
(2012). 
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1.1.4 Replication cycle of Flaviviruses 
The replication cycle commences with binding and uptake of the v1non through 
receptor-mediated endocytosis (Chambers et al., 1990; Lindenbach et al., 2007) (Fig. 
1.5). Candidate cellular receptors for E glycoprotein interaction include DC-SIGN and 
DC-SIGNR (Davis et al., 2006; Mukhopadhyay et al., 2005). Fusion of the viral 
envelope with the endosomal membrane is induced by low pH within the endosomal 
compartment (Allison et al., 2001; Bressanelli et al., 2004; Fritz et al., 2008; Huang et 
al., 2010). Following uncoating of the nucleocaspid, the viral genome is released into 
the cytoplasm. The RNA genome serves as the template for RNA replication, 
messenger RNA for viral protein translation, and genetic material for the formation of 
new viruses (Chambers et al., 1990; Chu and Westaway, 1985; Chu and Westaway, 
1992). The genome encodes for a single open reading frame of ,.__, 10,300 nucleotides, 
that is translated into an ,.__,3,400 amino acid long polypeptide, with structural proteins 
(C, E, and prM) encoded in the amino-terminal and the non-structural protein encoded 
in the carboxy-terminal portion (Lindenbach et al., 2007). Host and viral proteases 
subsequently cleave the polyprotein co- and post-translationally into 10 protein 
subunits. A negative sense RNA genome serves as an intermediate for RNA replication 
in the cytoplasm, with non-structural proteins involved in the replication complex. The 
virus assembles by budding through the membranes of endoplasmic reticulum, and 
progeny virions transit via the Golgi complex during virus egress from the infected cell 
.(Mackenzie and Westa\vay, 2001 ). 
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Figure 1.5 Flavivirus replication cycle. 
Mature virion 
Immature virion 
Sequential steps 1n flavivirus 
replication: attachment, fusion, uncoating, RNA replication and polyprotein synthesis, 
assembly, budding, and exocytosis. Figure adapted from Stiasny and Heinz (2006). 
1.1.5 History of JEV discovery and spread 
Description of encephalitis in humans was initially reported in Japan as early as 1871 
(van den Hurk et al., 2009) (Historical highlights summarized in Table 1.2). Minor 
epidemics occurring during summer have been reported regularly in Japan from 1873 to 
1968, with major epidemics documented in 1924, 1935, and 1948 (Shiraki, 1970; 
Vaughn and Hoke, 1992). In 1935, JEV was first isolated from the brain of an 
1 1 
individual who succumbed to encephalitis (Mitamura et al., 1936). It was originally 
designated as "type B encephalitis" to distinguish it from "type A encephalitis" (von 
Economo encephalitis or encephalitis lethargica). With regular "summer epidemics" 
every 2-3 years in Japan, Korea, and Taiwan until the middle of l 960's, historical 
records show its gradual spread as major epidemics in a southeast to southwest 
direction; commencing with mainland China in 1940, Philippines in l 950's, Vietnam in 
1965, Chiang Mai Valley of Thailand in 1969, West Bengal in 1973, Nepal in 1978, 
Pakistan in 1983, Sri Lanka in 1985 (Chakravarty et al., 1975; Grossman et al., 1973a; 
Grossman et al., 1973b; Grossman et al., 1973c; Mackenzie et al., 2007, Peiris et al., 
1992; Solomon, 2003; Umenai et al., 1985; Vitarana et al., 1988; Yamada et al., 1971) 
Phylogenetic analysis revealed that JEV isolates are classified into 5 genotypes (I-V) 
(Solomon et al., 2003b; Mohammed et al., 2011). In spite of the first case description in 
Japan, and the epidemiologic history of apparent southward spread, genetic studies have 
revealed that, on the contrary, the virus must have originated from the Malay 
archipelago, with subsequent outward spread all throughout Asia. This is supported by 
the discovery that all 5 genotypes (including the oldest genotype) were only found in a 
confined geographical area of Malaysia and Indonesia (Mohammed et al., 2011 ). It is 
estimated that the current JEV genotype strains evolved from an ancestral strain in the 
Malaysia-Indonesia region in the mid l 500's, with a mean evolutionary rate of 
4.35 x 10-4 (range: 3 .5 to 5 .3 x 10-4) nucleotides substitution/site /year. 
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Table 1.2 Historical highlights of JE 
Time 
1871 
1924 
1935 
1954 
1965 
1969 
1973 
1968 
1983 
1987 
1988 
1995 
1998 
2003 
2005 
2009 
2010 
2012 
Event 
First reported cases of JE in Japan 
First reported major epidemic in Japan 
Isolation of the virus from the brain of an infected individual 
Licensure of mouse brain-derived inactivated JE vaccine in Japan 
First reported major epidemic in Vietnam 
First reported major epidemic in Thailand 
First reported major epidemic in India 
Development of primary hamster kidney-cell grown inactivated JEV vaccine in China 
Documented westward expansion of JEV into Pakistan 
First complete nucleotide sequence of JEV RNA genome 
Licensure of live-attenuated vaccine SA-14-14-2 in China 
First 2 cases of JE in Torres Strait Islands, Australia 
First report of JEV infection on the Cape York Peninsula of mainland Australia 
Phylogenetic analysis classified JEV into 5 genotypes 
Cessation of production of mouse brain-derived inactivatea JE vaccine 
Licensure of Vero cell-grown formalin-inactivated JE vaccine in US, Europe, Australia 
Licensure of live-attenuated vaccine ChimeriVax-JE in Australia 
Crystal structure of JEV E glycoprotein determined 
1.1.6 Transmission cycle 
Mosquitoes of the rice paddy-breeding Culex vishnui subgroup are the established 
vectors for JEV, with Culex tritaeniorhynchus as the principal vector, and Culex 
-gelidus, Culex fuscocephala and Culex annulirostris as secondary vectors in limited 
geographical areas (Buescher et al., 1959c; Gresser et al., 1958b; Keiser et al., 2005; 
Mackenzie et al., 2002; Peiris et al., 1993; Reisen, 1981; Ritchie et al., 1997; 
Vythilingam et al., 1997). Infected mosquitoes transmit the virus to pigs and ardeid 
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birds, which serve as reservoir and amplifying hosts, and to humans and horses, which 
serve as accidental or dead end hosts (Buescher and Scherer, 1959; Scherer and 
Buescher, 1959; Scherer et al., 1959a) (Figure 1.6). Vertical transmission of JEV in 
mosquitoes has also been demonstrated; however, its role in viral persistence in the field 
remains unknown (Rosen et al., 1989; Rosen et al., 1978; Takashima and Rosen, 1989). 
Seroconversion is observed in cattle, dogs, monkeys, and sheep but is unlikely to play a 
role in the transmission cycle of JEV, given its inability to exhibit detectable viremia 
(Vaughn and Hoke, 1992; van den Hurk et al. , 2009). 
Figure 1.6 Natural transmission cycle of JEV. JEV is maintained in the 
environment through an enzoonotic cycle with pigs and ardeid birds. Culex mosquitoes 
serve as the vector. Infected Culex mosquitoes transmit JEV to humans and horses, 
which are dead-end or accidental hosts. 
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Due to the proximate location of human dwellings and pig-rearing facilities, pigs are the 
principal reservoir host of JEV causing human infections (Burke and Leake, 1988; 
Buescher et al., 1959a; Konno et al., 1966; Scherer et al., 1959d; Scherer et al., 1959e). 
Characteristics that make pigs an important amplifying host include i.) high natural 
infection rates, ii.) high viremia that can last up to 4 days, iii.) high porcine feeding rates 
of infected vectors, iv.) high birth rate, and v.) high turnover population needed for 
commercial use (Gresser et al., 1958a; Scherer et al., l 959f; Scherer et al., 1959g). 
Ardeid wading birds, such herons and egrets, on the other hand, are vital for the 
maintenance of JEV in the environment (Buescher et al., 1959b; Buescher et al., 1959d; 
Buescher et al., 1959e; Scherer et al., 1959c; Rodrigues et al., 1981 ). The propensity of 
ardeid birds to migrate great distances makes them a candidate reservoir host important 
in establishing JEV in new geographic locations (Nga et al., 2004; Solomon, 2004). 
Other postulated mechanisms by which JEV is established in- new areas include wind-
blown infected mosquitoes and travel or migration of infected individuals (Ming et al., 
1993; Ritchie and Rochester, 2001; Sellers, 1980; Vaughn and Hoke, 1992). 
Two typical patterns of JEV transmission are described. In tropical areas, such as 
Cambodia, Indonesia, Thailand and Vietnam, an endemic pattern with year-round 
transmission is observed, with occasional outbreaks during the rainy season or as a 
consequence of increased irrigation in rice paddy areas (Burke et al., 1985b ). In 
temperate areas, such as Japan, China and South Korea, an epidemic pattern is 
observed, with increased incidence during summer seasons. The latter was presented in 
a study by Konno et al. ( 1966), which earlier depicted a cyclical transmission pattern 
for JEV among humans, mosquitoes, and pigs (Fig. 1. 7). 
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Figure 1.7 Cyclical epidemic pattern of JE. Following JEV inoculation, pigs 
demonstrate viremia after 4 days, and detectable antibodies after 10 days. This initial 
outbreak occurs in early July, with 20% of pigs becoming infected. Mosquitoes acquire 
JEV from viremic pigs, become infectious after 14 days external incubation period 
(EIP), and transmit JEV into more pigs. This second outbreak results in 100% 
seroconversion in pigs. A larger pool of viremic pigs results in larger population of 
infected mosquitoes. Fourteen days after EIP in a new batch of infected mosquitoes, the 
outbreak of JE in humans starts to appear. Figure adapted from Konno et al. ( 1966). 
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1.2 Clinical spectrum of Japanese encephalitis 
1.2.1 Clinical manifestations 
Infection with JEV starts with a bite of an infected Culex mosquito, although the 
possibility of transplacental transmission has been demonstrated in mice, swine and 
humans (Chaturvedi et al., 1980; Mathur et al., 1981; Morimoto et al., 1972). The 
infection is largely subclinical with only 1 :50 to 1: 10,000 human infections resulting in 
symptomatic disease (Tsai, 2000). The clinical features of infection range from a non-
specific febrile illness, aseptic meningitis and poliomyelitis-like syndrome to a severe 
meningoencephalomyelitis (Solomon, 2003; Solomon et al., 2000; Solomon et al., 
1998). The incubation period is from 5 to 15 days before onset of prodromal symptoms, 
which include fever, generalized weakness, coryza, diarrhoea, and rigors. Afterwards, 
patients experience headache, vomiting, decreased sensorium and convulsion. Then a 
classic presentation ensues, including dull , flat, mask-like facies with wide unblinking 
eyes, tremor, generalized hypertonia and cogwheel rigidity. Other signs and symptoms 
found in a subset of patients include generalized tonic-clonic seizures, focal seizures, 
upper motor neuron facial nerve palsy, extrapyramidal manifestations, asymmetric 
paralysis and mental illness. Occasional extrapyramidal symptoms include non-
intention tremors, cogwheel rigidity, head nodding and pill rolling movements, 
opsoclonus, myoclonus, choreoathetosis, and bizarre facial grimacing and lip smacking 
(Solomon et al., 2000). The case fatality ratio can be as high as 50-60 % (Tsai, 2000), 
and one half of the survivors have long-term neurologic or psychiatric sequelae 
(Solomon, 2003). 
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1.2.2 Animal models 
JE is also a veterinary disease with occasional fatal outcome in horses, and abortions 
and abnormal births in pigs (Halstead & Jacobson, 2003). While pigs can act as 
amplifier host in the transmission cycle of the virus, JEV infection of horses, like that of 
humans, does not generate sufficient viremia for virus transmission. The clinical course 
of JE in horses resembles that found in humans (Gould et al., 1964; Lam et al., 2005; 
Miyake, 1964; Yamanaka et al., 2006). Bats have been shown to transmit JEV 
transplacentally, and to sustain low-level viremia in the lab via simulated hibernation, 
both of which are suggested to be a mechanism for overwintering of JEV (Sulkin et al., 
1964; Sulkin et al., 1966). Also, simulated hibernation experiments have shown 
detectable viremia in JEV-infected lizards, snakes, and frogs (Doi et al., 1983; Oya et 
al., 1983). 
Mice have been most extensively used as a model for studies on the pathogenesis of 
JEV (Kimura et al., 2010), and show significant similarity to natural human infection. 
Age, genetic background and route of inoculation are risk factors for severe encephalitis 
(Grossberg & Scherer, 1966). The pathologic changes seen in mouse brain infected with 
JEV are similar to those observed in humans, with perivascular cuffs, cellular infiltrates, 
and mild vascular damage (Hase et al., 1990; German et al., 2006). 
Immunohistochemical staining reveals JEV infected neurons in multiple loci , 
predominantly localized in the following areas: cortex, thalamus, and hippocampus 
-(Wang and Deubel, 2011 ). The initial local site of JEV replication following footpad 
infection probably involves dendritic cells, given the evidence that they support JEV 
replication (Aleyas et al., 2009; Cao et al., 2011; Li et al., 2010). Local spread then 
ensues with viremia and splenic viral load, detectable only by real time RT-PCR (Wang 
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and Deubel, 2011 ). Subsequently, virus enters the brain. Putative mechanisms for virus 
invasion into the CNS include i) hematogenous spread, ii) entry through olfactory 
neurons, iii) retrograde axonal transport through peripheral nerves, iv) a "Trojan horse" 
mechanism through infected monocytes and v) transcytosis through the endothelial cells 
of the blood-brain-barrier. JEV infection of neurons is accompanied by a local 
inflammatory reaction. Virus clearance from the CNS is complicated by the 
irreplaceable nature of neurons, and the fact that neuronal damage can be caused 
directly by virus infection or by infiltrating leukocytes in response to the infection 
(Griffin, 2011 ). 
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1.3 Innate Immune response to JEV 
1.3.1 Sensing of the pathogen 
Host cells detect distinct conserved molecular signatures (pathogen associated 
molecular patterns: P AMPs) of invading viruses through germ-line encoded 
transmembrane or cytosolic pathogen recognition receptors (PRRs) (Bowie & 
Unterholzner, 2008) (Table 1.3). This initial sensing and recognition is of paramount 
importance in viral immunobiology, where activating intracellular signalling cascades 
ultimately lead to the induction of antiviral, inflammatory and adaptive immune 
responses. Transmembrane PRRs include C-type lectin receptors (CLRs) and the widely 
studied toll-like receptors (TLRs), both of which are upregulated after JEV infection 
(Gupta & Rao, 2011). CLRs contain carbohydrate recognition domains interacting with 
mannose, fucose, and glucan carbohydrate structures of pathogens (Geijtenbeek & 
Gringhuis, 2009). A particular CLR, C-type lectin domain family 5 (CLECSA), is 
highly expressed after JEV infection and is associated with a proinflammatory profile 
(Gupta et al., 2010). Direct interaction of JEV with CLECSA, resulting in macrophage 
and microglial cell activation, has recently been reported (Chen et al., 2012). CLECSA 
has been implicated in the immunopathology of dengue hemorrhagic fever (Chen et al., 
2008). Similarly, CLECSA plays a role in JEV-induced inflammation and lethality 
(Chen et al., 2012). Treatment of JEV-infected mice with monoclonal antibodies against 
CLECSA resulted in reduced blood-brain-barrier damage, reduced microglial activation, 
-reduced bystander neuronal damage, and reduced cellular infiltration into the CNS 
(Chen et al., 2012). 
20 
Table 1.3 List of pathogen recognition receptors 
Membrane-bound receptors 
Toll-like receptors (TLRs) 
Structure: Composed of N-terminal leucine-rich repeats (LRR), transmembrane 
region , and cytoplasmic Toll/lnterleukin-1 receptor (TIR) domain 
Expression: predominantly in macrophages, dendritic cells , and other leucocytes; all 
other cell types 
Functions: recognition of all microbes, inflammation , Type-1 interferon induction , 
antimicrobial signalling 
Examples: TLRs 1-13 
C-type Lectin receptors (CLR's) 
Group 1 
CLR's 
Group 2 
CLR's 
Structure: Mannose receptors with 
Carbohydrate binding protein , recognize high mannose structures 
Expression: macrophages and dendritic cells 
Functions: inflammation , activate a pathway of the complement system, mediate 
endocytosis of pathogens, cell-cell recognition 
Examples: Mannose receptor (CD206), DEC205 
Structure Asialoglycoprotein receptors with 
Carbohydrate binding protein , recognize mannose, fucose , or glucan carbohydrate 
structures 
Expression: mainly macrophages and dendritic cells 
also on B cells and neutrophils 
Functions: inflammation , antigen presentation , mediate endocytosis of pathogens, 
ce ll-cell recognition 
Examples: DC-SIGN , CLEC2, CLEC4A, CLEC4C , CLEC4E, CLEC4K, CLEC5A, 
CLEC6A,CLEC7A, CLEC9A, CLEC10A, CLEC12A, CLEC128 
Cytosolic receptors 
NOD-like receptors 
Structure: Composed of LRRs domain ; a nucleotide binding oligomerization domain 
(NOD); and a domain for the initiation of signaling , such as caspase recruitment 
domains (CARDs) , pyrin , or baculovirus inhibitor of apoptosis repeat (BIR) domains 
Expression: mainly leucocytes, all other cell types 
Functions: recognition of bacteria and viruses , regulation of inflammation and 
apoptosis 
Examples: NOD1 , NOD2 
RIG-1-like receptors 
Structure: RNA helicases; composed of two N-terminal CARDs, a central DEAD box 
helicase/ATPase domain , and C-terminal regulatory domain 
Expression: mainly leucocytes, all other cell types 
Functions: intracellular recognition of viruses 
Examples: Retinoic acid-inducible gene I (RIG-1 ), Melanoma differentiation 
associated-protein 5 (MDA5) , LGP2 
TLRs are composed of a leucine-rich repeat-containing ectodomain, a transmembrane 
domain and an intracellular Toll- interleukin 1 receptor (TIR) domain (Kawai & Akira, 
2010) (Table 1.4). The ectodomain mediates recognition of PAMPs, while the 
intracellular TIR domain mediates downstream signal transduction. TLR signaling, 
except that via TLR3 , requires the TIR-domain adaptor molecule, MyD88, and 
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therefore can be prevented by MyD88 knockout (Kawai & Akira, 2010). Aside from 
MyD88, TLR4 can activate an alternative signalling pathway, which is through adaptor 
proteins TIR-domain-containing adaptor protein inducing interferon-~ and TRIP-related 
adaptor molecule (Lu et al., 2008). In the absence of MyD88, bone marrow-derived 
macrophages and dendritic cells infected with JEV have reduced production of 
inflammatory cytokines interleukin (IL )-6, IL-10, IL-12, and tumour necrosis factor 
(TNF)-a (Aleyas et al., 2009). This supports a role of TLR signalling through MyD88 
in shaping the immune responses to JEV. However, this is not reflected in a markedly 
altered disease outcome, given that MyD88_1_ mice only show a partial impairment in 
interferon (IFN)-a production and similar susceptibility to JEV in comparison to wild-
type mice (Kato et al., 2006), suggesting a redundancy in pathways for recognition of 
JEV infection. 
Table 1.4 List of toll-like receptors (TLRs) 
TLR 
TLR1 
TLR2 
TLR3 
TLR4 
TLR5 
TLR6 
TLR7 
TLR8 
TLR9 
TLR10 
TLR11 
TLR12 
TLR13 
Ligand 
Multiple triacyl lipopeptides 
Lipoteichoic acid, zymosan 
HSP?O, Lipoarabinomannan 
Double-stranded RNA 
Lipopolysaccharide 
Lipoteichoic acid 
Viral glycoproteins 
Flagellin 
Multiple diacyl lipopeptides 
Single-stranded RNA 
Single-stranded RNA 
Unmetheylated CpG DNA 
Unknown 
Pofilin 
Unknown 
Unknown 
Expression. location 
Cell surface 
Cell surface 
Cell compartment 
Cell surface 
Cell surface 
Cell surface 
Cell compartment 
Cell compartment 
Cell compartment 
Cell compartment 
Cell surface 
Unknown 
Unknown 
Adapte-r Protein 
MyD88/MAL 
MyD88/MAL 
TRIF 
MyD88/MAL 
TRIF/TRAM 
MyD88 
MyD88/MAL 
MyD88 
MyD88 
MyD88 
My88 
MyD88 
Myd88 
MyD88, TAK-1 
Functional TLR 10 is not found in mice. Functional TLR 11, 12, and 13 are not found in humans. 
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Cytosolic PRRs are essential for detecting pathogens invading the cytosol. They are 
classified into nucleotide binding oligomerization domain (NOD)-like and retinoic acid-
inducible gene (RIG)-1-like receptors (Wilkins and Gale, 2010) (summarized in Table 
1.3). NOD-like receptors, NOD2 and NLRP3, recognize ssRNA and dsRNA, 
respectively, and have significant antiviral activity through IFN signalling. Both 
proteins are expected to recognize flaviviral genomic RNA, although their role in JEV 
infection remains to be investigated. RIG-I-like receptors, also known as RNA 
helicases, have a conserved DExD/H box helicase domain and a C-terminal regulatory 
domain among the three recently identified members, RIG-1, melanoma differentiation-
associated antigen 5 (MDA-5) and laboratory of genetics and physiology 2 (LGP2) 
(Wilkins and Gale, 2010). The C-terminal regulatory domain serves as the recognition 
site for sensing ssRNA and dsRNA. Kato et al (2006) have shown that RIG-1 receptor 
signaling, but not that via MDA-5, is critical for the antiviral response against JEV: 
RIG-i-1-, but not MDA-s-1- mice, display impaired type 1 IFN production and increased 
susceptibility to JEV infection. LGP2 was initially reported as a dominant negative 
regulator of RIG-1 and MDA-5 signalling (Komuro & Horvath, 2006; Murali et al., 
2008); however, Satoh et al (2010) have demonstrated that bone marrow-derived 
dendritic cells from LGP2-1- mice infected with JEV have an impaired production of 
IFN-~, indicating that LGP2 functions upstream of RIG-1 and MDA-5 to potentiate 
viral RNA-induced signalling as a positive regulator. 
1.3.2 Type 1 interferon induction and signalling 
Interferons (IFN s) are a group of cytokines first discovered based on their antiviral 
activity against influenza (Borden et al., 2007). Three families of IFNs, type I, type II 
and the recently identified type III, can be distinguished. Type I IFN s include multiple 
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IFN-a subsets, a single IFN-~, IFN-co, and the recently discovered IFN-£ (Hardy et al., 
2004 ). All members bind to the same cell surface receptor, and are located in a single 
gene cluster both in humans and in mice. In addition to their antiviral activity, type I 
IFNs are key to efficient establishment of the adaptive immune responses (Borden et 
al., 2007). Type III IFNs (IFN-Al, -A2 and -A3) are new members of the IFN 
superfamily first discovered in 2003 and shown to be related to type I IFN (Ank et al., 
2006). However, they differ by signalling through a receptor complex that is different 
from that used by type I IFNs. Numerous RNA and DNA viruses induce and are 
sensitive to IFN-As, although it remains unclear if type III IFNs are important in the host 
response against JEV infection. Type II IFN consists of a single cytokine, IFN-y, and its 
function in JEV infection is described in Section 1.3 .3. 
IFN production after JEV infection was initially documented in mice (Rokutanda, 1969) 
and later in humans (Burke and Morill, 1987). Early in vitro and in vivo animal studies 
depicting its significance as an antiviral compound against JEV employed the use of 
IFN inducers (Ghosh et al., 1990; Taylor et al., 1980) and recombinant IFN-a (Crance 
et al., 2003). Furthermore, mice deficient in IFN-a receptor infected with JEV show 
sustained high viremia and fulminant disease (Lee et al., 2004; Lee & Lobigs, 2002; 
Lobigs et al., 2009), demonstrating that type I IFN is a key tropism determinant of JEV. 
IFN gene expression is induced by the binding of PRR-activated transcription factors to 
their promoters (Borden et al., 2007). They include IFN regulatory factor (IRF) proteins 
,and NF-KB (Honda et al., 2006; Tenoever et al., 2007). In the case of JEV infection, 
RIG-1-dependent IRF-3 and phosphatidylinositol-3 kinase-dependent NF-KB activation 
is essential for IFN production (Chang et al., 2006). NF-KB-dependent and NF-KB-
independent mechanisms of IFN induction after JEV infection have been suggested by 
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Abraham et al (2010). Binding of IFN to its cognate receptor at the cell surface triggers 
a signalling cascade, the Janus kinase - signal transducer and activation of transcription 
(JAK-STAT) pathway, ultimately triggering IFN-stimulated response element and 
expression of IFN-stimulated genes (ISGs). ISGs serve as mediators of IFN action 
directed towards initiation of antiviral and immunoregulatory functions (Borden et al., 
2007). Antiviral proteins associated with flaviviral infections include double-stranded 
RNA-activated protein kinase (PKR), the 2' ,5 '-oligoadenylate synthetases (2 '-5 '-OAS), 
ISG 15, ISG20, viperin and IFN-induced transmembrane proteins (Brass et al., 2009; 
Hsiao et al., ; Jiang et al., 201 O; Kajaste-Rudnitski et al., 2006; Samuel et al., 2006). Of 
these, 2 '-5 '-OAS proteins are the most widely studied and acts through activation of 
RNAse L, a potent endoribonuclease that cleaves viral RNA (Silverman, 2007). The 
critical role of 2 '-5 '-OAS in the control of West Nile virus (WNV) infection was first 
reported in mice (Mashimo et al., 2002; Perelygin et al., 2002) and recently in horses 
and humans, where distinct OAS 1 a gene polymorphisms were identified as a risk factor 
(Lim et al., 2009; Rios et al., 2010). Given the association of OAS with the flavivirus-
resistance phenomenon in mice (Brinton & Perelygin, 2003), this ISG most likely also 
plays an important role in recovery from JEV infection. ISG-15 is an additional ISG 
recently documented to be involved in the control of JEV infection (Hsiao et al., 2010). 
Considering its antiviral action, the therapeutic potential of recombinant IFN in human 
cases of JE has been investigated. While an initial study suggested a benefit (Harinasuta 
et al., 1985), a subsequent randomised double-blind placebo-controlled clinical trial did 
not (Solomon et al. , 2003b ). The failure to observe a benefit in the larger scale study 
posed the question of clinical relevance of IFN treatment. It remains to be seen, whether 
the outcome might differ if higher doses were given, given earlier in the course of 
infection, or given in combination with other drugs. It is likely that the failure of IFN 
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therapy after an established JEV infection can be attributed to the IFN-antagonistic 
mechanisms of the virus itself. JEV counteracts the effect of IFN by blocking tyrosine 
kinase 2 (Tyk2) and Stat activation (Lin et al., 2004). This is mediated by the viral NS5 
protein through the activation of protein tyrosine phosphatases (Lin et al., 2006). 
Additionally, JEV NS4A protein is reported to block IFN action through inhibiting 
phosphorylation of Stat 1 and Stat 2 (Lin et al., 2008a). Moreover, aside from IFN 
antagonism at the level of Jak-Stat signalling, JEV is also able to inhibit a downstream 
antiviral molecule, viperin, by promoting its degradation via a proteasome-dependent 
mechanism (Chan et al., 2008). 
1.3.3 Cellular factors, chemokines and cytokines 
Neutrophil leucocytosis is a unique feature in human cases of JE (Chaturvedi et al., 
1979; Singh et al., 2000a). A neutrophil chemotactic factor derived from JEV-
stimulated macrophages has been reported to induce neutrophilia (Khanna et al., 1991 ). 
Additionally, an increased level of the neutrophil chemoattractant, IL-8, found in CSF 
and serum of JEV infected individuals is significantly associated with neutrophilia and 
an elevated level of IL-8 in CSF and plasma is linked with adverse clinical outcome 
(Singh et al., 2000b; Winter et al., 2004). This contrasts with a potentially beneficial 
role of neutrophils in the control of JEV infection by a mechanism involving the 
degradation of virus via triggering a respiratory burst and the generation of toxic 
radicals (Srivastava et al., 1999). 
Cells of the monocytic lineage and the release of soluble factors thereof have been 
implicated in JEV pathogenesis. Macrophages predominate the inflammatory cells 
infiltrating the brain parenchyma of individuals with Japanese encephalitis (Johnson et 
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al., 1985). They are permissive for JEV replication, and provide a putative mechanism 
for JEV entry into the CNS (Aleyas et al., 2009; Hasegawa et al., 1990; Mathur et al., 
1988; Yang et al., 2004). Cathepsin L-mediated processing of the capsid protein 
appears to play a role in JEV replication in macrophages, since mutant virus resistant to 
cleavage by the protease has impaired growth in macrophage but not fibroblast or 
mosquito cell lines (Mori et al., 2007). Microglia are a brain-resident macrophage cell 
population, which can be infected with JEV for prolonged periods without 
morphological alteration, suggesting that microglia might serve as a reservoir for viral 
persistence in the CNS (Thongtan et al., 2010). Local immune responses initiated by 
microglial cells may provide protection against JEV infection of the CNS. However, 
microglial activation resulting in elevated levels of proinflammatory cytokines (IL-6, 
TNF-a, IL-1 ~) and chemokines (IL-8, RANTES, MCP 1) in the CSP and plasma may 
give rise to irreversible neuronal damage and correlates with an increased mortality rate 
(Chen et al., 2004; Chen et al., 201 Ob; Ghoshal et al., 2007; Ravi et al., 1997; Saxena et 
al., 2008; Winter et al., 2004). Astroyctes were originally classified as a subclass of 
glial cells with pleiotropic functions for maintenance of CNS homeostasis, and only 
recently were they shown to be immunocompetent cells (Dong & Benveniste, 2001 ). 
JEV infected astrocytes are an important source of chemokines (CCL5 and CXCLl0) 
for migration of leukocytes into the CNS (Bhowmick et al., 2007; Chen et al., 201 Oa). 
Lastly, natural killer (NK) and y/8 T cells form the cytotoxic arm of the innate immune 
pathways. Both exhibit cellular cytotoxicity by causing apoptotic lysis of virally 
infected cells, either through a direct cell-cell contact mechanism or, indirectly, by 
release of soluble cytokines, IFN-y and TNF-a. An in vitro study has demonstrated the 
antiviral activity of IFN-y against JEV (Hasegawa et al., 1990). IFN-y mediates its 
antiviral effect, at least in part, through induction of nitric oxide (NO) synthase 
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(Karupiah et al. , 1993) and an inhibitory effect of NO on JEV growth has been 
documented (Lin Y.L. et al., 1997; Saxena et al., 2000). IFN-y, derived from y/8 T cells 
is necessary for the early control of dissemination of WNV, which is closely related to 
JEV (Wang et al., 2003a). y/8 T cells may play a protective role at the interface of 
innate and adaptive immunity, since TCR8_1_ mice display higher susceptibility after 
secondary challenge with WNV compared to wild-type mice (Wang T. et al., 2006). It 
will be interesting to uncover whether y/8 T cells are also important in experimental 
models of JEV. 
Table 1.5 Innate immune factors affecting outcome of JEV infection 
Factor 
Pathogen Recognition 
Myd88 
RIG-1 
MDA-5 
LGP2 
Outcome after JliV rnfe.etion 
absence = l production of inflammatory cytokines, 
absence= l production of type 1 IFN; i disease severity 
absence= no effect on production of type 1 IFN; 
no effect on disease severity 
absence = i production of type 1 IFN 
Interferon Induction and Signalling 
NF-KB 
IRF-3 
IFN-a 
IFN-a receptor 
Jak-stat 
ISG15 
Viperin 
Cellular Factors 
i Pl3K dependent production of type 1 IFN 
i RIG-1 dependent production of type 1 IFN 
inhibits virus, no effect with treatment of human cases 
absence = i disease severity 
inhibited by viral NS4A and NSS proteins 
inhibits virus 
inhibited via proteosome-dependent mechanism 
Neutrophils neutrophilia , intracellular degradation of JEV 
i release of inflammatory cytokines ; i pathology 
Macrophage monocytosis; i migration of monocytes to CNS; 
i inflammatory cytokines 
Microglial Cells microgliosis; i release of inflammatory cytokines ; 
i pathology 
Astrocytes i release of inflammatory cytokines 
i = increase, t = decrease 
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1.4 Adaptive Immunity 
Adaptive immunity represents the second wave of immune responses and 1s 
characterized by specificity, high potency, and development of memory. For it to 
become activated, it requires signals from antigen presenting cells of the innate immune 
system. This can be directly through cell-to-cell communication or, indirectly, by 
recognition of soluble cytokines. Adaptive immunity is composed of the humoral and 
cell-mediated immune responses mediated by B and T lymphocytes, respectively. The 
essential contribution of the adaptive immune responses in recovery from viral 
infections has been evident from empirical observations in people with defective B cell 
or T cell development (Fulginiti et al., 1968; Wilfert et al., 1977; Wyatt, 1973). 
1.4.1 B cells 
Humoral immunity has paramount protective function in primary JEV infection. The 
importance of a vigorous, virus-specific, humoral immune response in ameliorating and 
preventing illness has been documented in human cases of JE (Burke et al., 1987; 
Libraty et al., 2002; McCallum, 1991) and in animal models by administration of 
antibody prior or subsequent to infection with JEV (Goncalvez et al., 2008; Gupta et al., 
2003; Kimura-Kuroda & Yasui, 1988; Zhang et al., 1989). 
Mechanistically, antibodies elicited against flaviviruses exhibit their action directly by 
neutralization of infectivity, or indirectly by antibody-dependent cell-mediated 
cytotoxicity, Fc-y-receptor-mediated clearance, or complement-mediated cytotoxicity 
(Pierson et al., 2008). Neutralizing antibodies predominantly target the E protein of the 
virion, although protective antibodies against prM and NS 1 proteins have also been 
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documented (Dewasthaly et al., 2001; Kolaskar & Kulkarni-Kale, 1999; Konishi et al., 
1991; Konishi et al., 1992a; Konishi et al., 1992b; Lin et al., 2008b; Lin et al., 1998; 
Nam et al., 1999; Seif et al., 1995; Wu et al., 2003; Wu & Lin, 2001; Xu et al., 2004). 
The latter can control JEV infection by their complement-mediated cytolytic potential 
(Krishna et al., 2009; Lin et al., 2008b; Lin et al., 1998). Antibody neutralizes flavivirus 
infectivity with high efficiency mainly by interfering with early steps of the viral entry 
pathway, including attachment, internalisation, and fusion (Butrapet et al., 1998; Crill & 
Roehrig, 2001; Goncalvez et al., 2008; Nybakken et al., 2005). 
1.4.2 T cells 
T cells can be classified phentoypically, on the basis of their antigen receptor usage ( a/~ 
vs y/8) and their co-receptor expression (CD4 vs. CD8), or functionally ( cytotoxic vs 
helper). Generally, cytotoxic T lymphocytes (CTLs) are predominantly of CD8+ and, at 
times, helper T (Th) cells of CD4+ phenotype. T cells of the y/8 phenotype recognize 
non-classical major histocompatibility complex (MHC) antigens and form part of the 
innate immune response as described earlier. On the other hand, CD8+ and CD4 + a/~ T 
cells recognize MHC-I and MHC-II plus peptide antigen, respectively, and serve as 
mediators of adaptive immune responses. 
1.4.2.1 CD4+ T cell immune response 
Multifaceted CD4+ T cells contribute to controlling infection by various mechanisms, 
including antiviral cytokine production, activation of antigen-presenting cells, antibody 
class switching, direct cytotoxicity, and maintenance of CD8+ T cell activity (Zhu et al., 
2010). Follicular helper T cells (T FH) are a subset of CD4+ T cells that enter B cells 
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follicles to provide help in germinal center formation. T FH require expression of 
inducible T cell co-stimulator (ICOS) and SLAM-associated protein (SAP) for optimal 
T FH-B cell interaction important in generation of long-lived plasma cells and memory B 
cells (Bertram et al., 2002; Crotty et al., 2003; Kamperschroer et al., 2006) (Fig. 1.8A). 
Direct costimulatory interactions, mainly through CD40L-CD40, between CD4+ T cells 
and B cells are also necessary for the optimal generation of humoral immunity (Borrow 
et al., 1996; Sangster et al., 2003). CD4+ T cell-mediated help for generation of effector 
CD8+ T cells is via various mechanisms, including paracrine release of interleukin-2 by 
CD4+ T cells, CD4+ T cell direct CD40L-CD40 interaction with antigen-presenting cell 
that enhances priming of CD8+ T cells, and upregulation of CD25 on CD8+ T cells 
(Swain et al., 2012; Obar et al., 2010; Williams et al., 2006) (Fig 1.8B). On the other 
hand, CD4+ T cell-mediated help for generation of memory CD8+ T cells is via 
downregulation of apoptotic genes in CD8+ T cells, such as TNF-related apoptosis-
inducing ligand (TRAIL) and programmed cell death protein 1 (PDl) (Fuse et al., 2009; 
Janssen et al., 2003; Janssen et al., 2005; Oh et al., 2009). Also, CD4+ T cell direct 
CD40L-CD40 interaction with CD8+ T cells has been shown to enhance generation of 
memory CD8+ T cells (Mueller et al., 2006). 
The protective value of JEV-immune CD4+ T cells has been explored in adoptive 
transfer experiments in mice (Biswas et al., 2009). Exposure to JEV induces effective 
CD4+ T cells immunity, characterised by T cell proliferation, production of Th 1 and 
Th2 cytokines, and immunoglobulin class switching (Konishi et al., 1995; Ramakrishna 
et al., 2003). Putative Th epitopes that elicit virus-specific and flavivirus cross-reactive 
proliferative responses in immune splenocytes have been mapped in E protein 
(Kutubuddin et al., 1991 ). In humans, exposure to live JEV infection or vaccination 
similarly induces JEV-specific and flavivirus cross-reactive CD4+ T cell responses 
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(Aihara et al., 1998; Konishi et al., 1995). A region of NS3 protein (residues 193 - 324) 
has been identified as the dominant source of peptide determinants for CD4 + T cells in a 
healthy JEV-endemic cohort (Kumar et al., 2004a; Kumar et al. , 2004b ). Patients with 
severe encephalitis had impaired NS3-specific CD4+ T cell responses, indicating a 
critical protective role of these immune cells in the pathogenesis of JE (Kumar et al., 
2004a). 
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Figure 1.8 CD4+ T cells helper functions. CD4+ T cell-mediated help of B 
cells (A) is mediated through a subset of CD4+ T cells called Follicular helper T (TFH) 
cells. In addition to release of soluble cytokines, direct interaction of TFH with B cells, 
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most importantly CD40L-CD40 interaction, induces germinal center formation, isotype 
switching and affinity maturation of antibody responses. All of which are important in 
the production of efficient neutralizing antibodies targeted towards eliminating viral 
pathogens. CD4+ T cell-mediated help of CD8+ T cells (B) via release of interleukin-2 
(IL-2), direct CD40L-CD40 interaction, and indirectly via activation of antigen-
presenting cells (APCs). Activation of APCs by CD4+ T cells, via direct CD40L-CD40 
interaction and cognate peptide-MHCII-II interaction, leads to enhanced priming of 
CD8+ T cells by activated APCs. CD4+ T cell-mediated help in generation of memory 
CD8+ T cells involves downregulation of pro-apoptotic genes in CD8+ T cells, such as 
TNF-related apoptosis-inducing ligand (TRAIL). BCR: B cell receptor, TCR: T cell 
receptor, TH: T helper, ICOS: inducible T cell co-stimulator, ICOSL: ICOS ligand, 
MHC: major histocompatibility complex. Figure was adapted from Swain et al. (2012). 
1.4.2.2 CDS+ T cell immune response 
Cytotoxic CD8+ T cells exert their function by lysing virally infected cells directly 
through Fas-FasL interaction or the perforin-granzymes exocytosis mechanism, and 
indirectly by release of soluble cytokines, IFN-y and TNF-a (Russel and Ley, 2002; 
Mullbacher et al., 2004) (Fig. 1.9). The binding of FasL, expressed on CD8+ T cells, to 
Fas receptor on infected target cell, initiates apoptosis via the activation of a caspase 
cascade (Rouvier et al., 1993; Nagata, 1997). FasL-Fas interaction induces the 
association of Fas-Associated protein with Death Domain, caspase-8, caspase-10, and c-
FLIP, which altogether form the death-inducing signaling complex (DISC) (Peter et al., 
2007). The formation of DISC transduces a downstream signalling pathway, leading to 
target cell apoptosis. 
Polarized release of pore-forming perforin and proteolytic granzymes by effector CD8+ 
T cells to infected target cells initiate apoptosis via caspase-dependent and independent 
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mechanisms (Henkart, 1994; Heusel et al., 1994; Simon and Kramer, 1994; Trapani and 
Smyth, 2002). It was originally thought that entry of granzymes into the target cell is 
mediated through the plasma membrane pores created by perforin, however recent 
evidence demonstrate that it is not the case (Chowdhury and Lieberman, 2008; Pipkin 
and Lieberman, 2007). The more accepted alternative mechanism of granzyme entry is 
still perforin-dependent. It speculates that the microscopic holes created by perforin 
induces a calcium influx, which subsequently activates a cellular membrane response 
leading to dynamin-dependent endocytosis of all substances, including perforin and 
granzymes, located at the narrow interphase between the effector and target cell (Keefe 
et al., 2005; Pipkin and Lieberman, 2007). 
To date, there are 5 identified human granzymes (Gzm) (A, B, H, K, M) and 11 mouse 
granzymes (A, B, C, D, E, F, G, K, L, M, N) (Granville, 2010). Among which, GzmA 
and GzmB are the most extensively studied. GzmA and GzmB induce apoptosis in 
target cells using different mechanisms, which is largely dependent on the cleavage 
specificities of the particular protease (Andrade, 2010). GzmB cleaves after aspartate 
residues (Asp-ase ), making it able to activate pro-apoptotic caspases 3, 7, and 8, and 
activate effector proteins important in caspase-independent apoptotic pathways, such as 
BH3 interacting domain death agonist and inhibitor of caspase-activated DNase 
(Casciola-Rosen et al., 2007; Cullen et al., 2007). Endpoint of cell-death induced by 
GzmB is characterized by oligonucleosomal DNA fragmentation (Chowdhury and 
Lieberman, 2008). GzmA, on the other hand, cleaves target substrates containing 
consensus sequences with arginine or lysine at the P 1 position, for instance Histone-A 1 
and lamins (Andrade, 201 O; Lieberman and Fan, 2003; Zhu et al., 2006; Zhu et al. , 
2009). GzmA-induced death is mechanistically independent to that of GzmB, and 
results in single-stranded DNA breaks in target cells (Andrade, 2010). 
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Figure 1.9 Effector pathways of cytotoxicity. T cell receptors (TCR) on the 
surface of CD8+ T cells recognize cognate peptide-MHC-I complex presented by an 
infected target cell. The specific recognition activates an intracellular signal that leads to 
unidirectional secretion of lytic granules, containing perforin (perf) and granzymes (A 
or B in circles) into the synaptic cleft. Perforin is required for the uptake of granzymes 
by the target cell. Granzymes induce target-cell apoptosis by caspase-dependent and -
independent mechanisms. Effector-target cell FasL-Fas interaction can trigger apoptosis 
mediated through activation of a caspase cascade. Simultaneously, TCR stimulation 
induces target cell production of soluble antiviral cytokines, tumor necrosis factor-alpha 
(TNF-a) and interferon gamma (IFN-y). Recognition of TNF-a by the TNF-a receptor 
expressed by target cells triggers apoptosis via the caspase cascade. IFN-y, on the other 
hand, enhances target cell transcriptional activation of Fas and molecules of the MHC-I 
antigen presentation pathway, which creates a positive feedback loop of enhancing 
target cell apoptosis. The figure was adapted, with some modifications, from 
Mullbacher et al. (2004 ). 
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Early reports demonstrated JEV-specific CD8+ T cell proliferative responses and 
cytolytic activity in humans and mice after vaccination or exposure to live JEV 
infection (Konishi et al., 1995; Konishi et al., 1997; Konishi et al., 1998a; Murali-
Krishna et al., 1995a; Murali-Krishna et al., 1994; Murali-Krishna et al., 1995b ). 
Peptide determinants recognized by JEV-immune CD8+ cells are starting to be 
identified: they include a H-2Kd-restricted E protein-derived peptide (CYHASVTDI) 
(Takada et al., 2000) and a H-2Db -restricted NS4B protein-derived peptide 
(SA VWNSTTA) (Trobaugh et al., 2010). In humans, the CD8+ T cell response against 
JEV appears to be biased to peptide determinants derived from the NS3 protein (Kumar 
et al., 2004b; Kumar et al., 2003), as was first reported for the CTL response against the 
closely related Murray Valley encephalitis virus (MVEV) in mice (Lobigs et al., 1994). 
This response against determinants in NS3 protein is broadly flavivirus cross-reactive 
and paradoxically recognises disparate epitopes from JEV and distantly related 
flaviviruses, but ignores more similar peptides from "self' and other virus families 
(Regner et al., 2001 ), suggesting that primary sequence homology is not always the 
crucial factor in peptide recognition in the cross-reactive cellular immune responses 
against flaviviruses. 
A dominant protective role of CD8+ T cells in JEV infection was initially reported by 
Murali-Krishna et al ( 1996); however, this involved co-injection of a large number of 
splenocytes with virus into the brain and required co-transfer of CD4 + T cells. A series 
of detailed studies have uncovered a conflicting role of CD8+ T cells in recovery from 
infection with encephalitic flaviviruses (Table 1.6). While essential for virus elimination 
from the CNS and survival in mouse models of West Nile encephalitis (Shrestha and 
Diamond, 2004; Shrestha et al., 2006a; Wang et al., 2003b; 2004), a disease-
potentiating effect of CTLs was documented in mice infected with MVEV (Licon Luna 
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et al., 2002). Notably, mice genetically deficient in the Fas- or perforin-dependent 
pathways of cytotoxicity show greatly increased susceptibility to virulent lineage I 
WNV infection (Shrestha and Diamond, 2007; Shrestha et al. , 2006a) , but do not differ 
from wild-type mice in susceptibility to infection with lineage II WNV strain, Sarafend 
(Wang et al., 2004), and are more resistant to infection with MVEV (Licon Luna et al. , 
2002). These findings highlight a difference in pathogenesis between even closely 
related flaviviruses belonging to the JEV serocomplex (Mullbacher et al. , 2004) that 
most likely involves a difference in the capacity of the cellular immune response to 
resolve the virus infections in the CNS. 
Table 1.6 Impact of cell-mediated immunity on pathogenesis 
Knock-out mice or Treatment 
CD8+ T cell-deficient or depleted 
~2m-deficient 
Perforin deficient 
Granzyme A & B deficient 
Perforin and Granzyme A & B deficient 
Fas ligand deficient 
Perforin x Fas Ligand deficient 
I FN-y-deficient 
WNV lineage 1 
i 
i 
i 
nt 
nt 
i 
nt 
i 
WNV lineage 2 
i 
i 
no effect 
i 
i 
no effect 
i 
no effect 
MVEV 
nt 
1 
no effect 
no effect 
no effect 
1 
1 
i 
i = increase, 1 = decrease, nt = not tested . Figure adapted , with some modifications , from 
Lobigs et al. (2009) 
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1.4.2.3 Modulation of MHC-I 
MHC-I is expressed on virtually all mammalian cells and the cell surface expression of 
this class of restriction elements for CTLs is up-regulated as a consequence of infection 
with JEV and other flaviviruses in a diverse range of cell types from different species 
(King and Kesson, 1988; Kesson et al.J 2002; Lo bigs et al., 2003 ). Fla vi virus-induced 
up-regulation of MHC-I cell surface expression is, at least in part, IFN-independent 
(Abraham et al., 201 0; Kesson & King, 2001; Mullbacher & Lo bigs, 1995), and also 
includes that of non-classical MHC-I (Abraham et al., 2008). Although the 
physiological relevance of this phenomenon in virus transmission remains unclear, it 
has been proposed that the process may contribute to reduced NK cell activity, which is 
inhibited by engagement with MHC-I by NK cell inhibitory receptors (Hershkovitz et 
al., 2008; Mom burg et al., 2001 ). It has also been hypothesised that flavivirus-induced 
up-regulation of MHC-I leads to transient T cell autoimmunity (given the increase in 
"self' antigen presentation), followed by subsequent suppression of "self' -reactive T 
cell activity, and that flavivirus infection or live vaccination of humans in the tropics 
could contribute to the observed lower incidence of overt autoimmunity in the tropics 
than in temperate climates, where flaviviruses are not endemic (Lobigs et al., 1996). 
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1.5 Control and Prevention of JE 
No approved therapeutic agent is available for JE. Treatment is mainly supportiv
e, for 
instance, using mannitol to decrease increased intracranial pressure (Solomon et al., 
2002). Clinical trials evaluating the efficacy of corticosteroids and IFN-a on improving 
the outcome of patients with JE have shown discouraging results (Hoke et al. , 2002; 
Solomon et al., 2003a). The only means to combat JE, therefore, is through effective 
means of control and prevention. 
Given that the life cycle of arboviruses alternates in stages between mosquito ve
ctors 
and animal or human hosts, vector control and mass vaccination are two su
itable 
approaches available for control and prevention. Chemical insecticides used in v
ector 
control were noted for their early successes (Walker and Lynch, 2007; World Health 
Organization, 2006). For instance, dichlorodiphenyletrichloroethane (DDT) is regarded 
as the instrumental insecticide that pave_d the way for the elimination of arthropod-
borne 
diseases, such as yellow fever and malaria, in North America (Gubler, 2004; 
Karunamoorthi , 2011 ). However, issues pertaining to its toxicity in humans and adverse 
environmental impact, such as bioaccumulation, brought forward its ban from
 use 
(Eskenazi et al. , 2009; van den Berg, 2009). Due to safety issues and environmental 
concerns of che1nical insecticides, recent alternatives were developed, including Re
lease 
of Insects containing a Dominant Lethal (RIDL)-based or Wolbachia-based strategies. 
Both strategies are designed to shorten the lifespan of mosquitoes, thereby preve
nting 
the development of vector-capable adult mosquitoes. The RIDL strategy employ
ed by 
Oxitec (United Kingdom) requires mass release of genetically modified mosquitoes that 
carry a dominant lethal gene (Alphey et al. 2002; Thomas et al. , 2000). The 
Wolbachia-based strategy involves mass release of mosquitoes infected with n
atural 
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strains of Wolbachia, an easily transmissible bacterium that causes life shortening in 
mosquitoes (Fu et al., 201 0; Moreira et al., 2009; McMeniman et al., 2009; Xi et al., 
2005). 
Experience with yellow fever vaccination revealed that eradication of arboviruses is not 
likely possible, for two main reasons: constant presence of reservoir or maintenance 
hosts in the environment, and constant presence of primary and alternative vectors 
maintaining the virus in both urban and rural cycles (Barrett and Higgs, 2007). It is then 
thought that the most cost-effective way of controlling spread of arboviral diseases is 
through mass vaccination. 
1.5.1 JE Vaccines 
Vaccination is the most cost-effective measure in controlling the spread of JE (Jelinek, 
2008). In countries were routine immunization against JE were implemented, the 
dramatic drop in annual incidence of JE was observed (Erlanger et al., 2009). For the 
past 50 years, the formalin-inactivated mouse brain-derived JEV was the only licensed 
vaccine for international use. However, due to the perceived issues of safety, the use of 
the vaccine was suspended, and its production was ceased since 2005 (Appaiahgari et 
al., 2010). It is though that the recommendation was done in the anticipation of the 
arrival of new generation JE vaccines. For a new JE vaccine to get through the 
regulatory process, it has to display non-inferiority to formalin-inactivated mouse brain-
derived JE vaccine. This is based on an established surrogate marker for JE vaccine 
efficacy, which is PRNTso titre (50% plaque reduction and neutralization test) of at least 
1: 10 (Hombach et al., 2005, Markoff, 2000). 
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1.5.1.1 Inactivated mouse brain-derived JE vaccine 
In 1954, a formalin-inactivated mouse brain-derived JE vaccine (JE- VAX®) was 
licensed in Japan (Fischer et al., 201 O; Scholer et al., 2009). Its formulation was 
subsequently modified through the decades, with the vaccine containing inactivated 
JEV strain Beijing-I and/or Nakayama. The internationally licensed vaccine is an 
inactivated JEV Nakayama-NIH strain produced in The Research Foundation for 
Microbial Diseases of Osaka University (Biken, Osaka, Japan), and distributed 
worldwide in the recent past by Sanofi Pasteur as JE-V AX. Each one ml dose 
formulation contains 500 µg of gelatin, <100 µg of formaldehyde, <0.0007% v/v 
Polysorbate 80, <50 ng of mouse serum protein, and 0.007% thimerosal preservative. 
Aside from effective use in military personnel and tourists from JE-nonendemic to JE-
endemic countries, JE- VAX® vaccine was instrumental in the dramatic decline of JE 
incidence in IE-endemic countries, such as in Japan, South Korea, Taiwan, and 
Thailand (Fischer et al., 2010). 
Two large clinical trials have demonstrated the efficacy of JE-V AX® vaccine. The first 
study demonstrated a vaccine efficacy rate of 80% after one year of follow-up in 
children receiving a two-dose regimen of the vaccine, while a single dose vaccine was 
not efficacious (Hsu et al., 1971 ). The second study demonstrated a combined vaccine 
efficacy rate of 91 % after two years of follow-up in children receiving monovalent 
vaccines ( containing either Nakayama or Beijing- I strain), while no difference was 
noted between monovalent vs. bivalent vaccines (Hoke et al., 1988). 
Twenty percent of JE- VAX® vaccine recipients were associated with local adverse 
events, such as localized erythema, tenderness, and swelling at the injection site, while 
41 
10% of vaccine recipients experienced mild systemic effects, such as fever, chills, 
headache, myalgia, rash, and gastrointestinal symptoms (Defraites et al., 1999; Poland 
et al., 1990). The frequency of severe hypersensitivity reaction is estimated to range 
from 10 to 260 cases per 100,000 vaccine recipients (Fischer et al., 2010). These 
serious, but rare, systemic allergic reactions include generalized urticaria, angioedema 
of the extremities, face, and oropharynx, with or without accompanying bronchospasm, 
respiratory distress, and hypotension. History of anaphylaxis, urticaria, or other allergies 
provides a 2 to 11 times likelihood of developing a reaction after JE- VAX® 
vaccination (Berg et al., 1997; Plesner et al., 2000; Sakaguchi et al., 2001 b ). A study in 
Japan has demonstrated gelatin, a vaccine stabilizer, as the likely compound that 
induces IgE-mediated immediate hypersensitivity reaction in children (Sakaguchi et al., 
1997; Sakaguchi et al., 1998; Sakaguchi et al., 2001a). Approximately 0.1-2 cases per 
100,000 JE-MB recipients demonstrated moderate to severe neurologic symptoms, 
including encephalitis, gait disturbances, Parkinsonism, and seizures (Fischer et al, 
2010). Cases of fatal acute disseminated encephalomyelitis (ADEM) were reported in 
Korea and Japan, and in 2005, this was one of the cited reasons that pro111pted Japanese 
officials to suspend the used of JE-MB vaccine (Ohtaki et al., 1995; Matsui et al., 2002; 
Takahashi et al., 2000). However, the WHO Global Advisory Committee on Vaccine 
Safety found no evidence of increased risk for ADEM after JE-MB vaccination (Fischer 
et al., 2010). 
1.5.1.2 Inactivated Beijing-3 strain JE vaccine 
In 1968, a primary hamster kidney cell culture-derived JEV Beijing-3 strain (P-3) was 
developed in China (Scholer et al., 2009). It was widely used in China until it was 
gradually replaced by a live, attenuated (SA 14-14-4) vaccine. No large-scale 
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randomized control trials were done to fully evaluate the safety and immunogenicity of 
the P-3 vaccine. A single case-control study revealed a limited protection of 78% after 
2-dose primary vaccination plus annual boosters (Luo et al., 1994). The limited efficacy 
and requirement of multiple doses was seen as the basis for the Chinese authorities to 
shift to using the SA14-14-2 vaccine (Scholer et al., 2009). 
1.5.1.3 SA14-14-4 JE vaccine 
In 1988, Chinese authorities licensed SA 14-14-2, a live attenuated JE vaccine produced 
at the Chengdu Institute of Biological Products (CD IBP), China. SA 14-14-2 was 
generated by serial passages of SA 14 strain in primary hamster kidney cell culture, and 
in live mice and hamsters, with subsequent plaque purifications in primary chick 
e1nbryo cell culture (Appaiahgari et al., 201 O; Halstead and Thomas, 2011 ). Q-One 
Biotech (UK) has determined the SA14-14-2 to be free of adventitious viruses after 
quality assurance check of the master seed vaccine and vaccine lots. It has been 
administered to more than 200 million children in China, and has recently been licensed 
in India, Sri Lanka, Nepal, and South Korea (Appaiahgari et al., 2010). 
Three small case-controlled studies (Hennessy et al., 1996; Bista et al. , 2001; Ohrr et 
al., 2005) demonstrated the efficacy rate of SA14-14-4 at> 95%. No large randomized 
trial was done to assess vaccine effectiveness; however, epidemiologic observational 
studies have revealed significant disease reduction in areas where the vaccine \Vas used 
(Zhou et al., 1999, Zhou et al., 2001 ). A cluster-randomized control trial by Liu et al. 
( 1997) has shown that SA 14-14-4 vaccine, relative to unvaccinated controls , was not 
associated with increased adverse events. In addition, the WHO 's Global Advisory 
Committee on Vaccine Safety has acknowledged the excellent safety and efficacy 
profile of the SA 14-14-4 vaccine. In over a million children followed up in safety 
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studies, approximately 5-10% present with transient fever, 1-3% present with local 
reactions, rash or irritability, and no reported cases of acute encephalitis or anaphylactic 
reactions (Halstead et al., 2004; Liu et al., 1997). The excellent safety profile was also 
supported by a post-marketing surveillance study of SA14-14-2 vaccine use in South 
Korea (World Health Organization, 2005). 
1.5.1.4 ChimeriVax-JE vaccine 
ChimeriVax-JE is a recent live attenuated recombinant JE vaccine produced by 
replacing the E and prM genes of YF-17D with JEV vaccine strain SA14-14-4 
(Chambers et al., 1999; Monath et al., 2012). The construct was created at the St Louis 
University Health Sciences Center and Acambis Inc., and was recently licensed for 
production by Sanofi Pasteur. ChimeriVax-JE is highly stable, and its infection and 
replication is restricted to mosquito vectors (Monath et al., 1999; Bhatt et al., 2000). Its 
safety, immunogenicity, and protective capacity have been demonstrated in preclinical 
studies (Monath et al., 1999). 
Two randomised control phase 3 clinical trials revealed noninferiority of a single dose 
of ChimeriVax-JE relative to 3 dose regimen of inactivated mouse brain-derived JE 
vaccine (Torresi et al., 2010). Long-term immunogenicity after single dose 
ChimeriVax-JE immunization was demonstrated in a study done by Nasveld et al. 
(2010), which showed seroprotection in 99% and 97% of participants at 1 and 6 months 
, 
post-immunization, respectively. Furthermore, 87% of the participants, who were 
seroprotected at month 6, were still be protected at month 60, while 96% of the 
participants, who received a booster dose at month 6, were still be protected at month 
60. 
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A series of clinical studies did not show serious or life-threathening adverse events that 
were related to ChimeriVax-JE immunization (Halstead and Thomas, 2011). The rate of 
mild adverse events in participants receiving Chimerivax-JE was lower relative to 
control YF-17D immunization (Monath et al., 2002; Monath et al., 2003 ), or similar 
compared to hepatitis A vaccination (Chokephaibulkit et al., 2010). A large post-
marketing surveillance study will be needed to fully assess the safety of ChimeriVax-JE 
vaccine. 
1.5.1.5 Alum-adjuvanted Vero cell culture-derived JE vaccine 
An inactivated Vero cell culture-derived JE vaccine ( ccJE) is manufactured by Intercell 
Biomedical (Livingston, United Kingdom) and is distributed by Novartis Vaccines 
(Fischer et al., 201 0; Schioler et al., 2007). The inactivated vaccine is adjuvanted with 
aluminium hydroxide (Alum), and is derived from the attenuated SA 14-14-2 JEV strain. 
Each 0.5-mL dose contains 6 µg of purified, inactivated JEV proteins, 0.1 % aluminum 
hydroxide, and does not contain gelatin stabilizers, antibiotics, or preservative 
thimerosal. Given that a correlate for protection was established for JE vaccines, no 
efficacy study was needed for licensure of Alum-adjuvanted ccJE vaccine. Instead, a 
noninferiority to JE-MB vaccine study was done, which revealed comparable 
immunogenicity (Fischer et al., 2010). Durability of protective neutralizing antibodies 
after a 2-dose regimen of Alum-adjuvanted ccJE vaccine was 95% at 6 months and 83% 
at 12 months (Schuller et al., 2008). In contrast, another study performed in a different 
vaccinee population, revealed a less durable protective neutralizing antibody response 
of 83% after 6 months, 58% after 1 year, and 48% after 2 years (Dubischar-Kastner et 
al., 2009). 
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A pooled analysis of seven studies on Alum-adjuvanted ccJE vaccine revealed a 
frequency of 3% of local adverse events, which was comparable to controls and better 
than for the JE- VAX® vaccine (14%) (Dubischar-Kastner et al., 2009). Mild systemic 
symptoms were comparable in Alum-adjuvanted ccJE, JE- VAX®, and placebo control 
groups (36% vs 40%, respectively). Only 1 % of subjects receiving Alum-adjuvanted 
ccJE vaccine presented with serious advents, while no serious anaphylactic reactions or 
neurologic adverse events were recorded (Dubischar-Kastner et al., 2009). However, 
given that only a small population has received the vaccine, a post-marketing 
surveillance study is underway to fully evaluate vaccine safety. 
1.5.2 Vaccine Adjuvants 
An adjuvant is a substance added to a vaccine formulation intended to enhance the 
quality of the immune response to the antigen. It is derived from the Latin word 
"adjuvare," meaning "to help". In the l 920's, the word adjuvant was first used by 
Gaston Ramon of the Institut Pasteur, upon observing that the immune response in 
horses given diphtheria toxin was enhanced when local inflammation is present at the 
inoculation site (Lombard and Moulin, 2007). An adjuvant, when added to a vaccine 
formulation, offers the following benefits: i.) increase potency of weak im1nunogen, ii.) 
improve immunogenicity of vaccines when given to aged or immunocompromised 
individuals, iii.) reduce dose of antigen used in vaccine formulation (antigen-sparing 
capacity), thereby lowering costs of vaccines, and iv.) enable various modes of vaccine 
delivery (Coffman et al., 2010). The latter is exemplified by mucosal vaccination using 
pertussis or cholera toxin adjuvants, which potentiates Th2 responses , and thereby 
increases neutralizing IgA and IgE antibody responses at mucosa! sites. 
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For the past -70 years, Alum has been the only adjuvant licensed for international use 
(Fig. 1.10). Multiple attempts were done to introduce novel adjuvants through the years, 
and yet failed due issues of safety and reactogenecity. However, this changed in recent 
years when empirical studies were replaced with in-depth investigations uncovering the 
molecular mechanisms of adjuvant mode of action, resulting in series of new generation 
adjuvants entering or about to enter the market (Coffman et al., 2010). A web-based 
vaccine adjuvant database has summarized a total of 104 adjuvants, both licensed and 
candidates included (Sayers et al., 2012). Adjuvants can be classified, based on their 
mode of action, into: i.) antigen delivery systems, ii.) immune potentiators, and iii.) 
combination systems (Table 1. 7). 
Europe MF59 Fluad® 
AS04 Fendrix ® 
Alum 
! I Cervarix® iSQ3 Prepandrix" 
f 
Alum 
2020 / 
l 
AS04 Cervarix® 
USA 
Figure 1.10 List of licensed adjuvants in Europe and USA. Alum is the only 
licensed adjuvant from 1926 until 1997. Since then, a series of adjuvants have been 
approved for use in Europe: MF59 in 1997 for seasonal influenza vaccine (Fluad), 
ASO4 in 2005 for hepatitis B vaccine (Fendrix) and human papilloma virus vaccine 
(Cervarix), and ASO3 in 2008 for pandemic flu vaccine (Prepandrix). In the United 
States, ASO4 was licensed in 2009 for Cervarix. MF59 (Novartis) and ASO3 
(GlaxoSmithKline): oil-in-water emulsion based on squalene, ASO4 
(GlaxoSmithKline): Monophosphoryl lipid A+ Alum. 
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Table 1.7 Classification of Adjuvants 
Type Mode of acUon 
1. Antigen delivery systems a.) Forming depots 
2. Immune potentiator 
b.) Antigen delivery to antigen-
presenting cell 
Act directly to activate immune 
system 
Examples 
Water-in-oil emulsion 
Liposomes 
ISCOMS 
TLR agonists 
MPL (TLR4) 
Flagellin (TLR5) 
lmiquinod (TLR7 and/or TLR8) 
CpG (TLR9) 
3. Combination systems Combination of antigen Aluminum salts 
delivery system and immune AS02 
potentiator AS04 
MPL: Monphosphoryl lipid A, AS02: oil-in-water emulsion containing MPL and QS-21, AS04: 
Alum and MPL, ISCOMS: immune stimulating complexes 
1.5.1.1 Alum adjuvant 
Alum (Aluminum salts) is the most commonly used vaccine adjuvant with a proven 
safety record (Exley et al., 201 0; Marrack et al., 2009). It has been extensively used in 
humans, and is included in vaccine formulations targeted against diphtheria, tetanus, 
pertussis, hepatitis A and hepatitis B. The mechanism of action of Alum was originally 
believed mainly through depot formation at the injection site, that facilitates efficient 
antigen uptake and presentation. However, recent studies have documented alternative 
mechanisms, mainly through enhanced immune stimulation, and involving i.) NRLP3 
inflammasome, ii.) lipid sorting, and iii.) extracellular signal-regulated kinase (ERK). 
An in vitro study has demonstrated the ability of Alum to stimulate caspase-1 and 
produce the inflammatory cytokines, IL-1 ~ and IL-18. The activation of caspase-1 by 
alum is mediated through the NRLP3 inflammasome (Eisenbarth et al., 2008; Hornung 
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et al., 2008; Li et al., 2007). The role of NRLP3 inflammasome was confirmed with the 
use of NALP3 _1_ or caspase-1-1- mice, which were unable to mount a substantial hum oral 
immune response after alum-adjuvanted immunization. Alum is also able to bind to 
sphingomyelin and cholesterol on dendritic cell surface membranes. The binding results 
in lipid sorting, such as clustering of immunorecpetor tyrosine-based activation motif-
containing receptors. Lipid sorting subsequently activates intracellular transduction 
pathways, mediated through Syk and phosphoinositide 3-kinase (Flach et al., 2011 ). 
Lastly, Alum is identified to interact with another kinase, ERK, which stimulates 
abortive phagocytosis in dendritic cells, and thereby facilitating the uptake of a specific 
antigen (Flach et al., 2011) 
Two main disadvantages have been associated with Alum. One is the recorded 
frequency of adverse side effects including injection site pain and inflammation, 
lymphadenopathy, and eosinophilia (Goto et al., 1993; Goto et al., 1997), and, in some 
cases, its association with a chronic inflammatory disease known as macrophagic 
myofascitis (Gherardi et al., 2001; Gherardi and Authier, 2003). Another limitation is 
the limited efficacy of Alum to enhance immune responses to a specified antigen 
(Doherty et al., 2006), for instance, its failure to augment cell-mediated im1nune 
responses and failure to provide durable memory B cell responses (Kool et al., 2011, 
Exley et al., 201 O; Marrack et al., 2009). 
1.5.1.2 Advax adjuvant 
Advax is a promising adjuvant that has been shown to enhance the protective value of 
vaccines targeted against influenza virus, human immunodeficiency virus, African 
Horse Sickness virus, and Burkholder fa mallei (Cristillo et al., 2011; Cooper and 
49 
Petrovsky, 2011; Eckersley et al., 2011; Layton et al., 2011; Lo bigs et al. , 2010). The 
delta inulin polysaccharide particle Advax is a strong candidate as an ideal adjuvant: it 
is safe, non-reactogenic, tolerable, immunogenic when combined with an antigen, and 
significantly antigen-sparing (Cooper and Petrovsky, 2011; Honda-Okubo et al., 2012). 
Recently, it has been shown that co-administration of Advax with inactivated ccJE 
dramatically improved the immunogenicity of the vaccine (Lobigs et al., 2010). This 
was reflected by solid neutralizing titres, which were known to be protective against 
JEV infection or heterologous challenges with MVEV or WNV. 
The simple inert polysaccharide composition of Advax adjuvant also imparts it an 
advantage as a safe formulation (Cooper and Petrovsky, 2011). Preclinical studies have 
revealed that, based on footpad swelling test, local injection site reactogenicity was very 
minimal when using Advax adjuvant relative to recently licensed adjuvants in the 
market (Honda-Okubo et al., 2012). The mechanism of action of Advax adjuvant is not 
yet completely understood. It is known to stimulate a balanced Th 1 and Th2 responses, 
and is associated with robust and durable antibody and T cell responses (Honda-Okubo 
et al., 2012). It is thought that Advax adjuvant does not work through enhanced 
activation of innate immune inflammation observed in Toll-like receptor agonists, nor 
does it have direct action on T cell activation. Advax adjuvant is known to bind to 
undefined receptors in mononuclear cells, with a consequent upregulation of co-
stimulatory molecules (CDl le, CD83, CD86, MHC-II) required for efficient antigen 
presentation (Cooper and Petrovsky, 2006; Honda-Okubo et al., 2012). It is then 
c_urrently hypothesized that Advax adjuvant works through enhancing early antigen 
presentation, and thereby boosting adaptive immune responses. 
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Aims of the study: 
The immunological correlates of recovery from JEV infection remains poorly defined. 
It is the aim of this study to establish the role of adaptive immunity in host recovery in 
mouse models of primary JEV infection. Furthermore, it is aimed to use these insights 
to establish the immunological mechanism of protection of candidate JE vaccines. 
Objectives: 
1. To establish a pathogenesis model of JEV infection that mimics natural infection 
route and dose in humans. 
2. To determine the role of humoral immunity in the pathogenesis of Japanese 
encephalitis. 
3. To determine the role of CD4+ and CD8+ T cell populations in the pathogenesis 
of Japanese encephalitis. 
4. To determine the role of effector mechanisms of cytotoxicity in the pathogenesis 
of Japanese encephalitis. 
5. To highlight the commonalities with and differences from WNV or MVEV in 
the role of adaptive immune pathways in recovery from JEV infection. 
6. To determine the role of the chemokine, CCR5, in the pathogenesis of Japanese 
encephalitis. 
7. To determine the impact of adaptive immune pathways in vaccine-mediated 
protection, and establish the mechanism of protection of a new generation JE 
vaccine. 
Hypotheses: 
In munne models of Japanese encephalitis, effectors of adaptive immunity play an 
important role in recovery from primary infection. Likewise, all components of the 
adaptive immune pathways are crucial for protection provided by JE vaccines. 
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Chapter 2 
Materials and Methods 
2.1 Viruses and cells 
Cell lines were originally obtained from the American Type Culture Collection 
(ATCC). Vero cells (African green monkey kidney) and YAC-1 cells (Moloney 
leukemia virus-induced T cell lymphoma) were grown at 3 7°C with 5% CO2 
atmosphere in Eagle's minimal essential medium plus nonessential amino acids (MEM) 
(Invitrogen) supplemented with 5% fetal bovine serum (FBS). Working stocks of JEV 
(strain Nakayama) were infected Vero cell culture supematants (2xl08 PFU/ml) stored 
in single-use aliquots at -70°C. Other previously prepared viruses (Table 2.1) stored in 
single-use aliquots at -70°C included MVEV (strain MVE-1-51 ), WNV strain Kunjin 
(WNVKUN), WNV strain New York 1999 (WNVNY99), ChimeriVax-JE, yellow fever 
virus (YFV), dengue virus type 2 strain PUO (DENV-2), vaccinia virus Western 
Reserve strain (V ACVWR). 
Table 2.1 List of viruses used in the study 
Virus Stock titrea Preparation 
JEV 2x108 PFU/ml Vero cell culture supernatant 
MVEV 2x109 PFU/ml 10% suckling mouse brain homogenateb 
WNVKUN 1x109 PFU/ml 10% suckling mouse brain homogenateb 
WNVNY99 1x108 PFU/ml C6/36 cell culture supernatant 
ChimeriVax-J E 1x107 PFU/ml Vero cell culture supernatant 
DENV-2 5x106 PFU/ml C6/36 cell culture supernatant 
YFV 1x107 PFU/ml C6/36 cell culture supernatant 
VACVwR 1x107 PFU/ml Infected CV1 cell lysate 
a Stocks stored in single use aliquots at -70 °C. 
b-Homogenates in Hanks' balanced salt solution (HBSS) containing 20 mM HEPES buffer (pH 
8.0) and 0.2% bovine serum albumin (HBSS-BSA) 
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2.2 Plaque Assay 
Titration of JEV was by plaque formation on Vero cells monolayers used at 80% 
confluence in six-well tissue culture plates (Nunc). Samples from infected cell culture 
supematants, serum, or tissue homogenates were serially diluted in ten-fold dilution 
steps in HBSS-BSA on ice, and 100 µl of diluted samples was inoculated on Vero cell 
monolayers. For virus adsorption, plates were incubated for 1 h at 37°C in an 
atmosphere of 5% CO2, with gentle shaking every 15 minutes. Four ml of agar overlay 
medium containing 1 % M 199 medium and Bacto-agar (Difeo, Detroit, Mich.), 
supplemented with 10 mM L-glutamine, 2% FCS, and 1 00U of antibiotics [penicillin 
(30 µg/ml; Sigma, St. Louis, Mo.), streptomycin sulfate (50 µg/ml; Sigma), and 
neomycin sulfate (50 µg/ml; Sigma)] was added to each well. Following incubation for 
72 to 96 h at 37°C, 1 ml of 0.03% neutral red (BDH Chemicals, Poole, England) in 
HBSS were added to stain the monolayers. After 16 hours incubation at 3 7°C, the stain 
and agar overlay were removed, and plaques were counted to quantify viral titer 
expressed in PFU (plaque forming unit). 
2.3 Mice 
C57Bl/6 (B/6), C57Bl/10 (B/10), CBA, Balb/c, 129xl /SvJAPB (129), B6.129P2/J 
(CCR5+1+) and various knockout mice strains ( summarized in Table 2.1) were bred 
under specific pathogen-free conditions, and supplied by the Animal Breeding Facility 
at the John Curtin School of Medical Research, The Australian National University 
(ANU), Canberra. Female mice were used in all experiments. All animal experiments 
, 
were conducted with approval from ANU Animal Ethics Committee. 
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Table 2.2 
Mice strain 
µMr-7-
MHCll-a~-t-
MHCll-a_1_ 
MHCll-~-t-
List of knockout mice strains 
Bri·ef description Reference 
B cell-deficient mice designed via targeted Kitamura et al., 1991 
disruption of a membrane exon of the 
immunoglobulin µ chain gene. 
MHC-I-deficient or CDS+ T cell-deficient Koller et al. , 1990 
mice designed via targeted disruption of 
the second exon of the ~2m gene. 
M HC-11-deficient or CD4 + T cell-deficient Madsen et al., 1999 
mice designed via targeted 80 kb deletion 
of the entire MHC-11 region . 
MHC-11-deficient or CD4+ T cell-deficient Cosgrove et al., 1991 
mice designed via targeted disruption of 
the H2-Aa gene. 
MHC-11-deficient or CD4+ T cell-deficient Grusby et al., 1991 
mice designed via targeted disruption of 
the H2-A~ gene. 
RAG-1 -t- Combined B and T cell-deficient mice 
designed via targeted disruption of the 
recombination activating gene-1 (RAG-1 ). 
Fas-deficient mice designed via targeted 
disruption of the Fas gene. 
Mombaerts et al., 1992 
Fas_1_ 
Perf1-
GzmA/B_1_ 
Adachi et al., 1995 
Kagi et al., 1994 
Simon et al. , 1997 
Perforin (Perf)-deficient mice designed via 
targeted disruption of perforin gene. 
Granzymes (Gzm) A and B-deficient mice 
pro?uced by crossing GzmA_,_ and GzmB-
mIce. 
Perforin (Perf), GzmA, and GzmB-
deficient mice produced by crossing Perf"'-
and GzmA/B_,_ mice. 
Eb net et al. , 1995 
Heusel et al., 1994 
Mullbacher et al., 1999 
F as-1-xGzmA/B-1- Fas, GzmA, and GzmB-deficient mice 
produced by crossing Fas_,_ and GzmA/B_,_ 
mice. 
Rode et al. , 2004 
IFN-f'- Interferon gamma (IFN-y)-deficient mice Dalton et al. , 1993 
designed via targeted disruption of the 
IFN-y gene. 
B6.129P2-CCR5_,_ Chemokine CC RS-deficient mice Kuziel et al., 2003 
designed via targeted disruption of the 
CCRS gene 
I FN-a-R-1- Interferon alpha receptor (IFN-a-R)- Muller et al. , 1994 
deficient mice designed via targeted 
disruption of the IFN-a-R gene. 
B6.MyO88_1_ Myeloid differentiation primary response Adachi et al., 1998 
gene 88 (MyD88)-deficient mice designed 
via targeted disruption of MyD88 gene 
Balb/c.MyO88_1_ MyD88-deficient mice on Balb/c Sutherland et al.,2011 
background produced by backcrossing 
MyDSS-1- mice 1 0 times on Balb/c wt mice. 
TNF-a-R-1- Tumor necrosis factor alpha receptor Korner et al. , 1993 
(TNF-a-R)-deficient mice designed via 
targeted disruption of TNF-a-R gene. 
All mice are in B6 background except otherwise indicated . 
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2.4 Mouse inoculation and tissue collection. 
For subcutaneous (sc) and intracranial (ic) inoculation, mice were anesthetized with 50 
µl of a 10% ketamine-xylazole solution in phosphate-buffered saline (PBS) by 
intramuscular injection. Mice were infected sc via the footpad or ic with a single 
injection of a defined dose of JEV in 20 µl HBSS-BSA. Mouse challenge experiments 
using intravenous (iv) inoculation were done via the lateral tail vein with a single 
injection of a defined dose of JEV in 100 µl HBSS-BSA. Mice were monitored twice 
daily. Daily changes in 5 parameters including hair coat, posture, breathing pattern, 
activity, and movement were recorded (scored) as normal (0), mild (1), moderate (2), or 
severe (3), and severely moribund mice ( clinical score > 7) and/or mice with hindlimb 
paralysis were euthanized by rapid cervical dislocation. For tissue processing, mice 
were euthanized at the time points indicated and a sterile midline vertical 
thoracoabdominal 1nc1s1on was made to expose the internal organs. After cardiac 
puncture for blood collection, animals were perfused with 10 ml sterile PBS. The brain 
and spinal cord were excised intact and collected for virus titration. For determination 
of virus titers, sample tissues were snap frozen on dry ice. One-half of the brain samples 
were placed in cell culture medium and homogenized for lymphocyte isolation. 
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2.5 Real-time RT-PCR. 
For determination of viral burden in mouse serum and spleen samples, total RNA in 50 
µl splenic homogenates ( 10% [ wt/vol]) and 50 µl serum was extracted using Trizol 
(Invitrogen) as described previously (Lee et al., 2004), and virion RNA content, 
expressed in genome equivalents, was determined by quantitative reverse transcription 
(RT)-PCR. For a genome copy standard, JEV RNA extracted from a Vero cell-grown 
virus stock and quantitated by spectrophotometry was used. RT was performed at 43 °C 
for 90 min in a 10 µl mixture containing 2 µl sample RNA, Expand reverse transcriptase 
(Roche), RN ase inhibitor (Invitrogen), 10 mM deoxynucleoside triphosphate, 10 pmol 
downstream primer (5'-TTGACCGTTGTTACTGCAAGGC-3'), 10 mM dithiothreitol 
(DTT), and the manufacturer's recommended buffer condition. Real-time PCR was 
performed using IQSybr qPCR mixture (Bio-Rad) and 0.2 nM downstream and 
upstream pnmers (5'-GCTGGATTCAACGAAAGCCACA-3 ' ) under cycling 
conditions of 95°C for 3 min for 1 cycle and 95°C for 30 sec, 63°C for 30 sec and 72°C 
for 60 sec for 40 cycles. Each sample was tested in duplicate, and genome copy 
numbers were determined by extrapolation from a standard curve generated within each 
experiment. The detection limit of the assay was 4xl 03 RNA copies/ml. 
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Figure 2.1 Real time RT-PCR for quantification of Japanese encephalitis 
viral RNA. Representative real time RT-PCR (A) standard curve and (B) plotted melt 
curve analysis performed for quantification of viral RNA in serum and tissues. 
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2.6 Histology and immunohistochemistry 
After dissection, brain tissue samples were placed in 10% neutral-buffered formalin 
fixative and stored at room temperature. For examination of basic cell morphology and 
neuronal myelin integrity, 6 µm sagittal brain sections were stained with hematoxylin & 
eosin and luxol fast blue, respectively. Immunohistochemistry was performed with an 
avidin-biotin-complex technique. Triplicate sagittal sections of brain samples were 
incubated overnight with anti-NS 1 monoclonal antibody, 404 (Clark et al., 2007), at 
4 °C to stain JEV antigen. After 10 min incubation at room temperature with 
biotinylated rabbit anti-rat lg (DAKO Corporation) as secondary antibody, specimens 
were incubated for 10 min at room-temperature with streptavidin-HRP complex 
(DAKO Corporation). Subsequently, a mixture of 3,3'-diaminobenzidine 
tetrahydrochloride-chromogen and substrate buffer (DAKO Corporation) was applied 
for 5 min at room temperature. Slides were examined under bright-field microscopy and 
brown staining of cells was indicative of positive immune reactivity. 
2.7 Lymphocyte isolation from the brain 
Homogenized brain samples were digested with 2 mg collagenase type I (Gibco-Life 
Technologies) in 5 ml MEM plus 5% FCS for 45 min at 3 7°C with intermittent shaking, 
then centrifuged at 400 g for 10 min. Pellets were resuspended in 2 ml 90% percoll in 
MEM plus 5% FCS and overlaid gently with 60%, 40% and 10% percoll (GE 
Healthcare) in MEM plus 5% FCS. The gradients were centrifuged at 800 g for 30 min 
at 25°C and lymphocytes collected from the 40 - 60% interface were subsequently 
, 
analysed by flow-cytometry. 
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2.8 Cell surface and intracellular cytokine staining. 
The surface marker staining employed in this thesis utilized the following reagents (all 
from Becton Dickinson except otherwise indicated): allophycocyanin (APC)-conjugated 
anti-CD8 antibody; phycoerythrin (PE)-conjugated anti-CD3, anti-CD25, anti-CD69, 
anti-NK.1.1, anti-F4/80 (Caltag) and anti-CCR5 antibodies; fluorescein isothiocyanate 
(FITC)-conjugated anti-CD4, anti-NK.1.1, anti-F4/80 (Serotec) and anti-CD19 
antibodies; and peridinin-chlorophyll-protein complex (PerCP)-conjugated anti-CD45 
and anti-CD3 antibody (BioLegend). 105 events were acquired for each sample on a 
four-color F ACSort flow-cytometer. Results were analyzed using Cell Quest Pro 
Software. For intracellular cytokine staining, 1x106 splenocytes were suspended in 100 
µl MEM with 5% FBS and stimulated for 16 h with 10-4 M H-2Db -binding 9-mer JEV 
NS4B protein-derived peptide, SA VWNSTT A, in the presence of 1 µ1/ml brefeldin A 
(eBioscience). An ectromelia virus (ECTV) H-2Kb-restricted peptide, TSYKFESV 
(Tscharke et al., 2005), was used at 10-4 M as a negative-control peptide. For 
stimulation of ex vivo splenocytes with JEV, splenocytes were infected at a multiplicity 
of infection (MOI) of 1 for 1 h at 3 7°C and washed twice with MEM containing 5% FBS 
before incubation for 16 h in MEM plus 5% FBS in the presence of brefeldin A. 
Enumeration of activated NK cells by intracellular staining for IFN-y expression was 
performed directly on ex vivo splenocytes. Cells were surface stained with anti-CD8-
APC or anti-NK.1.1-PE antibodies before paraformaldehyde fixation and 
permeabilization with saponin (Bio source) according to the supplier's instruction. Cells 
were then stained with anti-IFN-y-FITC (BioLegend) and/or anti-tumor necrosis factor 
alpha (TNF-a)-PE (Invitrogen), and washed twice with fluorescence-activated cell 
sorter (F ACS) washing buffer (2% FBS in PBS) before assessment by F ACS analysis. 
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Figure 2.4 Flow cytometry gating strategy. Representative dot plot for FACS 
analysis of intracellular cytokine staining of IFN-y and/or TNF-a in CD8+ T cells. 
Lymphocytes were isolated based on forward scatter and side scatter. Subsequently, 
CD8+ T cells were gated for analyzing intracellular expression of IFN-y, TNF-a, or 
both IFN-y and TNF -a. 
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2.9 In vivo depletion of CDS+ T cells 
CD8+ T cells in B/6 and 129 mice were depleted by ip injection with 0.5 mg of a rat 
anti-mouse CD8a monoclonal antibody (2.43, IgG2b, BioXcell). Control mice were 
injected with 0.5 mg of an isotype control antibody (MPC-11, IgG2b, BioXcell). The 
antibodies were diluted in 0.5 ml PBS and injected at 3, 2 and 1 days before and at 7 
days after virus infection. The efficiency of depletion was >98%, based on F ACS 
analysis of lymphocytes in blood on day 7 pi. 
2.10 In vivo depletion of NK1 .1 + cells 
NKl .1 + cells in B/6 mice were depleted by ip injection with 100 µg of a rat anti-mouse 
NKl.1 + monoclonal antibody (PK136, IgG2a, BioXcell). The antibodies were diluted in 
0.5 ml PBS and injected one day before, on the day, one day after virus infection, and 
-
every 4 days thereafter. Control mice were injected with corresponding volume of PBS. 
The efficiency of depletion was >98%, based on F ACS analysis of lymphocytes in 
blood on days 2 and days 7 pi. 
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Figure 2.4 In vivo depletion of cell popultions. Example dot plots 
representing in vivo depletion of (A) NK.l .1 + and (B) CD8+ T cells by ip injection of 
anti mouse NK.1.1 + (PK136) and anti-mouse CD8a (2.43) monoclonal antibody, 
respectively. Control dot plots represent untreated mouse. 
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2.11 T cell enrichment by nylon wool separation and 
complement-mediated lysis. 
For T-cell enrichment, l.2x108 splenocytes suspended in HESS plus 10% FCS were 
loaded onto I 0-ml nylon wool columns and incubated for 45 min at 3 7°C. Effluent from 
the columns was collected, and cells were pelleted by centrifugation at 400 x g for 5 
min. This procedure resulted in a population of 90% T cells with 5% B cell 
contamination. To further improve the purity of T cells eluted from nylon wool 
columns, the T-cell-enriched splenocyte population was incubated with anti-
CD45R/B220 supernatant (RA2-3Al) in minimal essential medium plus 5% FCS for 
30 min at 4 °C, followed by incubation with rabbit serum complement (Cedarlane 
Laboratories Ltd.) for 30 min at 37°C. Cells were washed twice with PBS before 
transfer into recipient mice. This procedure gave rise to a population of 95% T cells 
with I% B-cell contamination. 
2.12 Complement-mediated lysis of CD4+ and/or CD8+ T cells 
For CD4+ and CD8+ T cell depletion or for further enrichment of either CD4+ or CD8+ T 
cells, total splenocytes or B cell-depleted splenocytes were incubated with a 1 :3 dilution 
of either anti-CD4 (RLI 72) or anti-CD8 (3 lM) supernatant in MEM plus 5% FCS for 
30 min at 4 °C, followed by incubation with rabbit serum complement (Cedarlane 
Laboratories) for 30 min at 37°C. Cells were washed twice with PBS before transfer 
into recipient mice. The efficiency of depletion of CD4+ or CD8+ cells was >95% as 
assessed by FACS. 
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2.13 Positive selection of CD1 g+ B cells by magnetic bead 
separation 
Single-cell splenocyte suspensions were prepared by pressing the spleen tissue gently 
against a fine metal mesh tissue sieve. Erythrocyte lysis was by suspension of the 
splenocyte pellet in 4.5 ml distilled water followed immediately by the addition of 0.5 
ml of 1 Ox PBS. Lysed cells were discarded after centrifugation at 400 x g for 5 min. 
Cells were resuspended in 900 µJ of buffer (PBS containing 0.5% BSA and 2mM 
EDT A) per 108 cells. Then 100 µl of CD 19+ micro beads were added per 108 total cells. 
Following incubation for 15 minutes at 4°C, samples were washed with 1 ml of buffer 
per 107 cells, subjected to centrifugation at 400 x g for 5 minutes, and resuspended in 
500 µl buffer per 108 cells for magnetic separation. LD columns were placed in the 
MACS separator, and rinsed with 2 ml of buffer. The cell suspension was then loaded 
into the columns. Effluent from the columns, containing B-cell depleted cells, was 
collected, and cells were pelleted by centrifugation at 400 x g for 5 min. Efficiency of B 
cell depletion was >99% as assessed by FACS analysis 
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In vitro depletion of cell popultions. Example dot plots 
representing in vitro depletion of (A) CD4+ T and (B) CDS+ T cells by complement 
mediated lysis, and (C) B cells by magnetic beads separation. 
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2.14 Transfer experiments 
Eight-week-old B/6 mice were infected with 1x103 PFU of JEV, iv, and were sacrificed 
a week later for aseptic removal of spleens. Single-cell splenocyte suspensions were 
prepared by pressing the spleen tissue gently through a fine metal mesh tissue sieve. 
Erythrocyte lysis was by suspension of the splenocyte pellet in 4.5 ml distilled water 
followed immediately by the addition of 0.5 ml of 1 Ox PBS. Lysed cells were discarded 
after centrifugation at 400 g for 5 min. Cells were purified by antibody complement 
depletion and/or magnetic beads separation as described earlier. Splenocytes were 
resuspended in 100 µl PBS and injected through the lateral tail vein of 8-week-old B/6 
recipient mice. Recipient mice were challenged a day later with 1x103 PFU JEV via 
footpad injection. 
2.15 Serological tests 
For titration of JEV-specific antibody isotypes in mouse serum, ELISAs were 
performed with HRP-conjugated rabbit anti-mouse lg and the peroxidase substrate, 
2,29-azino-di(3-ethyl-benzthiasoline sulfonate). The JEV Nakayama strain was used for 
ELISA antigen production as described (Colombage et al. , 1998). For determination of 
ELISA end-point titres, absorbance cut-off values were established as the mean 
absorbance of eight negative-control wells containing sera of naive mice plus 3 SD. 
Absorbance values of test sera were considered positive if they were equal to or greater 
than the absorbance cut-off and end-point titres calculated as the reciprocal of the last 
dilution giving a positive absorbance value. 
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2.16 Neutralization assay 
Neutralization titers, measured in a 50% plaque reduction neutralisation test, were 
determined as previously described (Lobigs et al. , 2003c). Naive and JE-immune serum 
samples underwent complement-inactivation by heating at 56 °C for 30 minutes. Then, 
serum samples were serially diluted twofold with HBSS-BSA in 96-well trays, and 110 
µl of JEV at ".J 200 PFU was added. Plates were incubated at 3 7 °C for 1 h. Duplicate 
aliquots at 100 µl were assayed for infective virus by plaque formation on Vero cell 
monolayers in six-well plates as earlier described. JEV incubated with naive serum 
from the same mouse strain served as negative controls, and approximately yielded 50-
100 PFU per well. PRNT50 titres were calculated as the reciprocal of serum dilutions 
that resulted in a >50 % plaque number reduction. 
2.17 NK cell cytotoxic assay 
Mice were infected with 103 PFU of JEV, 1v, and sacrificed at days 4 and 7 post-
infection (pi). Spleens were collected and tested for NK cell cytotoxicity in a standard 
51 Cr-release assay (Mom burg et al., 2001 ), using uninfected Y AC-1 cells as targets. 
Splenocytes from uninfected mice were used as controls. P values were calculated from 
a four-point logarithmic regression curve, interpolated at an effector-to-target ( e/t) cell 
ratio of 30. 
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2.18 Preparation of L-929 conditioned medium 
A murine fibrosarcoma cell line, L-929, was used as a source of macrophage-colony 
stimulating factor (M-CSF) (Austin et al., 1971; Stanley, 1985). L-929 cells derived 
from ATCC (ATCC no. CCL-1) were grown in Dulbecco 's Modified Eagle Medium 
(DMEM, Gibco) supplemented with 10 mM 1-glutamine, 100 IU/ml penicillin, 100 
µg/ml streptomycin, and 10% FBS. After cells were grown to confluence, L-929 
conditioned medium was harvested, and subjected to centrifugation at 400 x g to 
remove cellular debris. Supematants were then collected and stored in 10 ml aliquots at 
-70°C. 
2.19 Preparation of bone marrow-derived macrophages 
B/6 or knock-out mice were euthanized by cervical dislocation. Aseptically, skin in the 
lower extremities was removed, and muscles dissected to exposed the femur, tibia, and 
fibula. Bones were excised through a cut in the proximal hip and distal ankle joints, and 
placed in dish containing complete Mixed Lymphocyte Culture media (MLC media 
supplemented with 1 % L-glutamine, 1 % NEAA, 1 % pyruvate, 50 µM 2-ME, 100 units 
PSN, and 10% FBS). Both ends of individual bones were severed to expose the cell-
filled marrow cavity. Using a 10-ml syringe, the marrow cavity was flushed with 
complete MLC media to expel cells. Collected cells were centrifuged for 5 minutes at 
400 x g, and resuspended in a complete MLC supplemented with 10% L-929 
supernatant. Bone marrow-derived cells were cultured at 1x10
6 
cells/well in 6-well 
plates, and incubated at 37°C in 5% CO2 atmosphere. Culture media were replaced with 
fresh complete MLC + 10% L-929 supernatant every 48 hours. Differentiation into 
mature macrophages was observed approximately on day 7 after start of culture. 
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2.20 JEV growth inhibition by IFN-a treatment 
Bone marrow-derived macrophages in 6-well plates were prepared as earlier described, 
and incubated with various concentrations of IFN-a (PBL Interferon Source) (250, 100, 
10, 1, and 0.1 Units) for 16 hours. Following washing with complete MLC media plus 
5% FBS, cells were incubated with 100 µl of JEV at MOI of 1, for 1 hr at 37°C, with 
intermittent gentle shaking. Cells were washed twice, and cultured with complete MLC 
media plus 10% L-929 supernatant for 48 hrs. Culture supernatant (100 µl) were 
collected at 12, 16, 24, and 48 hrs pi, and inhibition of virus growth by IFN-a was 
determined by plaque titration on Vero cell monolayers. 
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2.21 Interferon assay 
Determination of IFN-a levels in infected serum or tissue culture supematants were 
performed as instructed in the VeriKine™ mouse IFN-a ELISA kit. First, an IFN-a 
standard stock (10,000 pg/ml) was serially diluted in twofold dilution steps 
(concentrations from 400 pg/ml to 12.4 mg/ml). Samples (100 µl) and IFN-a standards 
were added into pre-coated microplate strips . Following addition of 50 µl of diluted 
antibody solution to each well, plates containing the strips were covered with plastic 
sealers, and incubated for 1 hr at 25°C with shaking at 450 rpm, and for 20 hrs at 4°C 
without shaking. Plate content was discarded, and plates were washed 4 times with 
diluted wash buffer solution. Following addition of 100 µl of diluted HRP solution to 
each well, plates were covered with plastic sealers and incubated for 2 hrs at 25°C with 
shaking at 450 rpm. Plate content was discarded, and plates were washed 4 times with 
diluted wash buffer solution. Substrate (100 µl) was then added to wells, and plates 
incubated unsealed for 15 minutes at 25°C in the dark and without shaking. Finally, 100 
µl of stop solution were added into the wells, and within 5 minutes absorbance at 450 
nm was determined spectrophotometrically. 
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2.22 Allelic discrimination by Amplifluor SNPs genotyping 
The genotyping team of the Australian Phenomics Facility (APP), headed by Dr 
Belinda Whittle, performed the allelic discrimination by Amplifuor SNPs genotyping. 
An amplification cocktail was prepared, with each 10 µl reaction volume containing 
3.15 µl distilled H20, 0.5 µl 20x amplifluor SNP FAM primer (Millipore), 0.5 µl 20x 
amplifluor SNP JOE primer (Millipore), 2 µl 20x SNP specific primer mix, 1 µl 1 Ox 
reaction mix S plus, 0.8 µl dNTPs (2.5 mM each), 0.05 µl Platinum hotstart Taq 
Polymerase (Invitrogen), and 2 µl DNA samples stored in Tris-Buffered H20. DNA 
from B/6, CBA and F 1 mice and distilled H20 were used as controls. Sample 
amplification cocktails (8 µl) were placed in 96-well plates. Plates were covered with 
optically clear strips, and run under cycling conditions of 95°C for 4 min for 1 cycle, 
95°C for 10 sec, 60°C for 20 sec, 72°C for 40 sec for 34 cycles, and 72°C for 3 min for 1 
cycle. Plates were read in a fluorescent plate reader using the following: excitation filter 
490/10 nm and emission filter 520/10 (gain 2200), and excitation filter 530/ 10 and 
emission filter 560/10 (gain 2400). Data was analysed using Fluostar optima software. 
72 
2.23 Nimblegen capture and re-sequencing 
Customized sequence capture by hybridization (Roche NimbleGen 2. lM capture array) 
was performed by the next generation sequencing team from the Australian Genomics 
Research Facility (AGRF, Melbourne), headed by Matthew Tinning. Ezra Lyon, and 
her team from Roche NimbleGen, designed the sequence capture probe set, and 
provided all the array reagents to AGRF. Re-sequencing of the captured samples was 
done using Illumina HiSeq sequencing system at AGRF. The bioinformatics team of 
AGRF performed the bioinformatic analysis. Alignment was performed with Illumina 
CASA VA vl .8.2 and aligner module ELAND v2 (Efficient Large-Scale Alignment of 
Nucleotide Databases). Illumina Exome script was applied to the primary alignment 
folder to generate CASA VA build folder and Exome coverage statistics. Functional 
annotation of genetic variants including single nucleotide variations, insertions, and 
deletions was done using the ANNOVAR software. A second bioinformatics analysis, 
using an in-house software, was done by the bioinformatics team of APF. 
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2.24 MHCII-Aa genotyping 
The genotyping team of APF, headed by Dr Belinda Whittle, performed the MHCII-Aa 
genotyping by PCR. Briefly, samples were prepared, with each 10 µl reaction volume 
contains 2.6 µl distilled H20, 0.4 µl of 10 µM MCHII-Aa wt reverse primer (5'-
GGTGTGAGCACGTACCATTG-3'), 0.2 µl of 10 µM MCHII-Aa common forward 
primer (5'-TGGAGACATTGGCCAGTACA-3'), 0.8 µl of 10 µM neomycin common 
primer (5'-GGATGATCTGGACGAAGAGC-3'), 5 µl 2x Mix (Qiagen Multiplex PCR 
kit), and 1 µl DNA sample. DNA samples from B/6 wt, Fl, and MCHII-Aa_1_ mice were 
used as controls. Samples were rin under cycling conditions 95°C for 4 min for 1 cycle, 
95°C for 15 sec, 60°C for 20 sec, 72°C for 30 sec for 35 cycles, and 72°C for 2 min for 1 
cycle. Following amplification, samples were added with 30 µl of loading buffer, were 
loaded into 1. 5 % agarose gel stained with gel red. The gel was electrophoresed for 10 
minutes at 350 volts. 
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2.25 ChimeriVax-JE immunization 
For challenge experiments, groups of 8-week-old B/6 or knockout mice were 
immunized sc with one dose of lx105 PFU of ChimeriVax-JE. A month after 
immunization, mice were inoculated, via the fp, with lx103 PFU of JEV. Mortality was 
recorded after a 28-day-observation period. For splenocyte transfer experiment, 6-week-
old donor IFN-a-R_;_ mice were immunized sc with lx105 PFU ChimeriVax-JE, and 
were sacrificed a month later for aseptic removal of spleens and blood extraction. 
Serum samples were isolated after centrifugation for 10 min at 10,000 rpm, heat 
inactivated for 30 min at 56°C, and stored at -70°C. Single-cell splenocyte suspensions 
were prepared, and T cells were enriched by nylon wool separation and complement-
mediated lysis of B cells as earlier described. Groups of ten-week-old IFN-a-R_
1
_ mice 
groups received either total splenocytes, T cells, immune serum, or immune serum plus 
T cells, and were challenged a day after splenocyte transfer with lx10
2 PFU MVEV via 
fp injection. Mortality was recorded in recipient mice after a 28-day-observation period 
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2.26 Inactivated Vero-cell culture derived-JE immunization 
Jespect (inactivated JEV SA14-14-2 strain) was obtained from CSL Ltd, Australia, and 
was diluted in PBS admixed with 0.1 % aluminum hydroxide. A formalin-inactivated 
Vero-cell culture-derived JE (Nakayama strain) vaccine was obtained from Kitasato 
Institute, Japan (Torinawa and Kamiya, 2008). A low or high dose ccJE vaccine (0.5 µg 
and 0.05 µg, respectively) was diluted in PBS alone or admixed with 1 µg of Advax. 
B/6 wt or knockout mice were immunized sc with various vaccine formulations, at two 
weeks apart, and challenged, one month after complete of the vaccination schedule, via 
the fp with lxl03 PFU of JEV or sc with lxl03 WNVNY99 . Mortality was recorded after 
a 28-day-observation period. For splenocyte transfer experiments, B/6 or ~2m_
1
_ donor 
mice were immunized twice with Advax-adjuvanted ccJE (0.5 µg), given 2 weeks apart. 
Splenocytes were isolated from donor mice one month, three months, or 6 months after 
completion of vaccine regimen. B cells were purified by complement-mediated lysis of 
CD4+ and CDS+ T cells, while CD4+ T cells were purified via magnetic separation of B 
cells plus complement-mediated lysis of CDS+ T cells. Recipients mice were challenge 
with a defined dose of JEV, WNVNY99 or MVEV, one day after splenocyte transfer. 
2.27 Statistical analyses 
Mortality data were plotted into Kaplan-Meier curves and assessed by the log-rank test 
for significance. The Mann-Whitney test was applied to assess differences in data 
gathered between two experimental groups. A P value of <0.05 was considered as 
significant. 
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Chapter 3 
Pivotal role of antibody and subsidiary contribution of 
CDS+ T cell to recovery from infection in a murine 
model of Japanese encephalitis 
The findings in this Chapter has been published: 
Larena, M., Regner, M., Lee, E., & Lobigs, M. (2011 ). Pivotal role of antibody and 
subsidiary contribution of CDS+ T cells to recovery from infection in a murine model of 
Japanese encephalitis. J. Viral 85(11 ):5446-55. 
3.1 Introduction 
Japanese encephalitis virus (JEV) is a mosquito-borne flavivirus belonging to the JEV 
serocomplex, which also includes the closely related Murray Valley encephalitis 
(MVEV) and West Nile viruses (WNV). In terms of incidence and severity of disease in 
humans, JEV is the most important member of this serocomplex. It is the leading cause 
of viral encephalitis in Asia, accounting for 35,000-50,000 cases per year and an 
estimated 10,000 deaths, with long-term neurologic sequelae in about one-half of the 
survivors (Solomon, 2004 ). In the past decades, there has been an expansion of the 
geographic distribution of the virus in Asia and emergence of virus transmission and 
human cases of encephalitis in Pakistan, the eastern Indonesian archipelago, New 
Guinea and northern Australia (reviewed in (Mackenzie et al., 2004)). Vaccination is 
the main measure for protection against Japanese encephalitis (reviewed in reference 
(Beasley et al., 2008)), but due to expense and logistics is not available to a large 
population in Asia that should be immunised. 
The majority of human infections with JEV are subclinical, with the ratio of apparent to 
inapparent infections estimated to range from I :25 to 1: I 000 (Solomon, 2004 ). Host 
factors, rather than variation in viral virulence, are thought to dominantly determine 
outcome of infection in terms of disease severity (reviewed in reference (Halstead and 
Jacobson, 2003)). Of these factors , an understanding of the immunological responses 
that lead to recovery from JEV infection is important in the design of rational 
approaches to new treatments and vaccines . 
However, insight into the immunological correlates of recovery from JE\t' infection is 
incomplete (reviewed in reference (Mullbacher et al., 2003)). Among the innate 
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immune pathways, an essential role of type I interferons (IFN) in recovery is illustrated 
by the uncontrolled growth of the virus in mice lacking a functional IFN-a receptor (Lee 
and Lobigs, 2002). Similarly, the importance of a vigorous humoral immune response 
in ameliorating or preventing illness has been documented in human cases of Japanese 
encephalitis (Burke et al., l 985a; McCallum et al., 1991; Libraty et al., 2002) and in 
animal models by administration of antibody prior or subsequent to infection with JEV 
(Goncalvez et al., 2008; Gupta et al., 2003; Kimura-Kuroda et al., 1988; Zhang et al., 
1989). 
In contrast, the relative contribution of the cellular immune responses to recovery from 
JEV infection remains unclear. A limited number of studies in mice suggest, for 
instance, a protective value of JEV-immune CD4+ T cells by a mechanism involving 
enhanced antibody production (Biswas et al., 2009) and a possi_ble role of CD8+ T cells 
in virus clearance (Murali-Krishna et al., 1996), although the latter study involved co-
injection of a large number of splenocytes with virus into the brain and required co-
transfer of CD4 + T cells. Thus, insight into the immunobiology of JEV is lagging in 
comparison to the significantly more detailed understanding of the role of innate and 
adaptive immune responses in recovery from infection with the related WNV, 
predominantly derived from studies on virulent lineage I North-American isolates in 
mice deficient in defined immune effector functions (reviewed in reference (Klein and 
Diamond, 2008)). 
This raises the question of generality of immunological correlates identified for WNV 
as determinants of disease outcome for JEV and other viruses of medical importance 
belonging to the JEV serocomplex (Mullbacher et al. , 2004). For instance, the 
contribution of CD8+ T cells to recovery from flaviviral infection is variable and can 
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range from protective to immunopathological outcomes (Licon Luna et al., 2002; Wang 
et al., 2003; Shrestha and Diamond, 2004). To begin to answer this question, I have 
established a pathogenesis model in adult C57Bl/6 (B/6) mice for Japanese encephalitis 
involving conditions that mimic natural infection route and dose, and report both 
commonality and differences with WNV in the role of adaptive immune pathways in 
recovery from JEV infection. 
80 
3.2 Results 
3.2.1 Mouse model of Japanese encephalitis by subcutaneous infection 
of adult B/6 mice with a low-dose virus inoculum. To establish a mouse model 
for Japanese encephalitis which resembles the natural infection route and virus dose and 
which allows investigation of the immunological correlates for recovery from infection, 
the pathogenesis of the prototype (Nakayama) strain in adult (8-week-old) B/6 mice was 
first characterised. After a low-dose sc challenge with 103 PFU of JEV, most mice 
presented with clinical signs of infection starting at day 10 pi, which included 
progressive generalized paresis, piloerection and rigidity. Severe neurological 
impairment demonstrated by ataxia, postural imbalance and generalized tonic-clonic 
seizures were evident later in the course of infection, invariably leading to fatality 
within 24 - 3 6 hrs after disease onset. A small number of mice presented with unilateral 
hind limb paralysis without central manifestations. A dose-insensitive survival curve 
was observed similar to previous findings with WNV and MVEV (Wang et al., 2003; 
Diamond et al., 2003a; Licon Luna et al., 2002) thus, over a dose range of 10 - 105 PFU 
the mortality rate was comparable (60 - 67%; Table 1). The mean survival time (MST) 
of animals that succumbed to infection was 12 - 13 days, except for the 10
5 PFU dose 
group, where a dual pattern of early (8 days pi) and late ( 11 days pi) mortality was 
observed, overall resulting in a shorter MST. Rapid and uniform mortality was seen 
when mice were infected with 10 7 PFU (MST = 6.0 days). All surviving mice infected 
by the sc route, even those infected with 10 PFU, seroconverted and showed high JEV-
specific antibody ELISA endpoint titers (>3 .5 log). 
When mice were infected via the ic route, the mortality rate and average time to death 
were dose dependent (Table 1 ). Virus doses of 10 and 100 PFU gave a 100% mortality 
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rate (MST = 8.0 and 6.4 days, respectively), while 1 PFU gave an 80% mortality rate 
(MST = 10.3 days) and 0.1 PFU did not result in disease. These data suggest that, in 
contrast to peripheral infections, the quantity of virus directly entering the brain serves 
as an accurate predictor of disease outcome. Consistent with the high lethality of JEV 
infection of the central nervous system (CNS) (a 50% lethal dose of <1 PFU given ic), 
partial seroconversion was found in the 0.1-PFU dose group. 
Viral burdens in serum, spleen, spinal cord, and brain samples were determined in order 
to elucidate the kinetics of growth of JEV in adult B/6 mice (Fig. 1 ). Virus was 
undetectable by plaque assay in both serum and spleen samples across all time points. A 
more sensitive assay utilizing real-time RT-PCR detected low levels of JEV RNA in 
serum and spleen samples (Fig. 2). Peak viremia occurred on day 2 pi with a geometric 
mean titer (GMT) of 9 x 104 RNA copies/ml of serum, wher~as splenic viral burdens 
peaked at day 4 p.i. with a GMT of 3 x 105 RNA copies/g of tissue. Virus invasion of 
the brain was first apparent on day 6 in only 3 out of 9 mice (Fig. 1 ). This increased to 
55% of the brain samples showing virus infection at day 8 pi (GMT= 1 x 104 PFU) and 
60% of the virus-positive brains at day 10 pi (GMT= 4 x 104 PFU). Viral dissemination 
to the spinal cord occurred later in the course of infection and was first detected on day 
8 pi in 33% of the samples (GMT = 1 x 103 PFU), increasing to 40% of the samples 
collected on day 10 p.i. (GMT= 2 x 103 PFU). Accordingly, viral entry into the CNS 
commenced in the brain, from where the virus spread centripetally to the spinal cord. 
Sections of brain were examined for histopathological changes at day 10 pi with JEV. 
Hallmarks of acute viral encephalitis, including microglial nodules surrounding 
degenerating neurons (Fig. 3A) and perivascular leukocytic infiltration (Fig. 3B) 
appeared widespread in focal regions of the brain. Meningeal inflammation 
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characterized by mononuclear infiltration into the leptomeninges was also seen (Fig. 
3C). There was no evidence of demyelination as indicated by intact myelinated axonal 
networks after luxol fast blue staining (Fig. 3D). Immunohistochemical staining 
utilizing an anti-flavivirus NS 1 antibody was employed to identify specific sites of 
neuronal lesions within the brain parenchyma. JEV infected neurons were found in 
multiple loci, predominantly localized in the following areas: cerebral cortex, 
hippocampus, thalamus, brainstem and cerebellum (Fig. 3E). The pathological lesions 
observed served as a clinical correlate of disease. 
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Table 3.1 Effect of JEV dose on mortality and survival time of 8/6 mice 
Challenge route and Mortality (No. of MST (days) % Seroconversion of 
dosea deaths/total) ±SD surviving miceb 
Subcutaneous 
10 PFU 63% (5/8) 11.8 ± 1.1 100 
102 PFU 67% (10/15) 12.8 ± 2.5 100 
103 PFU 63% (12/19) 13.3±1.7 100 
105 PFU 60% (3/5) 9.7 ± 1.5 100 
107 PFU 100% (5/5) 6.0 ± 0.7 
lntracranial 
0.1 PFU 0% (0/5) 60 
1 PFU 80% (4/5) 10.3 ± 1.0 100 
10 PFU 100% (5/5) 8.0 ± 1.4 
102 PFU 100% (5/5) 6.4 ± 0.5 
a Eight-week-old 8/6 mice were infected with various doses of JEV via the sc or ic routes ; virus 
dose in 20 µI HBSS/BSA. Surviving mice were monitored for 28 days. 
b Antibody against JEV in serum of surviving -mice was measured at 28 days pi by ELISA. 
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Figure 3.1 JEV burden in serum and tissues. JEV burden in serum (A), 
spleen (B), brain (C) and spinal cord (D)- of B/6 wt, µMT_;_ and MHCII-a~-/- mice after 
infection with 103 PFU of JEV, s.c. At the indicated time points, animals were 
sacrificed and virus content in serum and tissues measured by plaque titration. Each 
symbol represents an individual mouse and geometric mean titers (GMT) are indicated 
by horizontal bars. The lower limit of virus detection is indicated by the horizontal 
dotted line. 
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Figure 3.2 JEV RNA in serum and spleen. JEV RNA detected in serum and 
spleen samples of B/6 WT mice after sc infection with 10
3 PFU of JEV are shown. At 
the indicated time points, animals were sacrificed and the viral RNA contents of serum 
and spleen samples were measured by real-time RT-PCR. Each symbol represents an 
individual mouse, and GMTs are indicated by horizontal bars. 
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E Cortex Thalamus Brainstem Cerebellum 
Figure 3.3 Histology and immunohistochemistry. Brain sections of B/6 wt 
mice at 10 days pi with 103 PFU of JEV, s.c. Hematoxylin and eosin stain showing (A) 
microglial nodules (arrow) with neuronophagia (arrow head), (B) perivascular 
mononuclear infiltration (arrow) and (C) leukocytic infiltration of the meninges 
(arrows). (D) Intact myelinated axonal projections (arrows) of cerebellum after luxol 
fast blue staining. (E) Detection of JEV antigen by immunohistochemistry using anti-
NS 1 protein. Infected cells or injured neurons (arrows) in representative sections of 
-
cerebr~l cortex, brainstem, thalamus, hippocampus, and cerebellum. 
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3.2.2 Induction of humoral and cell-mediated immunity after JEV 
infection in B/6 mice. JEV-specific IgM appeared at day 4 pi and peaked at day 8 
pi with a mean titer of 1 :450 (Fig. 4A). Both anti-JEV lgG 1 and lgG2b appeared later in 
the course of infection and were first detectable at 8 day pi, attaining mean titers of 
1: 1400 and 1:275, respectively, at day 10 pi (Fig. 4B). Qualitative measurement of the 
antibody response revealed neutralizing activity as early as day 4 pi (PRNT 50 titer = 20 
in 2 of 4 mice), concomitant to the onset of detectable anti-JEV lgM antibody, and 
reached a mean PRNT50 titer of 330 (range: 80 - 640) at day 10 pi (Fig. 4C). 
B/6 mice produced a robust CD8+ T cell response following infection with 10
3 PFU 
JEV, i.v. The infection induced the characteristic up-regulation of expression of the 
early activation marker, CD69, which peaked on day 1 pi and that of the late activation 
marker, CD25, which peaked on day 4 pi (Fig. SA). Among ttie CD8+ T lymphocytes 
from JEV primed mice, ,_,53/o were stimulated to produce IFN-y with JEV NS4B 
peptide, SA VWNSTTA, also described by others to be recognized by H-2Db-restricted 
JEV-immune CD8+ T cells (Trobaugh et al. , 2010). Two other putative Db -binding JEV 
peptides ( on the basis of a predictive algorithm for MHC class I binding peptides using 
the SYFPEITHI database; (Rammensee et al., 1999) corresponding to amino acids 
TA WRNRELL in the E protein failed to stimulate IFN-y production, as did a Db -
restricted ectomelia virus (ECTV)-specific negative control peptide (Fig. SB). NS4B 
peptide stimulation of JEV-immune ex vivo splenocytes resulted in greater IFN-y 
expression than stimulation with live JEV, suggesting poor infection of splenocytes and 
suboptimal antigen presentation with the latter approach. 
The JEV-immune CD8+ T cell response in the spleen, defined here by the total number 
of NS4B peptide-reactive CD8+ lymphocytes, first appeared at day 4 pi, reached a peak 
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of -106 cells at day 7 pi, but markedly declined thereafter (Fig. 5C). The majority of 
these splenocytes were polyfunctional and expressed both IFN-y and TNF-a followed 
ex vivo stimulation with NS4B peptide, with peak numbers of 7 x 10
5 cells at day 7 pi. 
CD8+ T cell recruitment into the site of infection was measured by isolation of 
lymphocytes from JEV infected brains (Fig. 5D). CD8+ T cell infiltration was already 
apparent at day 4 pi, showing a 2-fold increase ( 1.2 x 104 cells) relative to baseline. On 
day 7 pi, corresponding to the peak of the primary JEV-specific CD8+ T cell response in 
spleen, CD8+ T cell numbers in JEV infected brains reached a plateau, which was 
maintained until day 10 pi (> 100-fold increase relative to baseline; P = 0.002). Ex vivo 
CD8+ T cells isolated from brain at day 7 pi secreted IFN-y both in the presence and 
absence of stimulation with NS4B peptide (Fig. 5E). This is in contrast to splenocytes 
harvested at day 7 pi, which required peptide stimulation for IFN-y production. 
Considering the presence of virus in the brain at this time point, the difference may 
reflect antigen presentation via JEV-infected mononuclear cells present in brain-derived 
cell preparations, resulting in CD8+ T cell activation and cytokine secretion in the 
absence of ex vivo peptide stimulation. Alternatively, brain-derived lymphocytes may 
show a greater background level of IFN-y secretion than those isolated from the spleen. 
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Figure 3.4 Antibody responses in 8/6 wt and MHCll-aB _,_ mice. Eight-
week-old B/6 wt and MHCII-a~-/- mice were infected withl0
3 PFU of JEV, s.c., and 
sera collected at the indicated time points. Anti-JEV IgM (A) and IgG (B) isotype 
antibody titers were determined by ELISA. Data presented are reciprocal mean endpoint 
titers representative of 4 mice per group with SD indicated by error bars. (C) 
Neutralizing antibody titers determined by plaque reduction neutralization assay. Data 
presented are mean PRNT5o titers representative of 4 - 7 mice per group and error bars 
indicate the SD. Asterisks denote significance of difference between samples from wt 
relative to l\1HCII-a~-/- mice(*= P <0.05; ** = P <0.01). 
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Figure 3.5 cos+ T cell response in B/6 wt mice infected with JEV. (A ) 
Eight-week-old B/6 mice were infected with 10
3 PFU of JEV, iv, or left uninfected. 
Spleens (n = 3/group) were collected at the indicated time points and splenocytes were 
stained for CD8 and lymphocyte activation markers, CD69 or CD25. Data presented are 
the percentage of CD8+ cells expressing the early activation marker, CD69, or the late 
activation marker, CD25. Error bars denote the SD and data are representative of 2 
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independent experiments. (B) Splenocytes harvested at 7 days pi, as above, were 
stimulated ex vivo with live JEV, Db-restricted JEV NS4B protein-, E protein- or NS 1 
protein-derived peptides, a Db-restricted ectomelia virus (ECTV) negative control 
peptide, or mock treated and IFN-g production in CD8+ T cells measured by flow-
cytometry. Means for 3 samples ± the SD are presented and data are representative of 2 
independent experiments. (C) Kinetics of JEV-immune CD8+ T cell activation 
measured after ex-vivo stimulation with Db-restricted JEV NS4B peptide. Data show 
the number of CD8+ T cells/spleen that express IFN-y, TNF-a, or both cytokines 
following stimulation. Means for 3 samples ± the SD are presented and data are 
representative of 2 independent experiments. (D) Kinetics of infiltration of CD8+ cells 
into the brain of 8-week-old B/6 wt mice infected with 10
3 PFU of JEV, sc. 
Lymphocytes were isolated from the brain of infected mice as described in Materials 
and Methods and stained for CD8 expression. Each symbol represents an individual 
mouse and horizontal lines indicate mean values for each time point. (E) JEV-immune 
CD8+ T cells in spleen and brain of B/6 wt mice infected with 10
3 PFU of JEV, s.c., at 7 
days pi were measured by IFN-g expression in CD8+ cells following ex vivo stimulation 
in the presence or absence of JEV NS4B peptide. Means for 6 ~-8 samples ± the SD are 
presented. Asterisks denotes significance(*= P <0.05; ** = P <0.01). 
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3.2.3 Antibody is essential for recovery from JEV infection. To assess the 
role of antibody in JEV pathogenesis, mortality and virus growth following infection 
with 103 PFU of JEV, sc, were assessed in µMT-/- mice, which are deficient in B cells 
and antibody production. The challenge was uniformly lethal and mortality occurred 
significantly earlier than was found in wt mice (MST = 11.1 and 12.1 days pi, 
respectively; P = 0.00 l; Fig. 3 .6). In contrast to wt mice, JEV infection produced high 
viremia in all µMT-/- mice on day 4 pi (GMT = 1.5 x 105 PFU/ml) and the viremia 
persisted at that level until the animals succumbed to infection (Fig. 3 .1 ). Virus was also 
detected in spleen of infected µMT- /- mice at 4 days pi and at later time points (Fig. 3.1 ). 
However, the viral load in spleen was mostly less than that in serum, making it unclear 
whether virus grew efficiently in that organ. For the same reason it is unclear, whether 
the viral titers detected in brains of all µMT-/- mice on day 4 pi were due to virus 
content in residual blood, although animals were perfused p~ior to organ collection. 
Viral load in brain increased 10- and 10,000-fold at 6 and 8 days pi, respectively, and 
the titers in µMT-/- mice exceeded those in wt mice by ~3 log and ~5 log on days 6 and 
8 pi (Fig. 3 .1 ). Viral dissemination into the spinal cord of µMT_;_ mice occurred earlier 
and was more widespread than in wt mice: virus was first detected on day 6 pi in 60% 
of mice (GMT = 3 x 104 PFU) and was present in spinal cords of all animals on day 8 pi 
with JEV titers exceeding those in wt mice by 4 log. Taken together, absence of 
antibody in µMT-/- mice leads to uncontrolled viremia, early neuroinvasion and 
widespread viral dissemination in the CNS, and a uniformly lethal outcome of infection 
with a shorter MST than in wt mice. 
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Figure 3.6 Susceptibility of 8/6 wt, µMT_,_ and MHCll-a~ _,_ mice to 
infection with JEV. Groups of 12-week-old mice were infected sc with 10
3 PFU of 
JEV. Morbidity and mortality were recorded daily and surviving mice were monitored 
for 28 days. Data was constructed from two independent experiments. Significance of 
difference in mortality between wt and knock-out mice was determined by using the 
log-rank test: * P = 0.028; *** P = 0.0002. 
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3.2.4 CD4+ T cell are instrumental for virus clearance but not for early 
virus-neutralizing antibodies. MHCII-a~-/- mice are deficient in CD4+ T cells 
which, in tum, are important in priming and memory formation of antiviral B and CD8+ 
T cell responses and the production of inflammatory cytokines (Zhu et al., 2010). All 
MHCII-a~-/- mice succumbed to JEV infection, in contrast to a mortality rate of 55% 
observed for a group of age-matched wt mice (P = 0.028; Fig. 3 .6). Interestingly, the 
MST of infected MHCII-a~-/- mice suggested a dual course of disease progression, 
where the MST of the majority of mice was similar to that of wt controls ( ~ 12.5 days 
pi), while 21 % of MHCII-a~-/- mice displayed a later average time to death ( ~20 days 
pi). Similar to wt mice, virus was not detectable in serum and spleen during the first 8 
days of infection and virus was found in brain in some mice at 6 and 8 days pi (Fig. 
3 .1 ). However, at 10 days pi, 3 out of 5 MHCII-a~-/- mice developed a moderate 
viremia and all animals showed virus in the brain with the GMT exceeding that in wt 
controls by 4 log. Virus dissemination into the spinal cord was also more prominent in 
MHCII-a~-/- than wt mice at 10 days pi (Fig. 3.1). 
The lack of CD4 + T cells did not prevent induction of a JEV-specific IgM response in 
infected MHCII-a~-/- mice, but markedly truncated this response (Fig. 4A). While 
peaking at day 8 pi in wt mice, JEV-specific IgM declined after day 6 pi in MHC-II-a~-
/- mice and was significantly lower on days 8 and 10 pi than in wt (P = 0.02). 
Immunoglobulin class-switching to IgG was significantly blunted in MHC-II-a~-/- mice 
with anti-JEV IgG 1 titers in wt mice exceeding those in the CD4+ T cell-deficient mice 
by ~ 10- and 20-fold on days 8 and 10 pi , respectively (Fig. 4B). IgG2b isotype 
antibodies against JEV first appeared at 10 days pi in wt mice but remained 
undetectable in MHCII-a~-/- mice (Fig. 4B). Importantly, the neutralising activity of the 
humoral immune response against JEV first detectable in both mouse strains at day 6 pi 
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only increased marginally on day 8 pi in infected MHCII-a~-/- mice and subsequently 
declined, while in wt mice neutralising antibody levels continued to increase. As a 
consequence, the PRNTso titer in JEV infected wt mice (mean = 330, range 80 - 640) 
significantly exceeded that in MHCII-a~-/- mice (mean= 40, range 20 - 80) at day 10 pi 
(P = 0.007; Fig. 4C). Accordingly, the deficient humoral immune response after day 6 
pi in MHCII-a~-/- mice most likely is the dominant factor contributing to the late 
viremia and high mortality in the JEV infected host lacking CD4 + T cell function. 
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3.2.5 Marginal contribution of CD8+ T cells to the control of JEV infection. 
To establish the role of CD8+ T cells in recovery from primary JEV infection, B/6 mice 
were depleted in vivo of CD8+ T cells and challenged with 10
3 PFU JEV, sc (Table 3 .2). 
Only a marginal, but statistically insignificant, increase in susceptibility to JEV of mice 
depleted of CD8+ T cells was seen compared to a group of B/6 mice treated with an 
isotype control antibody (84% and 67% mortality, P = 0.07). Similarly, the time to 
death was slightly earlier in CD8+ T cell-depleted mice than in the control group (P = 
0.12; Table 2). CD8+ T cell depletion did not allow the generation of detectable viremia 
during the course of JEV infection ( data not shown). However, CD8+ T cells 
contributed to a significant reduction in virus growth in the brain and spinal cord (Fig. 
3. 7). Thus, depletion of CD8+ T cells resulted in a ~ 100-fold increase in virus ti ters in 
both tissues on day 10 pi, relative to controls, accompanied by a greater number of 
spinal cord samples showing the presence of virus in treated ~elative to mock-treated 
animals. Thus, although CD8+ T cells did not provide a significant advantage in terms 
of survival following JEV infection, they demonstrated a beneficial role in controlling 
virus growth in the CNS, with the proviso that the latter may occur at the cost of 
increased immunopathology. 
The already high susceptibility of B/6 mice to JEV infection may have concealed a 
survival advantage mediated by CD8+ T cells in the depletion experiment. Therefore, 
the contribution of CD8+ T cells to recovery fro1n JEV infection was tested in the 129 
mouse strain, which shows a low mortality rate ( ~ 10%) following infection with 103 
PFU of JEV, sc. The depletion of CD8+ T cells had no impact on the survival rate of 
JEV infected 129 mice (Table 3.2). 
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Table 3.2 Effect of CDS+ T cell depletion on susceptibility to JEV 
infection in B/6 and 129 mice 
Mouse strain and treatment a 
C57Bl/6 
lsotype Control 
CD8+ T cell-depleted 
129x1 /SvJAPB 
lsotype Control 
CD8+ T cell depleted 
Mortality (No. of 
deaths/total) b MST (days)+ SD c 
67%(14/21) 13.0±1.7 
84% (16/19; P = 0.07) 12.1 ± 2.6 (P = 0.12) 
11 % (1 /9) 14 
0% (0/11; P = 0.26) 
a Eight-week-old mice were treated i.p. with 0.5 mg of CD8+ T cell-depleting or isotype control 
antibody in 500 µI PBS on days -1, 0, +1 and + 7 of sc challenge with 10
3 PFU of JEV. Surviving 
mice were monitored for 28 days. 
b Survival data were analysed for significance between the treated and corresponding control 
groups by the log-rank test. Data were constructed from two independent experiments. 
c Differences in mean survival times between treated and control groups were analysed for 
significance by the Mann-Whitney test. 
98 
A. 
7 
o E 
C) :::s 6 
....... 
"' Q) 
Q) "' 
'c. It- 5 
0 0 
0 -
< E 4 
z .. 
ex: 0 
C: 
~ I 3 
1 B/6 wt 
0 cos• T cell depleted 
I I 00 
-=:r~ 
I 0 
0 
C>-0 Cl 
.J "' 
2 •·----····-··-··---····-···-·-···-----·····-· 
~.s,._ 
1 
Ill 000 I 
Serum Spleen 
B. 
Q) 
::, 
"' 
"' ;; 
-... 
0 
C) 
...... 
:) 
LL 
C. 
10 
9 
8 
11 
7 
6 I 
---5 I I 
* 
0 
0 * 
0o0 
_A.,_ 000 
I 
I ~ 0 
~ 4 
C) 
0 
.J 
3 ···-····---··--········--····-·- ··--····----·· 
II 
2 I 0 
Ill 00 
Brain Spinal Cord 
Figure 3.7 In vivo depletion of CDS+ T cells increases viral burden in 
brain and spinal cord. Groups of CD8+ T cell-depleted and control antibody-treated 
8-week-old B/6 wt mice were infected sc with 10
3 PFU of JEV and sacrificed on day 10 
pi to determine the viral load in brain and spinal cord by plaque titration. Symbols 
represent individual mice and data was constructed from two independent experiments. 
Horizontal line denotes GMT. Asterisks denote significance(* = P <0.05). 
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3.2.6 The protective effect of JEV-immune T cells requires both the CD4+ 
and CDS+ subpopulations. Infection of B/6 mice with JEV elicits a vigorous 
cellular immune response, which is illustrated by the protective value of JEV-immune 
splenocyte transfer in recipient mice against JEV challenge (Table 3.3). Thus, total 
immune splenocytes and purified B cells protected all recipient mice against infection 
with 103 PFU JEV, sc, when transferred 1 day before challenge. However, transfer of 
purified JEV-immune CD4+ or CD8+ T cells did not provide a significant survival 
advantage to recipient mice challenged with JEV (Table 3.3). Interestingly, pooled 
transfer of both T cell subpopulations significantly reduced mortality in a group of 
recipient mice (P = 0.002; Table 3.3). These data yet again show the dominant 
protective role of the humoral immune response contrasting with an at best marginal 
contribution of CD8+ T cells in recovery from primary infection with JEV. 
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Table 3.3 Contribution of humoral and cellular immune responses to 
recovery from JEV infection 
Treatment a 
PBS control 
Na"fve splenocytes (1 x 107 cells) 
Immune splenocytes (1 x 107 cells) 
Immune B cells (5 x 106 cells) 
Immune T cells (5 x 106 cells) 
Immune CD4+ T cells (5 x 106 cells) 
Immune CDS+ T cells (5 x 106 cells) 
Mortality (No. of 
deaths/total) b 
70% (7/10) 
73% (22/30) 
0% (0/1 0; P = 0.0004) 
0% (0/1 0; P = 0.0004) 
29% (6/21; P = 0.0017) 
64% (9/14; P = 0.99) 
76% (16/21; P = 0.59) 
MST (days)± 
soc 
12.0 ± 2.0 
12.5 ± 2.0 
12.8±1.0 
12.1 ± 2.0 
12.0 ± 2.3 
a Eight-week-old donor B/6 mice were infected with 103 PFU of JEV, iv, or left uninfected and 
sacrificed 7 days later for splenocyte collection and purification of splenocyte subpopulations. 
Cells were transferred to 8-week-old B/6 mice and recipients infect~d a day later with 103 PFU 
of JEV, sc. Surviving mice were monitored for 28 days. 
b Data are representative of 2 or 3 independent experiments. Immune splenocyte treatment 
groups were compared to the na"fve splenocyte control group to test for statistical significance. 
c No significant difference was noted between immune splenocyte treatment and control groups. 
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3.2.7 Deficiencies in the cytolytic effector pathways of lymphocytes do 
not exacerbate the pathogenesis of JEV. CD8+ T cells exhibit direct antiviral 
activity by killing virus infected cells via two cytolytic effector mechanisms, the Fas-
mediated death pathway and the granule exocytosis pathway, involving the delivery of 
perforin and granzymes into the target cell. Having already demonstrated that neither in 
vivo depletion nor transfer of virus-immune CD8+ T cells significantly impacted on 
disease outcome, it is predicted that mice defective in Fas, perforin, or granzymes A and 
B would show comparable susceptibility to JEV as wt mice. This was confirmed in 
figure 3.8: neither mortality rate nor MST differed significantly between wt and Fas-1-, 
Perf1- or GzmAIB_1_ mice tested at 8 and 12 weeks of age. 
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Figure 3.8 Susceptibility of mice defective in cytolytic effector pathways 
to infection with JEV. Groups of 8-week-old (A) and 12-week-old (B) B/6 wt, Perf 
1
-, GzmAJB-1- and Fas_;_ mice were challenged sc with 103 PFU of JEV and monitored for 
28 days for mortality. Data was constructed from 3 independent experiments. 
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3.3 Discussion 
B/6 mice showed a partial susceptibility to s.c. infection via the footpad with the 
prototype strain of JEV and developed a lethal encephalitis in ~60% of animals over a 
wide dose range of 10 - 105 PFU. This lack of a dose response in mortality following 
virus challenge by an extraneural route is a hallmark of flavivirus infection (for 
instance, see references (Licon Luna et al., 2002; Diamond et al., 2003a)) and is 
thought to reflect, at least in part, the dose dependence of induction of the innate 
immune responses critical in early control of virus dissemination (Monath et al., 2003). 
Consistent with high-dose WNV and MVEV infections in B/6 mice (Licon Luna et al., 
2002; Wang et al., 2003), the sc injection of 107 PFU of JEV was uniformly lethal and 
the MST corresponded to that of groups of mice ic inoculated with 102 PFU of JEV. 
This finding and that of the presence of multiple loci of infection in the brain supports 
the hematogenous route as the principal pathway of JEV entry into the CNS and implies 
virus content in blood as a key determinant thereof. Vero cell-grown JEV was used 
exclusively in this investigation. Interestingly, studies with cell culture have suggested 
that flavivirus propagated in mosquito cells could differentially modulate innate 
immune responses from virus grown in mammalian cells (Arjona et al., 2007; Silva et 
al., 2007). However, this conclusion was not supported by pathogenesis studies with 
mice (Daffis et al., 2008; Lim et al., 2010). 
The humoral immune response was critically important for recovery of mice from 
extraneural challenge with JEV. Mice lacking B cells and the ability to produce 
antibody (µMT_;_ mice) developed a high viremia at day 4 pi, which persisted until all 
animals succumbed to infection; early entry of virus into the brain with widespread 
dissemination in the CNS were also found. Additionally, purified immune B cell 
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transfer fully protected recipient wt mice from JEV challenge. The appearance of 
viremia and splenic tissue viral titres at day 4 pi in µMT_;_ mice correlated with the time 
point when antibodies with neutralising activity became detectable in JEV infected wt 
mice. Antibodies elicited against flaviviruses clear virus by neutralization of infectivity, 
or indirectly by antibody-dependent cell-mediated cytotoxicity, Fc-y-receptor-mediated 
clearance or complement-mediated cytotoxicity (Pierson et al., 2008). Thus, in mice 
lacking the ability to clear virus by antibody, JEV and WNV (Chambers et al., 2008; 
Diamond et al., 2003a; Diamond et al., 2003b) produce a fulminating and lethal 
infection. 
T cell help was not required to mount an early IgM response against JEV; however, the 
response was truncated in MHCII-a~-/- relative to wt mice. As expected, IgG class-
switching first observed in wt mice at ~8 days pi was markedly blunted in the absence 
of CD4+ T cells. This dysfunctional antibody response largely explains the adverse 
outcome of JEV infection in MHCII-a~-/- mice, which was characterised by uniform 
mortality, elevated brain viral titres and viral dissemination into the spinal cord. 
Moreover, 60% of MHCII-a~-/- mice displayed detectable viremia late in the course of 
infection, when a significant disparity in neutralizing antibody titers in wt and MHCII-
a~-/- mice was found. Failure of effective virus clearance from extraneural tissues most 
likely accounted for CNS invasion in all infected MHCII-a~-/- mice and, as a 
consequence, a 100% mortality rate. Some JEV infected MHCII-a~-/- mice showed a 
markedly protracted time to death, which could either have been the result of a delayed 
'entry into the CNS following the late viremia associated with waning neutralising 
antibody, or reduced lymphocyte infiltration into the infected brain associated with 
reduced immunopathological manifestations. A study on the role of CD4+ T cells in 
WNV infection also found a truncation of IgM and blunting of IgG antibody responses 
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due to the absence of CD4+ T cells, as well as uniform mortality with prolonged 
survival of some mice (Sitati and Diamond, 2006). Accordingly, the protective role of 
CD4+ T cells by providing help for antibody responses is clearly apparent in both 
flavivirus models. However, a second critical function of CD4+ T cells required for a 
sustained CD8+ T cell response and, in turn, CD8+ T cell-mediated clearance of virus 
from the CNS documented for WNV (Sitati and Diamond, 2006) was not apparent in 
the mouse model for Japanese encephalitis, given the failure of CD8+ T cells to 
effectively clear JEV from the CNS and prevent a lethal disease outcome. 
A striking finding from this investigation was the lack of effect of CD8+ T cells on 
survival phenotype in the mouse model of Japanese encephalitis. I have confirmed that 
infection of B/6 mice with JEV elicited functional, virus-specific, CD8+ T cells, 
illustrated by production of IFN-y and TNF-a upon ex vivo stimulation of lymphocytes 
with a previously described H-2Db JEV NS4B peptide (Trobaugh et al., 2010). This 
response was comparable in magnitude to that elicited by WNV against the 
corresponding WNV NS4B peptide (Brien et al., 2007; Purtha et al., 2007) and 
followed the standard kinetics of induction of anti-flaviviral cytotoxic T cells with peak 
activity in the spleen at day 7 pi (Kesson et al, 1987; Purtha et al., 2007). It was also 
confirmed a high level of CD8+ T cell infiltration into the brain in response to JEV 
infection and showed activation and virus-specificity of lymphocytes isolated from the 
infected brain. Thus, given the effective induction and functionality of anti-JEV CD8+ T 
cells, it was surprising that transfer of this JEV-immune splenocyte population failed to 
vrovide protection against JEV in recipient mice. Similarly, in vivo depletion of >98% 
of CD8+ T cells in two mouse strains (B/6 and 129), which differed in susceptibility to 
JEV, did not markedly impact on mortality rate following JEV challenge. However, 
viral burden in the CNS was significantly higher following CD8+ T cell depletion than 
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1n control mice, showing in vzvo functionality of the response. It remains unclear, 
whether immunopathology associated with CD8+ T cell infiltration into the brain or an 
insufficient magnitude of the response, per se, explain why the viral load reduction in 
the CNS mediated by CD8+ T cells did not translate into a survival advantage. Finally, 
genetic deficiency in key molecules (Fas, perforin or granzymes A and B) of the two 
main CD8+ T cell cytolytic effector pathways did not alter susceptibility of B/6 mice to 
JEV. Collectively, these data suggest an at best marginal contribution of CD8+ T cells to 
recovery from infection with JEV. 
This and other investigations on the immunobiology of the encephalitic flaviviruses 
have uncovered a conflicting role of CD8+ T cells in recovery from infection. While 
essential for virus elimination from the CNS and survival in mouse models of West Nile 
encephalitis (Shrestha and Diamond, 2004; Shrestha et al., 2006a; Wang et al., 2003; 
Wang et al., 2004 ), I present in this chapter that the CD8+ T cell response did not 
markedly affect outcome of infection with JEV, whereas a disease-potentiating effect of 
cytotoxic T cells was documented in mice infected with MVEV (Licon Luna et al., 
2002). Notably, mice genetically deficient in the Fas- or perforin-dependent pathways 
of cytotoxicity showed greatly increased susceptibility to virulent lineage I WNV 
infection (Shresthaand Diamond, 2007), but did not differ from wt mice in susceptibility 
to infection with JEV (Fig. 8) or lineage II WNV strain, Saraf end (Wang et al., 2004 ), 
and were more resistant to infection with MVEV (Licon Luna et al., 2002). These 
findings highlight a difference in pathogenesis between closely related flaviviruses 
belonging to the JEV serocomplex, which most likely involves a difference in the 
capacity of the cellular immune response to resolve the virus infections in the CNS. It 
has been well documented that extraneural infection of adult mice with virulent lineage 
I WNV produces virus titers in brain of 103 - 105 PFU in the majority of animals 
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between days 6 and 10 pi and that CD8+ T cell-mediated clearance of virus from the 
CNS allows most mice to recover (for instance, references (Shrestha and Diamond, 
2004; Shrestha et al., 2006a)). Similar immune-mediated resolution of virus infection of 
the CNS leading to improved disease outcome is not apparent in murine infections with 
JEV and MVEV, where a strong correlation between rate of CNS infection and 
mortality exists (this chapter and reference (Licon Luna et al., 2002)). The mouse 
models of West Nile, Murray Valley and Japanese encephalitis reflect the human 
disease with these viruses, given that patients with West Nile virus meningitis and 
encephalitis often have less severe outcomes (Lindsay et al., 2010), in contrast to 
patients with Japanese or Australian encephalitis who frequently suffer debilitating 
neurological complications (Burrow et al., 1998; Solomon, 2004 ). 
108 
Chapter4 
-
Redundancy of Fas and granzymes in recovery from 
primary Japanese encephalitis virus infection 
4.1 Introduction 
Cytotoxic T lymphocytes (CTLs) and natural killer (NK) cells are key mediators of the 
host's direct antiviral functions (reviewed in (Clark and Tyler, 2009; Russel and Ley, 
2002)). Naive CTL precursors require activation through the recognition of specific 
viral peptide determinants on an antigen-presenting cell in the context of MHC 
restriction elements, mostly MHC-I. Induced CTLs require, as part of the adaptive 
immune responses, several days of proliferation before they can exert collectively the 
full extent of their antiviral functions. These virus-specific CTLs are mainly of the 
CD8+ T cell phenotype; however, the cytotoxic potential of CD4+ T cells has also been 
recognized (reviewed in (Brown, 201 O; van de Berg et al., 2008)). NK cells, on the 
other hand, are constitutively armed with preformed cytotoxic granules (reviewed in 
(Chowdhury and Lieberman, 2008)), making them readily inducible, and able to rapidly 
respond to a viral challenge. These effector cells of the innate arm of the antiviral 
immune response recognize virally infected cells through a combination of activating 
and inhibitory receptors (reviewed in (Lanier, 2008)). CTLs and NK cells utilize 
identical contact-dependent mechanisms for induction of target cell apoptosis for viral 
clearance, viz. the Fas-FasL and granule exocytosis pathways of cytotoxicity. 
Fas receptor (Fas, CD95 or Apo-1) is a transmembrane protein that is expressed on all 
nucleated cells (reviewed in (Kaufmann et al., 2012; Lavrik and Krammer, 2012)). 
Ligation of Fas on virally infected cells to Fas ligand (FasL) expressed on effector 
'cytotoxic cells initiates a classical caspase cascade, and ultimately leads to target cell 
death. In addition to its role in immune cell homeostasis and regulation of tumor 
progression (reviewed in (Bouillet and O'Reilly, 2009, Ehrenschwender and Wajant, 
2009)), the Fas-FasL pathway is vital for viral load reduction and/or recovery from viral 
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infections, for example in protection against hepatitis B virus (HBV) (Yang et al., 
2009), herpes simplex type 2 (HSV-2) (Ishikawa et al., 2009), and West Nile virus 
(WNV) infection (Shrestha and Diamond, 2007a). Moreover, it is considered as a key 
pathway necessary for preventing the development of chronic inflammatory disease 
after mouse cytomegalovirus (MCMV) infection (Fleck et al., 1998). On the contrary, 
the Fas-FasL pathway can also contribute to adverse disease outcomes, for example 
after LCMV (Zajac et al., 1996), MVEV (Licon Luna et al., 2002), SFV (Alsharifi et 
al., 2006), or reovirus infections (Lopez et al., 2009), and can sustain chronic hepatic 
inflammation caused by HCV infection (Cruise et al., 2006). 
The granule exocytosis pathway constitutes an effector cell release of pore-forming 
protein, perforin, and a family of serine proteases, predominantly granzymes (Gzm) 
(reviewed in (Chowdhury and Lieberman, 2008; Voskoboinik et al., 2010)). To date, 
there are 5 known human and 11 mouse Gzm. The pro-apoptotic Gzm A and B are the 
most abundantly released members of this family of molecules at the site of the 
immunological synapse, and are consequently the most extensively studied. The role of 
individual molecules involved in the granule exocytosis pathway varies amongst 
different viral infection models. A deficiency in perforin alone results in severe disease 
in models of Ebola (Gupta et al., 2005), LCMV (Walsh et al., 1994), MCMV (Loh et 
al., 2005; Dix et al., 2003), Theiler's virus (Rossi et al., 1998), and WNV infection 
(Shrestha et al., 2006a), as opposed to better outcomes in models of respiratory 
syncytial virus (Aung et al., 2001) and MVEV (Licon Luna et al., 2002). On the other 
hand, Gzms seem to display functional redundancy since a deficiency in individual 
Gzms usually does not result to increased susceptibility, except in certain cases, for 
instance, ectromelia (Mullbacher et al., 1999) and LCMV infection (Zajac et al. , 2003). 
1 1 1 
In the previous chapter, I have shown that Fas-1-, Perf1-, and GzmA/B_;_ mice did not 
display increased susceptibility to JEV infection, although defective clearance of virus 
from the CNS was observed. It remained uncertain whether immunopathology 
associated with leukocyte infiltration into the CNS, less than optimal killing of virus 
infected cells, or other factors explained why the viral load reduction in the CNS did not 
translate into survival advantage. Here, I re-evaluated the phenomenon with the use of 
mice deficient in both effector pathways of cytotoxicity. I also show that NK cells, 
which are competent, along with CD8+ and CD4+ T cells, in eliminating virus infected 
cells by triggering contact-dependent cell death pathways, do not significantly 
contribute to disease outcome in a mouse model of Japanese encephalitis. 
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4.2 Results 
4.2.1 Combined deficiencies . 1n Fas-Fasl and granule exocytosis 
pathways of cytotoxicity increase the susceptibility of mice to Japanese 
encephalitis. In chapter 3, I showed that single cytotoxic effector pathway defects 
did not result in increased mortality from low dose challenge with JEV. Mice deficient 
in Fas, perforin, or Gzms A and B had similar survival rates relative to wt controls. 
Here, I extend my investigation on the contribution of T (and NK) cell-mediated 
cytotoxicity in the recovery from Japanese encephalitis by examining the susceptibility 
of mice with combined deficiencies of essential mediators of the Fas-FasL and granule 
exocytosis pathways. Twelve-week-old Fas-1-, Perf1-xGzmA/B-1-, Fas-1-xGzmA/B-1-, and 
wt control mice were challenged sc with 103 PFU of JEV, and morbidity and mortality 
were recorded during a 28-day-observation period. In all groups, moribund mice 
presented with similar clinical signs starting with generalized piloerection, paresis and 
rigidity, and later progressing to severe neurological signs demonstrated by postural 
imbalance, ataxia and generalized tonic-clonic seizures. The median survival time of 
mice that succumbed to infection did not differ significantly between groups (12.7 + 1.5 
days for Fas-1-, 12.5 + 1.8 days for Perf1-xGzmAIB-1-, 12.4 + 0.7 days for Fas-1-
xGzmA!B-1-, and 12.7 + 1.6 days for wt control mice). The mortality rate of mice 
defective in either Fas-FasL or granule exocytosis pathways of cytotoxicity was 
comparable to that of wt controls: 50% for Fas-1-, 55% for Perf1-xGzmAIB-1-, and 60% 
for wt control mice. Interestingly, a combinatorial defect affecting both pathways of 
cytotoxicity resulted in a significant increase in mortality, where 90% of Fas_1_ 
xGzmA!B_1_ mice succumbed to infection (Fig. 4.1 ). These data indicate a redundancy of 
the two contact-dependent effector pathways of T or NK cell-mediated cytotoxicity in 
resistance to a lethal JEV infection. 
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4.2.2 Defective control of virus growth in the CNS of Fas-'-xGzmA/B_,_ mice. 
Viral load in serum, and peripheral and CNS tissues of wt and Fas-1-xGzmNB-/- mice 
infected sc with 103 PFU of JEV was determined at 2-day-intervals pi (Fig. 4.2). 
Viremia and viral load in spleen detected by real-time RT-PCR did not differ 
significantly between the two groups. Peak viremia was found at day 2 pi (5xl 04 vs. 
lxl05 RNA copies/ml of serum in groups of Fas-1-xGzmA/B-1- and wt mice, 
respectively) and peak splenic viral burden on day 4 pi (9xl04 vs. 7xl04 RNA copies/g 
of tissue in groups of Fas-1-xGzmA/B_;_ and wt mice, respectively) (Fig. 4.2A,B). 
However, the defect in Fas-FasL and granule exocytosis pathways significantly 
compromised the ability of mice to control virus growth in the CNS and/or prevent 
virus entry into the brain. Compared to wt, the proportion of Fas-1-xGzmA/B_;_ mice 
showing detectable virus titers in brain was markedly greater-, and viral load 10- and 
1000-fold higher on days 8 and 10 pi, respectively (Fig. 4.2C). In addition, 
dissemination of virus into the spinal cord was more evident in Fas-1-xGzmNB-1- mice, 
with viral titers exceeding those in wt mice by 2 log on day 10 pi (Fig. 4.2D). These 
findings were supported by markedly increased detection of JEV antigen in various 
regions of the brain of Fas-1-xGzmA/B_;_ relative to wt mice (Fig. 4.3). Altogether, these 
data indicate that failure of control of virus growth in the CNS, but apparently not in 
extraneural tissues, may explain the increased susceptibility of Fas-1-xGzmA/B_;_ mice to 
infection with JEV. 
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Figure 4.1 Susceptibility of Fas-'-, Fas-'-xGzmA/B-'-, Perr'-xGzmA/B-'-, and 
wild-type mice to JEV infection. Groups of 12-week-old mice were infected sc 
with 103 PFU of JEV, morbidity and mortality were recorded daily, and surviving mice 
were monitored for 28 days. The data presented were constructed from two independent 
experiments. Mortality in Fas-1-, Fas-1-xGzmAJB_;_ and Perf1-xGzmAIB_1_ mice was 
compared to wild-type mice to test for statistical significance using the log-rank test 
(**, P < 0.01). 
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Figure 4.2 JEV burden in Fas-'-xGzmA/B _,_ and wild-type mice. JEV burden 
in serum (A), spleen (B), brain (C), and spinal cord (D) samples of Fas-1-xGzmA/B·
1
· and 
wild-type after sc infection with 103 PFU of JEV is shown. At the indicated time points, 
animals were sacrificed and the viral RNA content of serum and spleen samples were 
measured by real-time RT-PCR, while viral content in brain and spinal cord samples 
were measured by plaque titration. Data shown were constructed from 2 independent 
experiments, each symbol represents an individual mouse, and horizontal lines indicate 
geometric mean titers. The lower limit of virus detection is indicated by the horizontal 
dotted line. Asterisks denote significant differences (**, P < 0.01 ). 
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Cerebral Cortex Hippocampus Thalamus Cerebellum Brainstem 
Figure 4.3 lmmunohistochemistry. Brain sections of uninfected Fas-1-xGzmA/B 
-!- mice, and Fas-1-xGzmA/B -!- and wild-type mice infected for 10 days with 103 PFU of 
JEV, sc. Detection of JEV antigen by immunohistochemistry was with the use of a 
monoclonal antibody that recognises the flavivirus NS 1 protein. Representative sections 
of the cerebral cortex, hippocampus, thalamus, cerebellum and brainstem are shown. 
Brown staining is indicative of infected cells. 
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4.2.3 Humoral immunity in Fas-'-xGzmA/8_,_ mice. Intact humoral immunity is 
absolutely required for protection from Japanese encephalitis (Chapter 3). Fas is highly 
expressed on activated and germinal center B cells, and is essential in maintenance of 
both T and B cell homeostatsis (Hao et al., 2008; Wang et al., 1996). In addition, 
expression of Fas and Gzms on CD4+ T cells may impact on its helper function in 
inducing efficient antibody production and maintenance (Desbarats et al., 1998; Gorak-
Stolinska et al., 2001; Maksimow et al., 2006). With this in mind, I investigated 
whether Fas-1-xGzmAJB-1- mice exhibited a defective humoral immune response against 
JEV. The kinetics and magnitude of antibody responses in Fas-1-xGzmA/B-/- mice did 
not differ significantly from that in wt mice. Generation of anti-JEV IgM antibody was 
comparable in both groups, appearing first on day 4 pi, and increasing thereafter (Fig. 
4.4A). Likewise, class switching to IgG 1 and IgG2b isotype antibodies was similar in 
both groups, initially detected on day 7 pi, and increasing on day 10 pi (Fig. 4.4B). The 
functional activity of the anti-JEV humoral immune response measured by 
neutralization assay was also comparable between both groups, with mean PRNT so 
titers of 536 (range, 80 to 1280) in Fas-1-xGzmA/B-/- mice and 656 (range, 40 to 1280) in 
wt mice on day 10 pi (Fig. 4.4C). In summary, these data indicate that the ability of 
Fas-1-xGzmA!B-1- mice to mount JEV-specific B cell immune responses remained 
unimpaired. 
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Figure 4.4 Humoral immune response in Fas·'-xGzmA/8 _,_ and wild-type 
mice. Eight-week-old Fas·1-xGzmAJB·1· and wild-type mice were infected sc with 103 
PFU of JEV, and serum samples were collected at the indicated time points. Anti-JEV 
IgM (A) and lgG (B) isotype antibody titers were determined by ELISA. The data 
presented are reciprocal mean endpoint titers representative of 4 mice per time point 
with the SEM indicated by error bars. (C) Neutralizing antibody titers determined by 
plaque reduction neutralization assay. The data presented are mean PRNT50 titers 
representative of 5 mice per time point with the SEM indicated by error bars. 
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4.2.4 Cytokine production in the absence of Fas and Gzm A and B. Besides 
direct cytotoxic action mediated through the Fas-FasL and granule-exocytosis 
pathways, the antiviral activity of NK and CDS+ T cells is also mediated indirectly by 
the release of soluble cytokines (Mullbacher et al., 2004) Therefore, I investigated the 
capacity of NK and CDS+ T cells from Fas-1-xGzmA/B-1- mice to produce IFN-y and/or 
TNF-a following infection with JEV. At day 4 pi (at the peak of the NK cell response in 
this infection model [ see Chapter 6]), the percentage of NK cells expressing IFN-y in 
spleens of Fas-1-xGzrnA/B_;_ mice was not significantly different relative to wt mice 
(5.2% in Fas-1-xGzmA/B_;_ vs. 5.5% in wt mice; Fig. 4.5A). Likewise, the CDS+ T cell 
immune response ( determined by intracellular cytokine staining following ex vivo 
stimulation of CDS+ lymphocytes with a JEV NS4B protein-derived H-2Db-binding 
peptide) in Fas-1-xGzmA/B_;_ was comparable to that of wt at day 7 pi (3.1 % in Fas_;_ 
xGzrnA/B-/- vs. 3.5% in wt mice; Fig. 4.5B). In addition, the percentage of 
multifunctional CD8+ T cells, characterized by expression of both IFN-y and TNF-a in 
single T cells did not differ significantly between the two groups (Fig. 4.5C). 
Collectively, these data indicate intact production of cytokines in NK and CDS+ T cells 
in Fas-1-xGzmA/B_;_ mice. 
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Figure 4.5 NK cell and CDS+ T cell cytokine production. Eight-week-old 
Fas-1-xGzmAJB-1- and wild-type mice were infected iv with 103 PFU of JEV or left 
uninfected. (A) Spleens were collected at indicated time points and the percentage of 
NKl. l + or CD8+ splenocytes expressing IFN-y were identified by flow cytometry. For 
CD8+ T cells, splenocytes were stimulated ex vivo with H2-Db -restricted JEV NS4B 
protein-derived peptide. Means for 4 samples + the SEM are presented. (B) CD8+ T 
cells expressing both IFN-y and TNF-a at the indicated time points. Means for 4 
samples + the SEM are presented. 
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4.2.5 Cellular migration into the CNS. To investigate whether trafficking of 
leukocytes was defective in Fas-1-xGzmA/B_;_ mice, leukocytes were isolated from brains 
of JEV infected Fas-1-xGzmA/B_;_ and wt mice by density gradient centrifugation and 
used to quantify leukocyte subpopulations by flow-cytometry. On days 7 and 10 pi, Fas-
1-xGzrnA/B_;_ mice did not show a significant difference in the numbers of NK cells, and 
CD8+ and CD4+ T cells in the brain relative to wt control mice (Fig. 4.6A-C). This 
result shows that deficiency of both cytolytic effector pathways did not alter the ability 
of NK and T cells to infiltrate the infected brain, and that the substantially higher viral 
burden in the CNS later in infection in Fas-1-xGzmA/B-1- mice did not result in 
augmented trafficking of these leukocyte subpopulations into the brain in comparison to 
wt mice. 
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Figure 4.6 Leukocyte trafficking into the CNS. Kinetics of cell infiltration 
into the brain of 8-week-old Fas-1-xGzmA/B_;_ and wi ld-type mice infected sc with 103 
PFU of JEV. Leukocytes were isolated by density gradient centrifugation at the 
indicated time points from brains, and stained for identification as CD8+ T cell (A), 
CD4+ T cell (B), NKl .1 + cell (C). Data are representative of 2 independent experiments 
(n = 4/group ), and error bars denote the SEM. 
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4.2.6 NK cells are dispensable for recovery from lethal JEV infection. In 
chapter 3, I showed that the combined transfer of immune CD4+ and CD8+ T cell 
provided partial, albeit significant, protection from lethal Japanese encephalitis. This 
may have been, at least in part, due to the cytotoxic potential of, and/or secretion of 
cytokines (IFN-y and TNF-a) from the two lymphocyte subpopulations. Given that 
these antiviral mechanisms are also exerted by NK cells, it was of interest to address a 
putative role of NK cells in recovery from infection with JEV, using the approach of in 
vivo depletion of NK cells with an antibody. Thus, 8-week-old B6 mice were treated 
with anti NKl. l antibody or mock-treated at days -1, 0, + 1, +4, and +8 of sc infection 
with 103 PFU of JEV (Fig. 4. 7). This protocol resulted in >98% depletion of NK cells 
on days 2 and 8 based on flow-cytometric staining of leukocytes using the NKl. l 
antibody. The mortality rate in the group of NK cell-depleted and mock-treated mice 
(55% and 60%, respectively) and MST (13 + 1.8 days and 12.8-+ 1.5 days, respectively) 
did not differ significantly between the two groups. 
To examine whether NK cells contribute to peripheral viral clearance, I determined the 
viral load in serum and spleen at early time points pi. Viremia and viral load in spleens 
did not show a significant difference between the two groups (Fig. 4.8A,B). Lastly, 
clearance of virus from the CNS was not defective in the absence of NK cells, since 
viral titers in brain and spinal cord were not significantly different between NK cell-
depleted and mock-treated mice on day 10 pi (Fig. 4.8C,D). 
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Figure 4.7 Susceptibility to JEV infection after in vivo NK cell depletion. 
Groups of 12-week-old mice were administered ip with either anti-NKI.1 antibody or 
PBS, and infected sc with 103 PFU of JEV. Morbidity and mortality were recorded 
daily, and surviving mice were monitored for 28 days. The data presented were 
constructed from two independent experiments. 
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Figure 4.8 Viral burden in the absence of NK cells. JEV burden in serum 
(A), spleen (B), brain (C), and spinal cord (D) samples of NK cell-depleted and mock-
treated B/6 wt mice after sc infection with 103 PFU of JEV is shown. On days 2 and 4 
pi, animals were sacrificed and the viral RNA content of serum and spleen samples 
were measured by real-time RT-PCR, while viral content in brain and spinal cord 
samples on day 10 pi were measured by plaque titration. Data shown were constructed 
from 2 independent experiments, each symbol represents an individual mouse, and 
horizontal lines indicate geometric mean titers. The lower limit of virus detection is 
indicated by the horizontal dotted line. 
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4.3 Discussion 
The biological significance of contact-dependent pathways of cytotoxicity in viral 
disease amelioration or exacerbation has become increasingly recognized over the past 
two decades with the availability of knockout mice with defects in key components of 
the pathways (reviewed in (Kaufmann et al., 2012; Mullbacher et al., 2003; 
Voskoboinik et al., 2010; Wang et al., 1996)). A multitude of studies using mice with 
single or combined deficiency in Fas, FasL, perforin, GzmA, or GzmB have revealed a 
lack of generalizability in terms of disease outcome between different viral models. 
This includes viruses that cause disease of the CNS, where one or both pathways may 
be absolutely required, partly beneficial, unnecessary, or detrimental to the host. For 
instance, an immunopathological role of the Fas-FasL and/or granule exocytosis 
pathways was observed in disease models of LCMV (Zajac et al., 1996), MVEV (Licon 
Luna et al., 2002), and SFV (Alsharifi et al., 2006). On the other hand, one or both 
pathways were required for protection from Theiler's virus (Rossi et al., 1998), WNV 
(Shrestha et al, 2006; Shrestha and Diamond, 2007a) and HSV-2 infection (Ishikawa et 
al., 2009). Even viral strain differences can account for distinct disease outcomes: for 
instance, intact granule exocytosis plus Fas-FasL pathways of cytotoxicity were 
essential for recovery from infection with a virulent North-American isolate of WNV 
(Shrestha et al., 2006a, Shrestha and Diamond, 2007), in contrast to a less virulent 
strain (WNV-Sarafend), which did not show increased disease in Perf\ Fas-1-, and 
FasL-deficient mice relative to wt (Wang et al., 2004) Similarly, mice deficient in Fas-
FasL signalling challenged with HSV-1 strain SC 16 presented with defective peripheral 
viral clearance (Johnson et al., 2008), as opposed to Fas receptor-deficient mice 
challenged with HSV-1 KOS strain, which did not present with increased peripheral 
viral load (Pellegrini et al., 2003). 
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Here I show that mice defective in both contact-dependent cell death pathways (Fas-/-
xGzmA/B-/- mice) display increased susceptibility to extraneural challenge with a low 
dose of JEV. The result resembles the finding of uncontrolled lethal infection of a 
neurotropic strain of mouse hepatitis virus in mice lacking both functional Fas-FasL and 
granule exocytosis-mediated effector pathways, but not in animals with single 
deficiencies in either Fas or perforin (Lin et al., 1997; Parra et al, 2000). Accordingly, 
both mouse models of neurotropic viral diseases showed redundancy of the two contact-
dependent cytolytic mechanisms for the control of lethal viral infections of the CNS. 
Intriguingly, in the mouse model of Japanese encephalitis, dispensability of either Fas-
FasL or granule exocytosis pathways in disease outcome measured by mortality rate 
(this Chapter and Chapter 3) contrasted with markedly increased viral burden in the 
CNS in single knockout mice defective in either Fas, perforin, or Gzms (Chapter 3). 
While the latter finding was explained by proposing a counter-acting balance of 
immunoprotection vs. immunopathology mediated by cytolytic leukocytes at the site of 
CNS infection, it casts doubt on an interpretation that posits solely absence of cytolytic 
clearance of JEV as the reason for the observed mortality rate increase in the double-
deficient mice. 
Other, non-cytolytic, functions of Fas and Gzms have been described that may have 
been beneficial in recovery from JEV, and could account for the discrepancy. 
Accumulating data suggest a physiological role of Fas in regulating neuronal 
development, growth, differentiation, and regeneration in the CNS (reviewed in 
(Desbarats et al., 2003; Peter et al., 2007; Tamm et al., 2004; Zuliani et al., 2006)). 
Accordingly, in line with proposed diverse non-apoptotic functions of Fas expression in 
T cell survival, proliferation and/or activation, and also liver cell regeneration, Fas may 
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act as a protector as well as a destroyer of cells of the CNS following infection with a 
pathogen or in inflammatory disorders. Fas is strongly upregulated in brains of mice 
infected with JEV and WNV (Gupta and Rao, 2011; Shrestha and Diamond, 2007) and 
disruption of this putative neuroprotective role of Fas may, at least in part, explain the 
increased susceptibility of Fas-1-xGzmAxB -/-mice to JEV infection. 
Granzymes, while residing in cytotoxic cells, are also found extracellularly, and their 
extracellular concentration is elevated during infection. Accordingly, it must be 
anticipated that the Gzms can act both intracellularly and extracellularly. Non-cytolytic 
activities mediated by GzmA and GzmB include diverse biological effects such as (i) 
stimulation of pro-inflammatory cytokines, (ii) remodeling of extracellular matrices that 
can result in cell death through anoikis, (iii) stimulation of type 1 IFN responses by 
deregulating the activity of the 1hree-prime repair exonuclease, TREX 1, and (iv) 
proteolytic cleavage and inactivation of viral or host factors essential for viral 
replication (reviewed in (Andrade, 21 0; Froelich et al., 2009)). Regarding the latter, the 
direct antiviral action of GzmB is crucial in the prevention of herpes simplex virus Type 
1 (HSV-1) reactivation, mechanistically through the degradation of a viral protein 
essential for gene expression (Knickelbein et al., 2008). It is of interest that GzmB-
deficient but not perforin knockout mice showed increased susceptibility to infection 
with WNV (strain Sarafend) (Wang et al., 2004), suggesting a beneficial non-cytotoxic 
effect of the molecule against flavivirus infection, which was also observed in flavivirus 
growth experiments in human fibroblasts stably expressing GzmB (Lobigs et al., 2008). 
The mechanism of this non-cytotoxic activity of GzmB against flaviviral infection has 
not been elucidated, but may involve viral or host protein cleavage by the serine 
protease. 
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Defective control of JEV infection in mice lacking functional death receptor and/or 
granule exocytosis pathways of cytotoxicity was reflected in reduced viral burden in 
brain and spinal cord at later time points pi, while viral titers in serum and spleen did 
not differ significantly. This suggested that the contact-dependent functions of the 
cellular immune response mediated predominantly by NK and T cells are not important 
in the control of JEV in extraneural tissues, or at early time points when relatively low 
viral load is detectable in serum and spleen. This observation, combined with the 
limited capacity of cells of the CNS to regenerate following viral or immune-mediated 
death, may explain the only subsidiary role of CD8+ T cells in protection against 
Japanese encephalitis. 
Other relevant immunologic factors that could account for increased susceptibility in 
Fas-1-xGzmAxB -!- mice were excluded. First, the magnitude and functional activity of 
antibody responses in Fas-1-xGzmAJB -/- mice remained intact, and displayed similar 
kinetics relative to wt. Second, NK and CD8+ T cell immune responses ( as measured by 
intracellular cytokine production) in Fas-1-xGzmAJB_;_ mice also displayed comparable 
activity relative to wt. Last, trafficking of leukocytes into the CNS remained unimpaired 
even with combined absence of Fas and Gzms. 
The second major finding from this investigation was that NK cells were dispensable 
for recovery from JEV infection. While infection with JEV resulted in early activation 
of NK cells (measured by intracellular IFN-y staining), depletion of NK cells did not 
produce increased mortality, or a difference in viral burden in serum, spleen or the 
CNS, relative to wt control mice. The result is consistent with the conclusion that NK 
cells do not provide a survival advantage in mice infected with other closely related 
flaviviruses belonging to the Japanese encephalitis serocomplex, viz. WNV and MVEV. 
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Flaviviruses are thought to have evolved an immune escape mechanism against NK cell 
attack involving up-regulation of MHC class I on the surface of infected cells (King and 
Kesson, 1988; Lobigs et al., 2003a). MHC class I can engage with NK cell inhibitory 
receptors and thereby down-regulate the NK cell response, which may explain why 
despite apparent NK cell activation, the leukocyte subpopulation did not promote a 
survival advantage against Japanese encephalitis. 
131 
Chapters 
Disease-ameliorating CNS viral load reduction by 
Interferon-y-producing T cells in a mouse model of 
Japanese encephalitis 
5.1 Introduction 
Interferons (IFN s) are glycoprotein cytokines important in the host defence response 
against diverse groups of infectious diseases (reviewed in (Macmicking, 2012; Sadler 
and Williams, 2008)). They are grouped into three classes based on the receptor 
complex through which they signal. IFN-a and IFN-~ are type I IFN s, and are produced 
early in the course of infection. Binding of IFN-a and -~ to a single (IFN-a) receptor 
leads to the activation of a large set of JPN-inducible genes involved in antiviral and 
immunoregulatory pathways. On the other hand, IFN-y is classified as a type II IFN, 
and is predominantly produced by NK, NKT, and yb T cells of the innate arm of the 
immune response, and CD4+ Thl and CD8+ T cells of the adaptive immune response 
(reviewed in (Schoenborn and Wilson, 2007)). The antiviral action of IFN-y is mediated 
through various mechanisms, including direct antiviral activity that overlaps with that 
triggered by the type I IFNs, activation and polarization of Th cell responses, enhanced 
major histocompatibility complex (MHC) class I antigen expression and presentation, 
and activation of phagocytic myeloid cells. Lastly, newly classified members of the IFN 
superfamily, the type III IFNs (IFN-Al, -A2 and -A3), trigger similar immune responses 
as the type I IFNs but engage a different receptor complex, containing the molecules 
IFNLRl and IL-1 OR2. Only limited information on the physiological role of the type III 
IFNs is yet available (reviewed in (Levraud et al. , 2007)). 
Mouse -models of flaviviral pathogenesis have established the critical requirement of 
type 1 IFN signalling in defence against diss~minating infections. Mice deficient in the 
IFN-a receptor presented with widespread viral tropism, uncontrolled viremia, early 
neurqinvasion, rapid CNS viral dissemination, and complete lethality when challenged 
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with Japanese encephalitis virus (JEV) (Lee and Lobigs, 2002), Murray Valley 
encephalitis virus (MVEV) (Lobigs et al., 2003b), and West Nile virus (Samuel and 
Diamond, 2005). In addition, challenge of IFN-a receptor-deficient mice with yellow 
fever virus (YFV) Asibi and Angola 73 strains resulted in severe viscerotropic disease 
and complete lethality (Meier et al., 2009). Although not lethal, dengue virus (DENY) 
infection of IFN-a receptor-deficient mice also showed rapid viral dissemination and 
increased viral load in comparison to type I IFN response sufficient mice (Shresta et al., 
2004). 
In contrast, the importance of IFN-y signalling on disease outcome after flaviviral 
challenge is variable. A modest increase in mortality was observed when B/6 IFN-y _1_ 
mice were challenged with a low dose MVEV (Lobigs et al., 2003b ), while no 
difference in susceptibility was observed \vhen challenged- with YFV (Liu and 
Chambers 2001; Meier et al., 2009). Moreover, viral strain and mouse genetic 
background appeared to be a confounding variable influencing disease outcome: a 
modest increase in mortality was seen in 129 Sv IFN-y _1_ mice challenged with either 
DENV-1 or DENV-2 (Shresta et al., 2004 ), however no effect was observed in an 
independent study where_BALB/c mice deficient in IFN-y were challenged with DENV-
2 (Johnson and Roehrig, 1999); furthermore, as opposed to the inconsequential effect of 
an IFN-y deficiency in challenge with WNV strains Sarafend and Kunjin (Wang Y. et 
al., 2006), IFN-y had an essential early antiviral role in recovery from infection with a 
more virulent North-American WN strain (Shrestha et al., 2006b ). 
In Chapter 4, the relevance of contact-dependent mechanisms of NK and T cell-induced 
cytotoxicity in the pathogenesis of Japanese encephalitis was presented. Independent of 
these direct effector mechanisms of cell-mediated immunity, NK and T cells also exert 
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their protective effect by the release of the soluble factors, TNF-a and IFN-y. In this 
Chapter, the role of the cytokine IFN-y in recovery from Japanese encephalitis will be 
explored with the use of knockout mice deficient in production of the cytokine. 
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5.2 Results 
5.2.1 IFN-y is required for protection against Japanese encephalitis. 
Twelve-week-old IFN-f1- and wt control mice were challenged sc with 103 PFU JEV, 
and morbidity and mortality were observed for 28 days. Similar initial clinical signs of 
generalized piloerection, paresis and rigidity, invariably progressing to severe 
neurological signs demonstrated by postural imbalance, ataxia and generalized tonic-
clonic seizures appeared in both groups. The median survival time of mice that were 
sacrificed when severe signs of encephalitic disease were apparent, did not differ 
significantly between the two groups (11.7 + 2.3 days for IFN-f1- and 11.1 + 2.1 days 
for wt mice. However, a deficiency in IFN-y resulted in a significant increase in 
mortality rate: 86% for IFN-f1- versus 43% for wt mice (Fig. 5.1 ). This result clearly 
demonstrates a beneficial role of IFN-y in the pathogenesis of Japanese encephalitis. 
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Figure 5.1 Susceptibility of IFN-y·'· and wild-type mice to JEV infection. 
Groups of 12-week-old mice were infected sc with 103 PFU of JEV, morbidity and 
mortality were recorded daily, and surviving mice were monitored for 28 days. The data 
presented were constructed from two independent experiments.- Mortality in groups of 
IFN-y_1_ mice (n = 22) was compared to that in groups of wt mice (n = 14) to test for 
statistical significance using the log-rank test(** , P < 0.01). 
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5.2.2 Increased viral burden in the CNS in the absence of IFN-y. To 
investigate further on the mechanism of increased susceptibility to JEV infection in 
mice deficient in IFN-y, viral titers in brain and spinal cord of IFN-{1- and wt control 
mice infected with 103 PFU of JEV, sc, were determined by plaque assay on Vero cell 
monolayers. A deficiency in IFN-y resulted in increased CNS viral burden, with viral 
load in brains of IFN-y -/- mice exceeding that in brains of wt mice by ~ 100- and ~ 1000-
fold on days 8 and 10 pi, respectively (Fig. 5.2C). Additionally, IFN-{1- mice exhibited 
more pronounced dissemination of virus into the spinal cord, with viral titers elevated 
by one log and three logs on days 8 and 10 pi, respectively, relative to wt (Fig. 5 .2D). 
Viral titers in serum and spleen were not detectable by plaque assay, and JEV RNA 
detection utilizing real-time RT-PCR did not show a significant difference between the 
groups. Peak viremia was on day 2 pi (GMT: l.lxl05 and 9.4x10
4 RNA copies/ml of 
serum in wt and IFN-{1- mice, respectively; Fig. 5.2A), and peak splenic viral burden 
occurred on day 4 pi (GMT: l.2x105 and l.9xl05 RNA copies/g of spleen in wt and 
IFN-{1- mice, respectively; Fig. 5.2B}. Together, these data indicate that IFN-y 
significantly contributes to the control of virus growth in the CNS, but is not critical for 
clearance of virus from extraneural tissues. 
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Figure 5.2 JEV burden in IFN-y_,_ and wt mice. JEV burden in serum (A), 
spleen (B), brain (C), and spinal cord (D) samples of IFN-f1- and wt mice after sc 
infection with 103 PFU of JEV is shown. At the indicated time points, animals were 
sacrificed, and the viral RNA content in serum and spleen samples measured by real-
time RT-PCR, while viral content in brain and spinal cord samples were measured by 
plaque titration. Data shown were constructed from 2 independent experiments, each 
symbol represents an individual mouse, and geometric mean titers (GMT) are indicated 
by horizontal lines. The lower limit of virus detection is indicated by the horizontal 
dotted line. Asterisks denote significant differences(* , P < 0.05; **, P < 0.01). 
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5.2.3 Intact humeral immunity in the absence of IFN-y. An optimal antibody 
response is an obligatory requirement for protection from lethal Japanese encephalitis 
(Chapter 3). Therefore, I investigated whether a deficiency in IFN-y resulted in a poorer 
antibody response, and thereby causing a lethal outcome. The magnitude of anti-JEV 
IgM in IFN-f1- mice presented with similar kinetics relative to wt mice, appearing first 
on day 4 pi and increasing thereafter (Fig. 5 .3A). Moreover, the kinetics of class 
switching to IgG did not differ significantly between the two groups. Anti-JEV IgG 1 
and IgG2b responses were similar in both groups, appearing initially on day 7 pi, and 
increasing on day 10 pi. (Fig. 5.3B). In both groups, the magnitude of the IgG2b 
response exceeded that of the IgG 1 antibody isotype. The functional activity of the 
antibody response, as determined by an in vitro virus neutralization assay, also 
displayed similar magnitude between both groups, with mean PRNTso titers of 768 
(range, 320 to 1280) in IFN-y -!- mice and 652 (range, 20 to 1285) in wt mice on day 10 
pi. (Fig. 5.3C). Together, these data suggest that IFN-f1- mice exhibit a humoral 
immune response after exposure to JEV that is comparable in quality and magnitude to 
that in wt mice. 
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Figure 5.3 Humoral immune response in IFN-y·'- and wt mice. Eight-week-
-, 
old IFN-y-/- and wt mice were infected sc with 10.) PFU of JEV, and serum samples 
were collected at the indicated time points. Anti-JEV IgM (A) and IgG (B) isotype 
antibody titers were determined by ELISA. The data presented are reciprocal mean 
endpoint titers representative of 4 mice per time point with the SEM indicated by error 
bars. (C) Neutralizing antibody titers determined by plaque reduction neutralization 
assay. The data presented are mean PRNT50 titers representative of 5 mice per time 
point with the SEM indicated by error bars. 
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5.2.4 Cellular Migration into the CNS. IFN-y-mediated induction of chemokines, 
such as CCL2, CCL3, CCL4, CCL5, CXCL9, and CXCLl0, which play a role in 
chemotaxis of leukocytes is well documented (reviewed in (Schroder et al., 2004)). To 
assess whether there was an impairment of trafficking of leukocytes to the site of 
infection in IFN-f1- mice, lymphocytes were isolated from brains of JEV infected IFN-f 
/- and wt mice by density gradient centrifugation, and leukocyte subpopulations 
quantified by flow-cytometry. On day 7 pi, IFN-f1- mice presented with similar 
numbers of NK, CDS+ T, and CD4+ T cells as compared to wt mice. This remained 
consistent on day 10 pi. Together, these data indicate that even in the absence of IFN-y, 
migration of lymphocytes into the CNS after JEV infection remains intact. 
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Figure 5.4 Leukocyte trafficking into the CNS. Kinetics of cell infiltration 
into the brain of 8-week-old IFN-{1- and wt mice infected sc with 103 PFU of JEV. 
Leukocytes were isolated by density gradient centrifugation from the brains of infected 
mice at the indicated time points, and stained for identification of CD8+ T cell (A), 
CD4+ T cell (B) and NKl. l + cell (C). Data are representative of 2 independent 
experiments (n = 4/group ), and error bars denote the SEM. 
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5.2.5 IFN-y-producing T cells are essential for viral clearance from the 
CNS. To confirm the protective role of IFN-y against protection from lethal Japanese 
encephalitis, total splenocytes and immune T cells from JEV-infected IFN-f1- or wt 
mice were transferred to naive wt recipients that were challenged with 103 PFU of JEV 
one day after transfer (Table 5.1). Consistent with the findings in Chapter 3, total 
splenocyte transfer from immune wt donors completely protected recipient wt mice 
from lethal infection. Likewise, total splenocyte transfer from immune IFN-f1- mice to 
wt recipients resulted in a 100% survival rate. On the other hand, immune T cell 
transfer from wt donor mice to wt recipients conferred substantial, albeit partial, 
protection from lethal encephalitis relative to naive T cell transfer (mortality rate: 28% 
and 75%, respectively). In contrast, immune T cell transfer from IFN-f1- mice to wt 
recipients did not result in significant protection (80% and 7 5% mortality in immune 
and nai"ve T cell recipients, respectively). 
Moreover, viral load in brain of recipients of IFN-f1- immune T cells was notably higher 
compared to that in mice that received immune T cells from wt donors (GMT: 4.8x 105 
versus l.2xl03 PFU/g of brain tissue on day 10 pi, respectively; Fig. 5.5A). Consistent 
with this finding, the viral load in spinal cord was also significantly higher in the former 
than in the latter group (GMT: 3.9xl04 vs. < lxl03 PFU/g of spinal cord tissue, 
respectively; Fig. 5.5B). Taken together, these data suggest that the IFN-y-mediated 
protection against lethal Japanese encephalitis is mediated, at least in part, by immune T 
cells, and involves partial control of virus growth in the CNS. 
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Table 5.1 
challenge. 
Protective value of T cell expressed IFN-y against lethal JEV 
Treatment a Mortality (No. of Mean survival deaths/ total) b time (days)± SD c 
PBS control 67% (6/9) 12.3 ± 1.4 
B/6 wt control donor mice 
NaYve wt total splenocytes (1 x 107 cells) 75% (15/20; P =0.94) 12.9±1.7 
Immune total splenocytes (1 x 107 cells) 0% (0/7; P =0.003) 
Immune T cells (5 x 106 cells) 28% (5/18; P =0.01) 12.2 ± 1.3 
IFN-f'- donor mice 
Immune total splenocytes (1 x 107 cells) 0% (0/5; P =0.01) 
Immune T cells (5 x 106 cells) 80% (12/15; P =0.10) - 12.7±1.5 
a Eight-week-old IFN-i'- or wt donor mice were infected with 103 PFU of JEV, iv, or left 
uninfected and sacrificed 7 days later for splenocyte collection with or without T cell purification. 
Cells were transferred to 8-week-old wt recipient mice that were infected one day later with 103 
PFU of JEV into the footpad. Surviving mice were monitored for 28 days. 
b Data are representative of 2 independent experiments. Immune splenocyte treatment groups 
were compared to the naive splenocyte control group to test for statistical significance. 
c No significant difference was noted between immune splenocyte treatment and control groups . 
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Figure 5.5 JEV burden in CNS tissue after immune splenocyte transfer. 
JEV burden in brain (A), and spinal cord (B) samples in wild-type recipients of mock 
(na"ive wt total splenocytes), IFN-{1-, or wt immune T cells is shown. Mice were 
sacrificed at day 10 post-challenge with 103 PFU of JEV injected into the footpad, and 
viral content in tissues measured by plaque titration. Each symbol represents an 
individual mouse, and geometric mean titers are indicated by horizontal lines. The 
lower limit of virus detection is indicated by the horizontal dotted line. Asterisks denote 
significant differences (*, P < 0.05). 
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5.3 Discussion 
The pleiotropic cytokine, IFN-y, provided a substantial contribution to protection from 
lethal Japanese encephalitis. This was documented in the following findings: (i) low 
dose JEV challenge of IFN-f1- mice resulted in significantly increased mortality, (ii) 
significantly increased viral burden in brain, and (iii) more widespread dissemination of 
the virus into the spinal cord, relative to wt control mice; (iv) in addition, JEV-infected 
recipients (B/6 wt strain) of JEV immune T cells from IFN-f1- donor mice displayed no 
survival advantage relative to infected recipients of na'ive T cells and a significantly 
higher mortality rate compared to recipients of immune T cells from IFN-y sufficient 
mice, as well as (v) increased viral burden in the CNS relative to the latter. These 
findings are supported by an in vitro study that showed dose-dependent inhibition of 
JEV replication in IFN-y-stimulated RAW 246.7 murine macrophages (Lin Y.L. et al. , 
1997). They are also consistent with reports from numerous investigation on the role of 
IFN-y in the control of other neurotropic viruses; for instance, Boma disease virus 
(BDV) (Friedl et al., 2004; Hausmann et al. 2005), herpes simplex virus type 1 (Liu et 
al. , 2001), measles virus (Finke et al. , 1995; O'Donnell et al. , 2012; Patterson et al. , 
2002), mouse hepatitis virus (Bergmann et al. , 2003; Bergmann et al. , 2004; Parra et 
al. , 1999; Pearce et al. , 1999), lymphocytic choriomeningitis virus (Friedl et al. , 2004 ), 
Sindbis virus (Binder and Griffin, 2001; Burdeinick-Kerr et al. , 2007), and Theiler ' s 
murine encephalomyelitis virus (TMEV) (Rodriguez et al. , 2003) all require IFN-y as a 
critical cytokine for limiting viral dissemination within the CNS. 
Mechanistically, IFN-y mediates clearance of virus (directly or indirectly) through 
cytolytic and non-cytolytic means (reviewed in (Chesler and Reiss , 2002; Schroder et 
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al., 2004)). Induction of cytolytic mechanisms include stimulating cell-mediated 
immunity by up-regulation of MHC-1 antigen processing and presentation, increasing 
sensitivity of target cells to apoptosis by up-regulation of Fas and TNF-a receptors, and 
facilitating target cell death by up-regulation of the pro-apoptotic proteins caspase-1 and 
IRF-1. However, given that in Japanese encephalitis the induction apoptosis in vital 
permanent neuronal networks would likely be counterproductive in achieving survival 
outcomes, the non-cytolytic mechanisms of IFN-y action may have been of greater 
importance. One major non-cytolytic pathway activated by IFN-y is through the 
induction of nitric oxide synthase type 1 (NOS-1) protein with consequent production of 
the antiviral molecule, nitric oxide (NO) (Karupiah et al., 1993). As a first in vitro 
proof, Lin et al. ( 1997) have shown that the activation of the NO pathway is responsible 
for IFN-y-mediated antiviral activity against JEV. The direct antiviral action of NO 
against JEV was corroborated in subsequent studies using~ various experimental 
approaches (Saxena et al., 2000; Saxena et al., 2001 ). Other than the NO-dependent 
mechanisms, IFN-y-mediated generation of indoleamine 2,3-dioxygenase (Adams et al., 
2004; Mao et al., 20011; Terajima and Leporati, 2005), protein kinase RNA-activated 
(PKR), dsRNA-specific adenosine-deaminase (ADAR), and guanylate-binding proteins 
(GBP) (reviewed in (Chesler and Reiss, 2002; Schroder et al., 2004)) have also been 
implicated as antiviral proteins, although further investigations are required to confirm 
activity of these factors in inhibition of JEV replication. 
Interestingly, other studies have shown a neuroprotective role of IFN-y after CNS injury 
(Baron et al., 2008; Gao et al., 2000; Garg et al., 2009; Imai et al., 2007; Lee J. et al., 
2006). Glial cells and neurons express the IFN-y receptor, and thus unsurprisingly their 
growth and plasticity are influenced by the IFN-y ligand (Butovsky et al., 2006; Song et 
al., 2005; Wong et al., 2004). Moreover, certain neurons express the IFN-y ligand itself, 
148 
and when released can act in an autocrine or paracrine fashion to influence neuronal 
differentiation (Neumann et al., 1997). Independent from its immune-mediated role in 
viral clearance, IFN-y was implicated to have a neural protective effect after infection 
with BDV (Hausmann et al., 2005) and TMEV (Rodriguez et al., 2003). Given that 
IFN-{1- mice, relative to wt, are more susceptible to infection with MVEV (Lobigs et 
al., 2003b) and the WNV-NY strain (Shrestha et al., 2006b), and yet did not display 
viral load difference on day 8 pi, it can be speculated that IFN-y may, in part, play an 
undefined neuroprotective role in flaviviral encephalitis, apart from its immune-
mediated effects. 
Defects in humoral immunity were not responsible for the adverse outcome observed in 
mice deficient in IFN-y, since IFN-{1- mice displayed comparable kinetics of antibody 
responses and virus neutralizing titers relative to wt mice. In addition, wt recipients of 
total immune splenocytes, but not immune T cells, from IFN-{1- donor mice were 
completely protected from JEV challenge, thereby indicating an intact B cell response. 
The splenocyte transfer experiments also attributed IFN-y-producing immune T cells as 
the n1ain effector cell population responsible for the disease-ameliorating effect of IFN-
y involving the partial control of virus growth in the CNS. This protective function of 
IFN-y was most likely a synergistic effect provided by both CD8+ and CD4 + T cell 
populations, since ( as demonstrated in Chapter 3) only a combined transfer of both cell 
populations afforded protection. Here I confirmed that both cell populations efficiently 
trafficked into the infected brain in the absence of IFN-y. 
NK cells are also an important source of IFN-y in viral infections, including JEV 
infection, which was confirmed by intracellular staining for IFN-y in NK cells isolated 
from JEV infected mice (Chapter 4). It has been suggested that NK cell-expressing IFN-
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y has a contributory early role in viral clearance after DENV-2 challenge (Fagundes et 
al., 2011). However, in the case of JEV infection, IFN-y-producing NK cells most likely 
did not play a crucial role in recovery, since in vivo depletion of NK cells in JEV 
infected mice did not reduce survival rate nor impact on viral burden in CNS (Chapter 
4). Finally, activated y6 T cells of the innate immune response are thought to be the 
main IFN-y-producing cells responsible for early viral clearance and protection from 
lethal West Nile encephalitis (Shrestha et al., 2006b; Wang et al., 2003). This is, 
however, unlikely the case in the mouse model of Japanese encephalitis, given that IFN-
f 1- mice did not display increased early viremia or peripheral viral load, nor shorter 
average survival times, relative to wt mice. Nevertheless, further research is required to 
confirm or discount a contribution of y6 T cells in the control of JEV infection. 
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Chapter 6 
The Chemokine Receptor CCRS, a Therapeutic Target 
for HIV/ AIDS Antagonists, is Critical for Recovery in 
a Mouse Model of Japanese Encephalitis 
The findings in this Chapter has been accepted for publication: 
Larena, M., Regner, M., & Lobigs , M. (2012). The chemokine receptor CCR5 , a 
therapeutic target for HIV/AIDS antagonists , is critical for recovery in a mouse model of 
Japanese encephalitis. PLoS One. 
6.1 Introduction 
The migration of leukocytes in lymphoid organs and to sites of inflammation is 
coordinated by an array of chemokines that bind to specific receptors on immune cells 
(reviewed in reference (Allen et al., 2007)). Of these, the chemokine receptor, CCR5, is 
expressed on natural killer (NK) cells, macrophages, and CD4+ and CD8+ T cells. In 
these cell types, it regulates chemotaxis and cell activation through interaction with the 
chemokine ligands CCL3, CCL4 and CCL5, which are up-regulated at the site of 
infection (reviewed in reference (Sorce et al., 2011 )). Understanding the role of CCR5 
in the control of pathogen infections has important implications for human health 
beyond that of other chemokine ligand/receptor interactions, in view of the discovery 
that CCR5 is a major co-receptor for HIV-1 (reviewed in reference (Alkhatib, 2009)). 
Therefore, the chemokine receptor is an important target for therapeutic intervention 
against HIV/ AIDS, and recent clinical trials investigating the efficacy of CCR5 
antagonists in patients with HIV/ AIDS have provided promising results (reviewed in 
reference (Wilkin and Gulick, 2012)). However, it has been argued that if CCR5 had a 
protective role against another group of pathogens, for instance in flaviviral 
encephalitis, it follows that a therapeutic treatment, which aims to block the receptor, 
could exacerbate the diseases caused by these pathogens (Lim et al. , 2006; Klein, 
2008). 
CCR5 was the first chemokine receptor recognized to play a critical role in recovery 
from flavivirus encephalitis in a study that showed that absence of CCR5 prevented 
efficient leukocyte trafficking to the brain and viral clearance in mice infected with 
West Nile virus (WNV) (Glass et al., 2005). The important role of CCR5 in the human 
host -response against West Nile encephalitis was supported by a retrospective cohort 
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study involving persons homozygous for CCR5Ll32 (Glass et al., 2006), a loss-of-
function mutation found in 1-2% of Caucasians (Sorce et al., 2011 ). Compared to 
individuals without the mutation, persons carrying a homozygous CCR5Ll32 allele had 
an increased risk for symptomatic WNV infection. This finding was corroborated with a 
large-scale database study, which associated homozygosity for CCR5L'l32 with an 
increased risk of early and late clinical manifestation following WNV infection (Lim et 
al., 2010). 
CCR5Ll32 homozygosity has also been associated with severe tick-borne encephalitis 
symptoms (Kindberg et al., 2008) caused by infection with tick-borne encephalitis 
virus, and a severe case of yellow fever virus-associated viscerotropic disease 
(Pulendran et al., 2008). Tick-borne encephalitis and yellow fever viruses are also 
members of the Flavivirus genus, raising the question of generality of CCR5 as an 
important host factor in recovery from flaviviral infections. Confirmation of a broader 
link between CCR5 deficiency and augmented incidence and severity of flaviviral 
disease would add to the concern of potential adverse outcomes associated with CCR5 
antagonist use, in view of the large number of human infections inflicted by the 
different pathogenic members of the Flavivirus genus, and their widespread global 
distribution (reviewed in reference (Gould and Solomon, 2008)). 
In this chapter, I investigated the role and mechanism of CCR5 in recovery from 
infection in a mouse model of Japanese encephalitis. Japanese encephalitis virus (JEV) 
is -closely related to WNV, and in terms of human disease incidence and severity the 
most important member of a serocomplex of mosquito-borne, encephalitic flaviviruses 
(reviewed in reference (Solomon, 2004)). It is the leading cause of viral encephalitis in 
Asia, annually accounting for 30,000 to 50,000 cases and ~ 10,000 deaths. 
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Approximately 3 billion people in the Asia-Pacific region are at risk of infection with 
JEV. Host immune factors are thought to be the dominant determinants of disease 
outcome in Japanese encephalitis (reviewed in (Halstead and Jacobson, 2003)), with 
intact type I interferon (Lee and Lobigs, 2002) and vigorous humoral immune responses 
(Chapter 3) essential for recovery, and CD8+ T cell immunity providing a subsidiary 
contribution to controlling JEV infection. With the use of CCR5-deficient mice I 
present in this chapter that the chemokine receptor is an additional important host factor 
involved in reducing disease severity with Japanese encephalitis. 
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6.2 Results 
6.2.1 CCR5 is required for protection from Japanese encephalitis. To 
assess the impact of CCR5 on the pathogenesis of Japanese encephalitis, mortality was 
recorded in 8-week-old congenic CCR5_1_ and CCR5+/+ wild-type mice after i.v. 
challenge with 103 PFU of JEV. Moribund mice in both groups presented with similar 
clinical signs starting with generalized piloerection, paresis and rigidity, invariably 
progressing to severe neurological signs demonstrated by postural imbalance, ataxia and 
generalized tonic-clonic seizures. Median survival time amongst mice that succumbed 
to infection did not differ between the two groups ( 11. 7 + 2.3 days for CCR5_1_ and 11.1 
+ 2.1 days for CCR5+;+ mice). Nevertheless, absence of CCR5 resulted in a significant 
increase in mortality: 64% in CCR5_1_ versus 28% in CCR5+;+ mice (Fig. 6.1 ). 
To address the mechanism for increased susceptibility of mice to JEV infection in the 
absence of CCR5, viral titers in CCR5_1_ and control mice infected with 103 PFU, i.v., 
were determined by real-time RT-PCR in serum and spleen, and by plaque assay in 
brain and spinal cord. Both groups displayed similar viral burden in serum from day 2 
to day 6 pi, with peak viremia occurring on day 2 pi (Fig. 6.2A). Similarly, viral load in 
spleen did not differ significantly between the two groups (Fig. 6.2B). On the other 
hand, viral spread into and/or clearance from the CNS was significantly affected by the 
absence of CCR5: compared to control mice, viral load in brains of CCR5_1_ mice was 
between 10- and 10,000-fold higher on days 8 and 10 pi, respectively, with the 
proportion of mice showing detectable virus titers markedly greater in CCR5_1_ mice 
than that in the control group (Fig. 6.2C). In addition, viral spread in the CNS was 
more pronounced in CCR5_1_ mice, with viral titers in spinal cord exceeding those in 
CCR5+;+ mice by four log on day 10 pi (Fig. 6.2D). 
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Together, these data suggest that CCR5 is critically required for recovery from JEV 
infection. 
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Figure 6.1 Susceptibility of CCRS+t+ and CCRS_,_ mice to infection with 
JEV. Groups of 8-week-old mice were infected iv with 103 PFU of JEV. Morbidity 
and mortality were recorded daily, and surviving mice were monitored for 28 days. The 
data shown were constructed from two independent experiments. The significance of 
differences in mortality between wild-type (n=28) and knockout mice (n=42) was 
determined by using the log-rank test(**, P < 0.01). 
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Figure 6.2 JEV burden in serum and tissue samples. JEV burden in (A) 
serum, (B) spleen, (C) brain and (D) spinal cord of CCR5+;+ and CCRs-1- mice after iv 
infection with 103 PFU of JEV. At the indicated time points, animals were sacrificed 
and the viral RNA content of serum and spleen samples were measured by real-time 
RT-PCR, while viral content in brain and spinal cord samples were measured by plaque 
titration. Data shown were constructed from 2 independent experiments. Each symbol 
represents an individual mouse, and geometric mean titers are indicated by horizontal 
lines. The lower limit of virus detection is indicated by the horizontal dotted line. 
Asterisks denote significant differences(**, P < 0.01). 
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6.2.2 Humeral immunity in the absence of CCRS. In chapter 3, I have 
established a pivotal role of antibody in recovery from JEV infection. Given that CCR5 
is expressed on CD4 + T cells, which are required for efficient generation and 
maintenance of hum oral immunity against JEV, I investigated whether a deficiency in 
CCR5 would result in poorer JEV-specific antibody responses. However, the kinetics 
and magnitude of the IgM response was similar in CCR5_1_ and control mice, appearing 
first on day 4 pi, and peaking on day 8 pi (Fig. 6.3A). Class switching to IgG production 
was also comparable between both groups, initially detected on day 8 pi, and increasing 
on day 10 pi (Fig. 6.3B). Assessment of functional activity of the antibody responses by 
neutralization assay revealed no significant difference between the two groups, reaching 
mean PRNT 50 titers of 660 (range, 80 to 1280) in CCR5_1_ mice and 570 (range, 160 to 
1280) in CCR5+/+ mice on day 10 pi (Fig. 6.3C). 
These data indicate that a deficiency in CCR5 does not compromise the ability of mice 
to prime JEV-specific B cell immune responses. 
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Figure 6.3 Antibody responses in CCRS+t+ and CCRS_,_ mice. Eight-week-
old CCR5+;+ and CCRs-1- mice were infected iv with 103 PFU of JEV, and serum 
samples were collected at the indicated time points. Anti-JEV IgM (A) and IgG (B) 
isotype antibody titers were determined by ELISA. The data presented are reciprocal 
mean endpoint titers representative of 4 mice per time point with the SEM indicated by 
error bars. (C) Neutralizing antibody titers determined by plaque reduction 
ne~tralization assay. The data presented are mean PRNT 50 titers representative of 5 
mice per -time point, and error bars indicate the SEM. 
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6.2.3 Blunted NK and CDS+ T cell responses in CCRS_,_ mice. NK cells form 
an important part of the cellular arm of the host's innate immunity, and function by 
killing virally infected cells and by release of the cytokines, IFN-y and TNF-a. NK cell 
activity in JEV infected CCRs-1- and control mice were determined by measuring 
cytolytic activity against Y AC-1 cells and by intracellular staining of IFN-y. At the peak 
of NK cell activity ( day 4 pi), lysis of Y AC-1 cells was significantly reduced in CCRs-1-
mice compared to CCRS+I+ mice (Fig. 6.4A,B). This was substantiated by a 
significantly reduced number of activated, IFN-y-expressing, NK cells in spleen of 
CCRs-1- relative to control mice at day 4 pi based on the expression of IFN-y (Fig. 
6.4C). 
CD8+ T cells form the dominant cytotoxic arm of the adaptive immune system. I 
chapter 3, I have presented a subsidiary role of CD8+ T cells ~in recovery from JEV 
infection. It is hypothesized that a defective CD8+ T cell response could, at least in part, 
account for the increase in susceptibility of CCRs-1- mice to JEV infection. The primary 
murine CD8+ T cell response against JEV and other flaviviruses peaks at 7 days pi, and 
thereafter markedly decline (Chapter 3; Kesson et al., 1987; Purtha et al., 2007). Figure 
6.4D demonstrates a significantly blunted JEV-immune CD8+ T cell response in 
CCRs-1- relative to control mice, determined by intracellular cytokine staining following 
ex vivo stimulation of CD8+ lymphocytes with a JEV NS4B protein-derived H-2Db-
binding peptide. Relative to CCR5+;+ mice, CCRs-1- mice showed a 61 % and 74% 
reduction in the number of IFN-y-secreting CD8+ T cells, and a 60% and 64% reduction 
in the number of TNF-a-secreting CD8+ T cells in spleen on days 4 and 7 pi with JEV, 
respectively (Fig. 6.4E). This was also reflected in a significantly smaller number of 
multifunctional JEV-immune CD8+ T cells ( defined as the number of CD8+ T cells 
expressing both IFN-y and TNF-a following stimulation with cognate peptide), which 
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was reduced by 3-fold and 4-fold on days 4 and 7 pi, respectively, in the absence of 
CCR5 expression (Fig. 6.4F). 
Collectively, these data indicate that a deficiency in CCR5 results in blunted NK and 
CD8+ T cell responses after JEV infection. 
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Figure 6.4 NK and c□a+ T cell responses in CCRS+t+ and CCRs·'· mice 
infected with JEV. Eight-week-old CCR5+;+ and CCRs·1- mice were infected iv with 
103 PFU of JEV or left uninfected. (A) Spleens were collected at day 4 pi and tested for 
NK cell cytotoxicity in a standard 51 Cr release assay using uninfected Y AC-I cells as 
targets. The percentage of NK cell lysis is plotted against an increasing e/t cell ratio. 
Means for 5 samples + SEM are presented, and data are representative of 2 independent 
experiments. (B) NK cell cytotoxicity at indicated time points with an e/t cell ratio of 
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120: 1. Means for 5 samples + the SEM are presented, and data are representative of 2 
independent experiments. (C) Numbers of NKl.1 + stained splenocytes expressing IFN-y 
were identified by flow cytometry at day 0 and 4 pi Means for 5 samples + the SEM are 
presented, and data are representative of 2 independent experiments. (D) Splenocytes 
harvested at day 7 pi and stimulated ex vivo with live JEV, H-2Db-restricted JEV NS4B 
protein-derived peptides, H-2Db -restricted ECTV negative-control peptide or mock 
treated, and IFN-y production in CD8+ T cells was measured by flow cytometry. Means 
for 3 samples + the SEM are presented, and data are representative of 2 independent 
experiments. (E) Kinetics of JEV immune CD8+ T cell activation measured after ex vivo 
stimulation with Db-restricted JEV NS4B peptide, showing percentage of CD8+ T cells 
per spleen that express IFN-y, TNF-a, or (F) both cytokines following stimulation. (G-I) 
Representative dot plots of cytokine production in NK and CD8+ T cells at indicated 
time points. Asterisks denote significant differences (*, P < 0.05). 
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6.2.4 Impaired leukocyte proliferation and trafficking in CCR5_,_ mice. 
CCR5 expression drives the migration of leukocytes into the CNS after WNV infection, 
and thereby contributes to viral clearance and recovery from infection (Glass et al., 
2005). To investigate whether this is also evident in this mouse model of Japanese 
encephalitis, I isolated leukocytes from brains of JEV infected CCR5+/+ and CCR5_1_ 
mice by density gradient centrifugation and quantified leukocyte subpopulations by 
flow-cytometry . On day 7 pi, CCR5_1_ mice showed a significant (~50%) reduction in 
infiltration of leukocytes into the brain relative to control mice, and this effect was 
found for all CCR5-expressing subpopulations, viz. NK cells, F480+/CD45hi 
macrophages, CD8+ T cells and CD4+ T cells (Fig. 6.5A-D). This difference ceased to 
be significant by day 10 pi. These data show that in the case of Japanese encephalitis, 
the absence of CCR5 resulted in delayed trafficking of leukocytes into the brain, despite 
the much higher virus titers in the CNS of infected CCR5_1_ than CCR5+;+ mice. 
Given the role of CCR5 expression in augmented leukocyte trafficking into the brain, I 
then assessed the proportion of cells of the different leukocyte subpopulations that 
express the chemokine receptor using CCR5+/+ mice that were infected with JEV. On 
day 7 pi, 15% of NK cells, 12% of F4/80+/CD45hi infiltrating macrophages, 8% of 
CD8+ T cells and 20% of CD4+ T cells were CCR5-positive (Fig. 6.5E). This proportion 
increased on day 10 pi in the case of CD8+ T cells (19%) and F4/80+/CD45hi infiltrating 
macrophages (16%), but decreased for NK and CD4+ T cells. Similar numbers of 
infiltrating CCR5-positive cells as a proportion of the different leukocyte 
subpopulations in the brain have been observed in mice with West Nile encephalitis 
(Glass et al., 2005) 
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To assess whether impaired trafficking of leukocytes, per se, or a failure of leukocyte 
expansion in the periphery accounted for the reduced numbers of immune cells in the 
brain of infected CCR5_1_ relative to control mice, splenic cellularity in CCR5_1_ and 
CCR5+;+ mice were quantified at various time points after JEV infection. As expected, 
given that spleen serves as the main immune-responsive lymphoid organ after an iv 
challenge, total splenocyte numbers in CCR5 +;+ n1ice increased following infection with 
JEV, with the peak expansion on day 7 pi (8 x 107 cells/spleen; Fig. 6.6A). This 
contrasted with a significantly lower number of splenocytes in JEV infected mice 
lacking CCR5 expression, although the kinetics of the response was similar between the 
two groups of mice (Fig. 6.6A). The deficit in cell numbers was found across the 
different CCR5-encoding splenocyte subpopulations, showing a reduction of 43% for 
NK cells, 33% for F4/80+ macrophages, 34% for CD4+ T cells, and 39% for CD8+ T 
cells in CCR5_1_ mice relative to control animals on day 7 pi -(Figure 6.6B-E). The 
percentage reduction of T cell numbers and activation phenotype (Fig. 6.4) in spleen on 
day 7 pi correlated closely with the differential leukocyte migration into the brains of 
CCR5_1_ and wt mice (Fig. 6.5). 
Together these data imply that the impaired trafficking of leukocytes into the CNS after 
JEV infection in CCR5_1_ mice may, at least in part, be a direct result of a deficit in 
leukocyte numbers in the periphery. 
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Figure 6.5 Leukocyte trafficking into the CNS. Kinetics of cell infiltration 
into the brain of 8-week-old CCR5+;+ and CCRs-1- mice infected iv with 103 PFU of 
JEV. Leukocytes were isolated at indicated time points from the brains of infected mice 
and stained for identification as (A) CDS+ T cell, (B) CD4+ T cell, (C) NKl .1 + cell and 
(D) F4/80+/CD45Hi infiltrating macrophages. Leukocyte subpopulations were gated for 
CCR5 expression (E) with representative histograms on day 10 pi (F). Means are 
derived from 4-9 samples per time point, error bars denote the SEM, and data are 
representative of 2 independent experiments. Asterisks denote significant differences (*, 
P < 0.05; **, P < 0.01). 
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Figure 6.6 Leukocyte numbers in spleen after JEV infection. Kinetics of 
cell expansion in spleens of 8-week-old CCR5+;+ and CCRs·1- mice infected iv with 103 
PFU of JEV. (A) Spleens were collected at indicated time points from infected mice and 
total splenocyte numbers were determined. Cells were then stained and identified as 
CD8+ T cell (B), CD4+ T cell (C), NKl .1 + cell (D) and F4/80+ macrophages (E). Means 
are derived from 4-8 samples per time point, error bars denote the SEM, and data are 
representative of 2 independent experiments. Asterisks denote significant differences (* , 
P < 0.05; .** , P < 0.01; ***, P < 0.001). 
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6.2.5 Early transfer of CCR5-deficient splenocytes increases survival of 
recipient CCR5_,_ mice challenged with JEV. The mechanistic studies on the role 
of CCR5 in recovery from JEV infection showed deficiencies in leukocyte trafficking to 
the CNS, blunted NK and CD8+ T cell responses, and low splenic cellularity, while a 
previous investigation on WNV concluded that CCR5 increased host survival 
predominantly by promoting leukocyte migration to the infected brain (Glass et al., 
2005). To test whether defective immune cell priming and expansion significantly 
contributed to the increased susceptibility of CCRs-1- mice to JEV infection, I 
adoptively transferred splenocytes from JEV infected CCRs-1- and CCR5 +;+ mice to 
CCRs-1- recipients lethally challenged with the virus. Complete protection was achieved 
when total immune splenocytes from either donor strain were transferred at day 1 pi 
with JEV (Table 6.1 ). In contrast, no increase in survival was observed when the 
transfers were performed at 3 days pi, independent of whether- the donor mice were 
CCR5 sufficient or deficient. This suggested that following the establishment of a CNS 
infection, viral clearance and protection mediated by the adaptive immune responses is 
ineffective in the case of Japanese encephalitis. This conclusion is not limited to the 
CCR5-deficient recipient mice, since a similar lack of protective value against JEV of 
late transfer ( day 3 post-challenge) of immune spleen cells was also found in wild-type 
B6 recipients (unpublished data). 
Given the dominant role of B cells (which do not express CCR5) in recovery from 
Japanese encephalitis (Chapter 3), I then performed adoptive transfer experiments of B 
ceU-depleted splenocytes from CCRs-1- and CCR5+;+ donor mice to CCR5_1_ recipients at 
one day after JEV infection. Interestingly, even B cell-depleted splenocytes from both 
donor mice provided significant, albeit not complete, protection, increasing the survival 
rate of recipient mice to that of untreated CCR5+;+ mice infected with JEV (Table 6.1 ). 
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Together, these data confirm the important role of B cells in protection against Japanese 
encephalitis, and indicate that CCR5 expression was not required for the disease-
ameliorating effect of B cell-depleted lymphocytes primed against JEV. The data also 
suggest that in the adoptive transfer model, control of JEV infection by immune T cells 
likely occurred extraneurally, since protection was seen only when the cells were 
provided early pi. Accordingly, migration of the lymphocytes to peripheral sites of 
infection did not require expression of CCR5. 
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Table 6.1 Adoptive transfer of immune splenocytes from CCRS+t+ or 
CCRS_,_ donor mice protect CCRS-deficient recipient mice against 
Japanese encephalitis. 
Treatment a 
PBS control 
Transfer at one day post-challenge 
Na"fve CCR5+/+ splenocytes (1 x 107 cells) 
Na·,ve CCR5_1_ splenocytes (1 x 107 cells) 
+/+ 7 Immune CCR5 splenocytes (1 x 10 cells) 
Immune CCR5_1_ splenocytes (1 x 107 cells) 
Mortality (No. of 
deaths/total) b 
71 % (15/21) 
MST (days)± 
soc, 
11.4 ± 1.5 
67% (8/12; P =0.92) 11.3 ± 2.3 
78% (10/14; P =0.93) 11.6 ± 2.2 
0% (0/1 0; P =0.0006) -
0% (0/1 0; P =0.0006) -
Immune CCR5+/+ splenocytes, B cell-depleted (5 x 106 cells) 33% (2/9; P =0.019) 12.0 ± 2.8 
Immune CCR5_1_ splenocytes, B cell-depleted (5 x 106 cells) 20% (2/10; P =0.012) 11.5 ± 0.7 
Transfer at three days post-challenge 
Immune CCR5+/+ splenocytes (2 x 107 cells) 
Immune CCR5_1_ splenocytes (2 x 107 cells) 
67% (6/9; P =0.57) 
80% (8/1 0; P =0.65) 
12.2 ± 1.9 
11.8 ± 2.8 
a Eight-week-old donor CCR5+/+ or CCR5_1_ mice were infected with 103 PFU of JEV, i.v., or left 
uninfected and sacrificed 7 days later for splenocyte collection with or without depletion of B 
cells. Cells were transferred to 8-week-old CCR5_1_ recipient mice infected 3 days or 1 day 
earlier with 103 PFU of JEV i.v. Surviving mice were monitored for 28 days. 
b Data are representative of 2 independent experiments. Immune splenocyte treatment groups 
were compared to the naive splenocyte control group to test for statistical significance. 
c No significant difference was noted between immune splenocyte treatment and control groups. 
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6.3 Discussion 
The role of the chemokine receptor CCR5 in infection is variable in terms of its impact 
on pathogenesis and disease outcome. An important disease-ameliorating contribution 
of CCR5 has been documented in settings of trypanosomiasis (Hardison et al., 2006), 
toxoplasmosis (Khan et al., 2006), influenza (Fadel et al., 2008; Dawson et al., 2000) 
parainfluenza (Kohlmeier et al., 2008), West Nile encephalitis (Glass et al., 2005), tick-
borne encephalitis (Kindberg et al., 2008), genital herpes (Thapa et al., 2007), and 
chlamydia infection (Olive et al., 2011 ), while no significant effect of CCR5 deficiency 
on the outcome of other microbial infections could be found (Zhong et al., 2004; 
Peterson et al., 2004; Nansen et al., 2002; Ank et al., 2005; Algood and Flynn, 2004). 
Mechanistically, the protective value of CCR5 has been largely attributed to its 
regulatory effect on leukocyte trafficking to the site of infect1on, although additional 
functions of CCR5 in the immune response involving antigen recognition (Castellino et 
al., 2006; Ank et al., 2005; Aliberti et al., 2000), priming and proliferation of 
lymphocytes (Hickman et al., 2011; Castellino et al., 2006; Ank et al., 2005; Aliberti et 
al., 2000; Thapa et al., 2007; Floto et al., 2006; Hugues et al., 2007; Nansen et al., 
2002), and T cell memory formation (Kohlmeier et al., 2011; Kohlmeier et al., 2008) 
have also been recognized. In contrast, a disease-potentiating effect of CCR5 has been 
found in experimental cerebral malaria (Belnoue et al., 2003), schistosomiasis (Souza et 
al., 2011 ), leishmaniasis (Sato et al., 1999), cryptococcosis (Huffnagle et al., 1999), 
herpes keratitis (Komatsu et al., 2008), mouse hepatitis virus-induced multiple sclerosis 
(Glass and Lane, 2003), and HIV/ AIDS (Salazar-Gonzalez et al., 2009), mostly as a 
consequence of increased immunopathology, and in the case of HIV/ AIDS due to usage 
of CCR5 as an alternative receptor for virus infection (reviewed in reference (Alkhatib, 
2009)). This dichotomy in the role of CCR5 in the immune response to infection with 
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different pathogens prevents generalization of the impact of the chemokine receptor in 
disease prognosis. 
In this chapter, I establish a critical role of CCR5 in recovery from Japanese 
encephalitis, which was reflected in increased viral burden in the CNS, but not 
extraneural tissues, and increased mortality in the absence of CCR5 expression. It was 
previously shown that type I interferon and antibody, but not T cells, are key to control 
of virus replication in peripheral tissues in the mouse model of Japanese encephalitis, 
while T cells play a role in reducing viral burden and dissemination in the CNS. CCR5-
deficient mice displayed a wide-ranging debilitation of JEV-specific immune responses; 
these included poor NK cell activity, a suboptimal JEV-immune CD8+ T cell response, 
low splenic cellularity, and impaired trafficking of leukocytes (NK cells, macrophages, 
and CD8+ and CD4+ T cells) to the brain. These factors most likely acted in concert to 
create a lethal combination of defective viral clearance from peripheral tissues and the 
CNS, thereby increasing the susceptibility of the host to JEV infection. In addition, 
recent findings suggest that CCR5, which is expressed in neurons and is up-regulated in 
the brain in pathological conditions, could have a direct neuro-protective function by 
increasing neuronal survival (reviewed in reference (Sorce et al. , 2011)). 
Our results are consistent with the previous finding of increased susceptibility of CCR5-
deficient mice in a model of West Nile encephalitis (Glass et al. , 2005), although 
mechanistic differences in the role of CCR5 in recovery from WNV and JEV infection 
-are apparent. While a significant (>50%) overall reduction in migration of NK cells, 
CD4+ and CD8+ T cells, and activated infiltrating macrophages to the brain of JEV and 
WNV infected CCR5_1_ mice was seen in both investigations, this difference relative to 
CCR5+;+ control mice narrowed between days 7 and 10 pi in the case of JEV infection, 
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but became more pronounced for WNV. More importantly, the WNV study found 
similar splenic immune responses in CCR5 sufficient and deficient mice, whereas I 
observed markedly reduced numbers of lymphocytes in spleens of mice lacking CCR5 
expression. It is likely that the latter was a major factor contributing to the severe 
phenotype in JEV infected CCR5-deficient mice, since adoptive transfer of B cell-
depleted immune splenocytes corrected the phenotype, independent of whether the cells 
were derived from CCRs-1- or CCRS+I+ donor mice. Low splenocyte numbers in the 
absence of CCR5 may reflect restricted leukocyte proliferation secondary to poor early 
priming, increased cell turnover to other lymphoid organs, and/or increased T cell 
death. However, since the spleen is the main responsive peripheral lymphoid organ 
following an iv challenge, defective proliferation most likely accounts for the 
diminished splenocyte numbers in CCRs-1- mice. Moreover, other studies have also 
observed restricted proliferation of splenocytes, or specific -subsets thereof, in the 
absence of CCR5, both in physiologic (Weiss et al., 2011) and pathologic conditions 
(Ank et al., 2005; Thapa et al., 2007). The latter studies deal with virus challenge 
models with a resultant impairment in control of infection. 
Concomitant with the limited number of leukocytes in spleens of CCR5-deficient mice 
infected with JEV, the functional activities of NK and CD8+ T cell responses were 
blunted, while the antibody response against JEV did not significantly differ from that 
elicited in infected wild-type mice. This finding was consistent with several other 
studies that demonstrated a critical role of CCR5 expression on na"ive T cells in 
activation of CD8+ T cell responses by guiding the cells to and enhancing interaction 
with antigen-presenting dendritic cells in immunogen-draining lymph nodes (Aliberti et 
al., 2000; Floto et al., 2006; Hugues et al., 2007; Hickman et al., 2011; Castellino et al., 
-l.. -l.. 
2006). In chapter 3, I have found that co-transfer of immune CD4 ' and CD8 ' T cells, 
but not individual transfer of either lymphocyte subpopulations, was protective in lethal 
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infection with JEV. Thus, the suboptimal stimulation of virus-specific T cell responses 
together with their reduced migration into the CNS most likely accounted for the 
increased susceptibility of CCR5-deficient mice to Japanese encephalitis. 
It is unclear whether the reduced NK cell activity in CCR5-deficient relative to wild-
type mice contributed to the increased disease severity with Japanese encephalitis, as 
has been proposed in studies on herpes simplex virus in CCR5_1_ mice (Ank et al., 2005; 
Thapa et al., 2007). Fla vi viruses are in general poor inducers of NK cells, and flavivirus 
infection reduces the susceptibility of target cells to NK cell lysis (Momburg et al., 
2001; Lo bigs et al., 1996). The latter is thought to be a consequence of virus-induced 
up-regulation of MHC-I on the surface of flavivirus-infected cells (Abraham et al., 
201 0; Kesson and King, 2001; King and Kesson, 1988; Lo bigs et al., 2003a; 
Mullbacher and Lobigs, 1995). Therefore, it appears that NK cell responses do not 
markedly enhance recovery from flavivirus infection. Consistent with this 
interpretation, in chapter 5, in vivo depletion of NK cells using monoclonal antibody 
anti-NKI. l did not result in increased mortality or increased viral burden in the CNS in 
adult mice infected with JEV. 
In conclusion, this chapter established CCR5 as a host factor against severe disease in a 
mouse model of Japanese encephalitis. Control and elimination of viral spread is largely 
dependent on rapid activation of antiviral leukocytes, and their recruitment to the sites 
of peripheral infection and/or into the CNS. In the absence of CCR5, an extensive 
immune dysfunction ensued, encompassing probable involvement of defective early 
priming and subsequent aberrant leukocyte activation, restricted splenocyte expansion, 
and limited trafficking. This finding raises possible safety concerns regarding the use of 
CCR5 antagonists in HIV individuals, particularly in regions where both HIV and JEV 
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are endemic (Erlanger et al., 2009; Simon et al., 2006). While the benefits of taking the 
drug most likely far outweigh the potential risk of enhanced susceptibility to Japanese 
encephalitis, mitigating the latter risk factor by instituting precautionary measures 
including patient education, limiting mosquito exposure, and/or vaccination may be 
warranted. 
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Chapter 7 
Forward genetics approach in localizing loss-of-
function mutation spontaneously generated in an 
inbred knockout mouse strain 
7.1 Introduction 
The host 'resistome' is a collection of non-redundant genes that confers resistance from 
challenge with pathogens (reviewed in (Beutler et al., 2006, Beutler et al., 2007)). 
While some genes are pathogen-specific, mostly provide resistance against diverse 
group of pathogens. The resistome defines the survival outcome with which a particular 
susceptible host may present after an infectious insult. The acquisition of this vital 
network of resistant genes allowed the selection and survival of certain species, and 
served as a dominant force in evolution. Identifying the list of genes catalogued under 
resistome is fundamental in the understanding of host-pathogen interactions. 
The recent technological advancements in forward and reverse genetics enabled the 
discovery and dissection of viral resistance/susceptibility genes (reviewed in 
(Gruenheid and Gros, 2010)). Much of our understanding on the immune system is 
derived from studies utilizing the reverse genetics approach; where a gene of interest is 
knocked-out by various recombinant techniques, and subsequent recording of the 
observable phenotype upon exposure to a particular pathogen. Techniques used in 
reverse genetics would include site-directed mutagenesis, gene targeting via 
homologous recombination, gene silencing via RNA interference, and interference via 
transgenes (reviewed in (Adams and van der Weyden, 2008)). On the other hand, the 
classic or forward genetic approach to biological problems is unbiased by hypotheses: it 
begins with a phenotype of unknown origin and ends with the identification of 
mutation(s) that are responsible for the phenotype. The unidentified mutation can occur 
spontaneously or naturally, or can be randomly introduced via artificial means though 
radiation mutagenesis, ENU (N-ethyl-N-nitrosourea) mutagenesis, or Sleeping Beauty 
transposon system (reviewed in (Carlson and Largaespada, 2005)). 
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For the past 25 years, gene mapping and positional cloning are regarded as useful 
experimental approaches utilized in forward genetics to successfully uncover 
spontaneous mutations naturally generated in inbred mouse strains (reviewed in 
(Gruenheid and Gros, 2010; Vidal et al., 2008)). These forward genetic approaches 
brought about remarkable discoveries, depicting for the first time various genes with 
diverse immunologic roles vital for defense against microbial infections; including NK 
cell activity, macrophage intraphagosomal activity, pathogen sensing, intracellular 
signal transduction pathway intermediates, and interferon-inducible effector antiviral 
proteins (Table 7 .1 ). Furthermore, the availability of the assembled sequences of the 
human and mouse genomes and major advances in genome sequencing technologies 
have made gene discovery based on the classic genetic strategy a relatively 
straightforward process (Nelms and Goodnow, 2001). 
In this chapter, I will present a finding of a virus resistance/susceptibility gene mutation 
spontaneously generated in an inbred knockout mouse strain. A classic genetic approach 
was employed: starting with a phenotype of increased susceptibility to viral infection, 
subsequently localizing the gene of interest in Chromosome 1, and finally short-listing 
candidate genes responsible for the loss-of-function mutation. A novel mouse strain, 
carrying the unknown mutation, was generated, and was designated as the 'Tuara' mice 
(Originally derived from a Visayan language "Tua ra!" which is literally translated in 
English as: "There it is" . The expression is commonly used in the context of 
discovering an object after a long, patient, and hardwork search. It is also fitted with the 
acronym Translated Unit with Antiviral and Regulatory Activity). 
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Table7.1 Summary of resistance/susceptibility genes identified through classical or forward genetics approach 
Year 
1988 
1993 
1998 
2001 
2002 
2003 
2003 
2004 
2005 
2005 
2005 
2005 
2006 
2006 
2006 
2007 
2007 
Locus 
Mx . 
Bcg/Ity/Lsh 
Lps 
Cmvl 
Flv 
Lgnl 
Lps2 
Char4 
Cmv3 
Sstl 
Obi 
heedless 
Crtq3 
3d 
Ltsxl 
Myls 
Char9 
Chromosome 
16 
1 
4 
6 
5 
13 
17 
3 
6 
1 
5 
18 
11 
19 
11 
8 
10 
Table adapted from Grunheid and Gros (2010) 
Mouse strain 
Several 
Several 
C3H/HeJ 
C57BL/6J 
Several 
A/J 
ENU-induced 
AcB55, AcB61 
MA/My 
C3HeB/FeJ 
ENU-induced 
ENU-induced 
C3H/HeJ 
ENU-induced 
Several 
BXH2 
A/J 
Gene (mutation) 
Mxl (loss of expression) 
Nrampl (G169D) 
Tlr4 (P714H) 
Ly49h (presence versus 
absence) 
Oaslb (premature 
STOP) 
Naip5 
TRIF/Ticaml (1 bp 
deletion) 
Pklr (I90N) 
Ly49p + H2k 
Iprl(loss of expression) 
CD36 (premature STOP) 
CD14 
Irgbl0 (reduced 
expression) 
Unc93b (H412R) 
Nalplb (gain of 
expression) 
Irf8 (R294C) 
Vnnl/3 (reduced 
expression) 
Phenot~e 
Susceptibility to influenza 
Susceptibility to infection with BCG, S. 
typhimurium, L. donovani 
LPS non-responsiveness, susceptibility to 
S. typhimurium infection 
Resistance to MCMV infection 
Susceptibility to West Nile virus infection 
Increased L. pneumophila replication in 
macrophages 
Defective response to TLR-3 and -4 ligands 
Resistance to P. chabaudi infection 
Resistance to MCMV infection 
Susceptibility to pulmonary TB 
Reduced response to TLR-2 and 6 ligands. 
Susceptibility to S. aureus infection 
No activation of TRIF/TRAM pathway downstream 
of TLR-4. Defective response to TLR-2 and 6 
ligands 
Susceptibility to C. trachomatis infection 
Diminished response of TLR-3, -7 and -9 antigen 
presentation defect 
Susceptibility to anthrax lethal toxin 
Susceptibility to M. bovis, S. typhimurium and P. chabaudi 
infection 
Susceptibility to P. chabaudi infection 
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7.2 Results and Discussion 
7.2.1 Spontaneous mutation in MHCII-Aa_,_ mice resulting in enhanced 
susceptibility to flavivirus infection. In chapter 3, the antiviral role of adaptive 
immune response-effector cell populations in recovery from JEV infection was 
presented. For instance, MHC-II-deficient mice that lack the four classical MHC-II 
genes via a large deletion of the entire class II region (MHCII-Aa;p-1-) were used as 
model to elucidate the role of CD4+ T cells in JEV pathogenesis. Infection of MHCII-
Aa;p-1- mice, relative to B/6 wt control mice, displayed 100% mortality and comparable 
overall mean survival time (MST) (Fig. 3.6). Most of MHCII-Aa;p-1- mice succumbed 
to infection by day 12, while a remaining 21 % had a MST of -20 days, reflecting a 
failure to clear infection in the absence of CD4+ T help required for maintenance of the 
antiviral antibody response. 
MHCII-Ap-1- is another available MHC-"Il knockout mice designed via inactivation of 
the AP locus of the MHC-II complex. Challenge of MHCII-Ap-1- mice with JEV 
similarly presented with 'delayed mortality ', commencing at 12 days pi and onwards. 
Although, for reasons not clear, MHCII-Ap-1- mice also displayed mortality rate that is 
comparable to B/6 wt (Fig 7. lA). MHCII-Aa-/- is the third alternative MHC-II-deficient 
mice designed via selective disruption of Aa locus of the MHC-II complex. 
Interestingly, sc infection of MHCII-Aa-/- mice with JEV presented with an unexpected 
disease outcome. Relative to wt, MHCII-Aa/p-/- and MHCII-Ap-/- mice, infection of 
MHCII-Aa-1- mice resulted in a surprising phenotype of complete and rapid mortality, 
with MST of 8.7 + 3 days (Fig. 7. lA). The .' early mortality ' observed in MHCII-Aa_1_ 
suggests an unknown spontaneous mutation generated independently of the known 
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MHC-II gene defect. The phenotype was more pronounced when MHCII-Aa-1- mice 
were infected with a naturally attenuated Australian strain of WNV, Kunjin virus 
(WNVKUN) (Fig. 7. lB). All wt and MHCII-Aa/~-/- survived WNVKUN challenge, while 
100% MHCII-Aa-/- mice succumbed to infection with MST of 9 + 2.0. 
The investigation on the relative value of the putative viral resistance gene was then 
extended to a flavivirus outside of JE serocomplex. Given its importance in terms of 
global disease burden (reviewed in (Simmons et al., 2012)), MHCII-Aa-1- and B/6 
control mice were challenged intravenously (iv) with lxl 05 PFU of dengue virus 
serotype 2 (DENV-2), and mortality recorded over a 60-day observation period (Fig. 
7 .2A). As expected, all wt controls survived, and did not present with any signs of 
disease. On the contrary, 29% (2 out of 7) of MHCII-Aa_;_ mice succumbed to infection, 
with late time of death on days 49 and 59 pi. Although not statistically significant, the 
data suggest that MHCII-Aa-/- mice are more susceptible with to infection with DENV-
2 than wt mice. 
Even more surprising is the finding that MHCII-Aa_;_ mice were also susceptible to an 
infection with a live-attenuated vaccine, ChimeriVax-JE. ChimeriVax-JE is a recently 
FDA-approved vaccine against JEV, that was genetically engineered via a construct 
composing of genes encoding for premembrane and envelope proteins of JEV ( vaccine 
strain SA 14-14-2) and nonstructural proteins of yellow fever 17D (YF-17D) vaccine 
(Monath et al., 2003). Subcutaneous challenge of MHCII-Aa_1_ mice with lxl05 PFU of 
ChimeriVax-JE resulted in 44% mortality, with a MST of 33.0 + 5.4 days (Fig. 7.28). It 
was shown in early preclinical studies that ChimeriVax-JE has a superior safety profile 
relative to its partially neuroattenuated, YF-1 7D vaccine. Thus, 4-week-old B/6 wt mice 
survived intracranial (ic) inoculation of 1x103 PFU of ChimeriVax-JE, as compared to 
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complete lethality observed when the same dose of YF-17D was given (Guirakhoo et 
al., 1999, Monath et al., 2000). Similar to this finding, I have demonstrated that all B/6 
wt mice survived ic challenge with lx103 PFU of ChimeriVax-JE (Fig. 7.2C). In 
contrast, 100% of MHCII-Aa_;_ mice succumbed to the infection, with a MST of 21.4 + 
0.6 days. 
Altogether, these data show that MHCII-Aa-1- mice display an extraordinarily 
sensitivity to flaviviral challenge. This susceptibility phenotype cannot be explained per 
se by a defect in MHC-II genes. It was hypothesized that in addition to the targeted 
disruption of Aa gene, a spontaneous mutation had occurred in MHCII-Aa_;_ mouse 
strain resulting in the acquisition of an unidentified susceptibility allele for flaviviral 
infection. 
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Figure 7.1 Susceptibility of MHCII-Aa/B-'-, MHCII-Aa-'-, MHCII-AB-'-and 8/6 
mice to flavivirus infection. Groups of 8-week-old mice were infected sc via the 
footpad with 103 PFU of JEV (A) or WNVKUN (B). Morbidity and mortality were 
-
recorded daily, and surviving mice were monitored for 28 days. The data shown were 
constructed from two independent experiments. Asterisks denote statistical significance 
in mortality between B/6 and various knockout mice(* , P < 0.05; *** , P < 0.001). 
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Figure 7.2 Susceptibility of MHCII-Aa·'-, and B/6 wt mice to infection with 
DENV-2 and ChimeriVax-JE. Groups of 6-week-old mice were inoculated iv with 
105 PFU of DENY (A) or sc with 105 PFU of ChimeriVax-JE (B). Morbidity and 
mortality were recorded daily, and surviving mice were monitored for 60 days. Groups 
.., 
of 4-week-old mice were inoculated ic with 1 0-' PFU of ChimeriVax-JE (C), and 
morbidity and mortality recorded daily for a 28-day-observation period. The data shown 
were constructed from two independent experiments. Asterisks denote statistical 
significance(*, P < 0.05; ***, P < 0.001). 
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7.2.2 High viral burden in MHCII-Aa_,_ mice. After sc challenge with JEV, viral 
load in serum and CNS were significantly higher in MHCII-Aa-1- mice relative to B/6 
wt controls (Fig. 7.3). At day 2 pi viral load in serum of MHCII-Aa_;_ mice was> 100-
fold higher than that in control mice (Fig. 7.3A). All infected MHCII-Aa-1- mice 
presented with rapid and uncontrolled virus dissemination into the CNS. At day 6 pi, 
viral load in brains of MHCII-Aa_1_ mice exceeded that in control mice by -1,000-fold 
(Fig. 7.38). In addition, virus dissemination into the spinal cords of MHCII-Aa-1- mice 
appeared earlier with a significantly elevated geometric mean titer (GMT) of 2.2xl 09 
(Fig. 7 .3C). This is contrasted with undetectable levels of virus in control mice. As 
presented in chapter 3, virus spread from brain to spinal cord of wt mice takes place 
between day 8 and day 10 pi in <50% of animals. It should also be noted that, in 
chapter 3, virus dissemination into the spinal cord of MHCII-Aa/~-/- mice occurred after 
day 8 pi (Chapter 3). Together, these data strongly suggest that in MHCII-Aa-1- mice, an 
unknown defect independent of MHC-II deficiency is responsible for the fulminant 
disease phenotype after JEV infection. 
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Figure 7.3 Viral burden in B/6 and MHCII-Aa_,_ mice after exposure to 
JEV. Eight-week-old mice were challenged with 103 PFU of JEV injected into the 
footpad, bled on day 2 pi for serum collection, and sacrificed on day 6 pi for collection 
of CNS tissues. Viremia was measured in RNA copies/ml by qRT-PCR; viral load in 
tissues was measured by plaque titration in Vero cells. The lower limit of virus 
detection was lxl 02 PFU/g tissue. Asterisks denote statistical significance(* , P < 0.05). 
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7.2.3 Enhanced virus growth in pnmary macrophages isolated from 
MHCII-Aa_,_ mice. Bone marrow-derived macrophages from mutant and B/6 wt mice 
were infected with JEV at multiplicity of infection (MOI) of 1, and virus yield in culture 
supernatant measured by plaque assay (Fig. 7 .4 ). At 24 hour pi, virus growth in MHCII-
Aa-1- macrophages was increased ~ 100-fold relative to that in cells from wt mice. This 
significant difference is similarly observed when bone marrow-derived macrophages 
were infected with WNV KUN or YFV (Fig. 7 .4 ). Relative to cells from wt mice, virus 
growth at 24 hours pi in MHCII-Aa-1- macrophages infected with WNVKUN or YFV was 
increased by ~50-fold. This cell culture model clearly demonstrates that an innate 
immune factor, unrelated to CD4+ T cell deficiency, is responsible for the enhanced 
susceptibility to viral infection. 
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Figure 7 .4 Susceptibility of 8/6 and MHCII-Aa _,_ bone marrow-derived 
macrophages to infection with flaviviruses. Bone marrow cells were isolated 
from lower extremity bones of B/6 wt and MHCII-Aa-1- mice as described in materials 
and methods, and selectively cultured for 7 days towards macrophage differentiation. 
Mature macrophages were then infected with JEV, WNVKUN; or YFV at MOI of 1. 
Virus load in culture supematants at 24 pi was determined by plaque titration in Vero 
cells. Asterisks denote statistical significance (* , P < 0.05). 
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7 .2.4 The unknown susceptibility allele in MHCII-Aa_,_ mice is a recessive 
trait with full penetrance. The genetic mapping approach enables rapid localization 
of a spontaneous mutation to a particular chromosomal region by co-segregation of the 
mutation with genetic markers interspersed throughout the genome (reviewed in (Nelms 
and Goodnow, 2001)). First, MHCII-Aa-1- mice were crossed with a mapping strain 
(B/10 mice) to produce F 1 (B6xB 10) progeny (Fig. 7 .5). The phenotypic outcome of the 
progeny F 1 (Filial 1 generation) mice after flaviviral challenge will define the 
subsequent cross necessary for genome mapping. If all Fl' s succumbed to infection, the 
mutation is expressed in a dominant fashion, and F 1 progenies should be intercrossed 
with each other to successfully segregate and localize the gene of interest. If all Fl' s 
survived the infection, then the phenotypic expression of the mutation is due to a 
recessive allele, and Fl progenies should be backcrossed with the original MHCII-Aa_;_ 
mice for a successful subsequent linkage mapping. All eight-week-old F 1 mice infected 
sc with 103 PFU WNVKUN survived the challenge (Table 7.2). Similarly, all MHCII-
Aa~-1-, B/6, and B/10 control mice survived the infection. In contrast, 100% of MHCII-
Aa-1- mice (n = 7) succumbed to the infection with WNVKUN. This indicates that the 
unknown susceptibility allele is a fully penetrating recessive trait. 
Given that the unknown mutation is a recessive phenotype, FI (B6xB I 0) mice were 
backcrossed to MHCII-Aa_;_ mice to generate N2 (nuclear or backcross generation) 
(B6xB6.B 10) progeny (Fig. 7 .6). Fifty percent of the N2 progenies were expected to 
carry the unknown mutation (affected), \vhile 50% were expected to be resistant 
(unaffected); also, 50% of N2 progeny were expected to be homozygous for the targeted 
disruption of the MHC-II Aa gene, and 50% heterozygous for this mutation. Progeny 
N2 mice were then screened phenotypically by sc challenge with WNV KUN· The result 
displayed consistency with the expected outcome and confirmed the presence of an 
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unknown susceptibility gene defect independent of MHC-II (Table 7.3). The 
susceptibility allele segregated form the MHC-II locus in simple Mendelian pattern of 
inheritance: 47% of the total were affected mice with 24% carrying the MHCII-Aa +/-
allele and 24% carrying the MHCII-Aa_;_ allele, while 53% of the total were unaffected 
with 21 % and 32% respectively carrying either MHCII-Aa +!- or MHCII-Aa-1- alleles. 
Meiotic recombination in F 1 and subsequent N2 mice generation acts as a genetic 
shuffle that can be used to distinguish regions of the genome that are closely linked to 
the susceptibility allele from regions that are unlinked. These regions were determined 
by linkage analysis in a last step of the mapping process by analysing the recombinant 
chromosomes inherited by N2 mice with a panel of single-nucleotide polymorphisms 
(SNPs) genetic markers that span the genome (Myajishev et al., 2001; Petkov et al. , 
2004a; Petkov et al., 2004b ). N2 mice were grouped as affected or unaffected for the 
virus susceptibility phenotype based on the outcome of infection with WNVKUN · DNA 
from tail samples of each infected N2 mouse was isolated, stored, and subsequently 
pooled in affected or unaffected groups. Pooled DNA was then analysed with the use of 
,___,90 SNPs genetic markers that can distinguish between B/6 and B/10 mice strains. 
Thus, SNPs closely linked to the unknown susceptibility allele will only yield the 
homozygous B/6 allelic fragment in N2 mutant mice, whereas analyses with unlinked 
markers will yield heterozygous B/6 and B/10 strain alleles. However, this initial 
attempt was unsuccessful. It was discovered that the original MHCII-Aa_;_ mice, 
initially thought to be of purely B6 background, were in fact a mixture of B/6 and B/ 10 
( data not shown). Accordingly the B6B 10 nomenclature is used for a second attempt of 
genome mapping. 
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F1 mice (MHCII-Aa·1--xB 10) heterozygous for mutation 
Screened for susceptibility to Kunjin virus 
If all F1s succumbed If all F1 s are resistant 
to infection to infection 
Mutation is of Mutation is of 
dominant phenotype recessive phenotype 
Figure Description: Wild-type, male or female 
Square - Male mouse 
Circle - Female mouse 
Empty Figure - Presence of unknown mutaion 
Couloured Border- Presence of MHCIIAa. mutation 
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Homozygous for MHCII-Aa & 
Homozygous for unknown mutation 
Heterozygous for MHCII-Aa mutation & 
Heterozygous for unknown mutation 
Heterozygous for MHCII-Aa mutation & 
Homozygous for unknown mutation 
Homozygous for MHCII-Aa mutation & 
Heterozygous for unknown mutation 
Wild type for MHCII-Aa & 
Homozygous for unknown mutation 
Figure 7.5 Initial mouse-cross design for genome mapping. MHCII-Aa_1_ 
mice were crossed to B/10 mice, and all progenies (Fl) produced are heterozygous for 
the MHCII-Aa defect and the unidentified mutation. Two probable outcomes were 
i~entified in the chart when Fl mice are challenged with WNV KUN · If all Fl 's 
succumbed to infection, the unknown susceptibility allele is a dominant trait; whereas 
when all Fl 's survived the infection, the unknown susceptibility allele is a recessive 
trait. 
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MHCII-Aa-1- (B6810) 
i 
N2 mice (B6810xB6810B10) 
50% of mice carry the unknown mutation (affected) 
50% of mice does not carry the unknown mutation (unaffected) 
50% are homozygous for MHCII-Aa mutation 
50% are heterozygous for MHCII-Aa mutation 
I 
Figure 7.6 F1 x MHCII-Aa-'-mouse cross design for genome mapping. Fl 
(MHCII-Aa-1-xB 10) mice were backcrossed to MHC-II-Aa_1_ mice, which were 
identified as B/6 contaminated B/10 background, hence the symbol, B6810 . Progenies 
produced (N2) are expected to be: 25% homozygous for unknown mutation and 
homozygous for MHCII-Aa defect, 25% homozygous for unknown mutation and 
heterozygous for MHCII-Aa defect, 25% heterozygous for unknown mutation and 
homozygous for MHCII-Aa defect, 25% heterozygous for unknown mutation and 
heterozygous for MHCII-Aa defect. 
192 
·---· - 'b 
Table 7.2 Susceptibility of F1 and vanous control mouse strains to 
WNVKuN infection. 
B/6 
B/10 
MHCII-Aa/~-i-
MHCII-Aa_1_ 
Fl 
Mortalityh 
0% (0/5) 
0% (0/5) 
0% (0/4) 
100% (7 /7)*** 
0% (0/6) 
MST 
10 + 0.00 
a Eight-week-old mice were challenged sc with 1x103 PFU sc WNVKuN virus. Morbidity and 
mortality were recorded for 30 days. 
b Statistical significance was computed in comparison with B/6 mice control. Asterisks denote 
significant difference(***, p < 0.001 ). 
Table 7.3 Susceptibility of N2 mice to WNVKuN infection. 
MHCII genotype Number (percentage) Number (percentage) Total 
of affected mice of unaffected mice 
MHCII-Aa+1- 9 (24%) 8 (21 %) 17 (45%) 
MHCII-Aa_1_ 9 (24%) 12 (32%) 21 (55%) 
Total 18 (47%) 20 (53%) 38 (100%) 
Thirty-eight 8-week-old N2 (B6810xB6810_B lO) mice were challenged sc with 1x103 PFU of 
WNVKuN, and observed for 28 days to record mortality. All mice were genotyped by PCR for the 
MHCII-Aa mutation as described in materials and methods . 
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Given that the original MHCII-Aa_;_ mice were in fact a mixture of B/6 and B/ 1O strain 
( earlier designated as B6B 10), a second attempt of genome mapping, using CBA mice as 
the mapping strain, was then performed. MHCII-Aa-1- mice were crossed with CBA 
mice to produce Fl progenies (B6B1oCBA) (Fig. 7.7). As expected, all Fl, CBA, and 
B/6 control mice were resistant to challenge with WNVKUN, while 100% of MHCII-Aa-
/- succumbed to infection (Table. 7.4). This is consistent with the phenotypic outcome 
observed in F 1 after the initial genome mapping, again confirming that the 
susceptibility allele is a fully penetrant recessive trait. 
Thereafter, Fl (B6B1oxCBA) mice were backcrossed to MHCII-Aa_1_ (B6810) mice to 
generate N2 (B6810CBAxB6810) progeny (Fig. 7.7). Phenotypic screening of the 
progeny N2 mice by WNV KUN challenge revealed the expected outcome, where the 
susceptibility allele segregated from the MHC-II locus: 54% of the total are affected 
mice with 29% and 21 % respectively carrying either MHCII-Aa +I- or MHCII-Aa_1_ 
alleles, whereas 46% of the total are unaffected mice with 25% each carrying either 
MHCII-Aa+/- or MHCII-Aa-1- alleles (Table 7.5). DNA from each infected N2 mouse 
was stored, and subsequently pooled in affected or unaffected groups. Pooled DNA was 
then analysed with the use of ~ 110 SNPs genetic markers that can distinguish B/6 or 
Bil 0 against CBA (Fig. 7 .8). This second screen of pooled DNA from affected and 
unaffected mice localized the unknown virus susceptibility allele to a ~60 MB region on 
chromosome I (Fig. 7 .9). 
To confirm and further fine-map the location of the susceptibility allele, additionally 
designed SNP markers that distinguish B/6 or B/ 10 against CBA were used that span 
across the identified ~60 Mb region on chromosome 1 (Fig. 7 .10). DNAs from affected 
and unaffected mice were screened individually, and based on the outcome of this 
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screen the unknown susceptibility allele was mapped and narrowed down to a 6.86 Mb 
region on chromosome 1 (Fig. 7 .11-12). The identified region spans 93 genes on 
chromosome 1 (Mouse Genome Informatics browser [http://www.informatics.jax.org/]). 
However the region does not contain a strong candidate that can explain host 
resistance/susceptibility to viral infection. 
A siRNA screen for human genes associated with WNV infection identified 22 host 
resistance factors, 21 of which were novel (Krishnan et al., 2008). Of these, 2 mouse 
orthologs map to chromosome 1, but to sites that are 66 and 149 MB distal to the r--.; 7 
MB region, to which the unknown susceptibility allele was mapped (Table 7 .6). 
The 6.86 Mb region of interest contains two genes associated with immune function: 
interleukin 1 receptor type 1 (IL-lRl) and interleukin-18 receptor 1 (IL-l 8Rl) (Fig. 
7 .12). Most cells constitutively express IL-1 R 1, which plays an important role in 
inflammatory processeses (reviewed in (Dinarello et al., 2009)). Mice devoid of IL-lRl 
exhibit attenuation of inflammatory responses, which predisposes to either increased or 
reduced susceptibility to microbial infections. The impact of IL-lRl deficiency in viral 
infection models, however, is not pronounced nor did it display with a fulminant disease 
phenotype. This was exemplified by infections with V ACY or influenza virus in IL-
1 Rl -/- mice (Belisler et al., 201 O; Schmitz et al. , 2005; Szretter et al. , 2007; Zhao et al. , 
2009). Moreover, downstream signalling of IL-1 through the IL-1 R 1 requires the 
adaptor protein, MyD-88, recruited to the cytoplasmic domain for its activity. MyD88_1_ 
mice infected sc with 103 PFU of JEV did not display a significant difference in 
mortality or time to death as compared to wt (Fig. 7 .13 ). Lastly, the clinical use of IL-1 
response antagonists in > 100,000 patients \.Vith inflammatory diseases , for instance 
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rheumatoid arthritis, did not present with maJor adverse events such as increased 
susceptibility to viral infections (Dinarello et al., 2009). 
The receptor for IL-18 (IL-18R) is a pleiotropic cytokine belonging to the Toll/IL-IR 
superfamily, and is implicated in augmentation of cell-mediated immunity through 
interferon-y (IFN-y) production, enhancement of proinflammatory responses, and 
defense against bacterial, fungal and parasitic pathogens (Biet et al., 2002). In spite of 
this, there is a less pronounced requirement for IL-18 signalling in recovery from viral 
infections. First, a defect in the IL-18Rl gene does not reflect fulminant disease 
phenotype observed when MHCII-Aa-1- mice were challenged with a flavivirus or a 
poxvirus (presented later). Second, IFN-f1- mice did present with 'early death' 
phenotype when challenged with JEV (Chapter 5), and are not susceptible to WNVKUN 
infection (Wang Y. et al., 2006). Third, Poxviruses, which are -able to cause fulminant 
disease in MHCII-Aa-1- mice ( as described later), encode a soluble IL-18 binding 
protein that blocks biological activity of IL-18 in infected mice (Reading and Smith, 
2003). 
It should be highlighted that the gene of interest is not in absolute certainty located in 
the identified ~ 7 Mb genomic region. Based on SNP genotyping by amplifluour 
technology (Fig. 7 .11 ), some unaffected mice presented to carry the mutation 
(unaffected mouse number 6), while some affected mice appeared to be wild type 
(affected mouse number 6). It can be argued that some unaffected mice might have 
succumbed to WNV KUN challenge, and some affected 1nice might have survived the 
infection. This is supported by the fact that based on previous experience in the lab. 
Occasionally, one or few B/6 wt mice succumbed to WNVKUN infection (unpublished 
data), and my observation that a small number of MHCII-Aa_1_ or tuara mice succumb 
196 
to flaviviral challenge late in the course of infection (> 20 days pi). Thus, an affected 
mouse could succumb to WNV KUN infection beyond the 28-day-observation period, and 
is the ref ore be recorded as unaffected. 
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MHCII-Aa·1- (B6810) CBA 
MHCII-Aa·1- (B6810) F1 (B681oXCBA) 
i 
N2 mice (86810.x 86810CBA) 
50% of mice carry the unknown mutation (affected) 
50% of mice does not carry the unknown mutation (unaffected) 
50°/4 are homozygous for MHCII-Aa mutation 
50% are heterozygous for MHCII-Aa mutation 
I 
Figure 7.7 Second mouse cross design for genome mapping. MHCII-Aa-
1- mice on B6B 10 background were crossed to CBA mice, and all progenies (Fl) produced 
are heterozygous for MHC-II-Aa-1- and the unidentified mutation. All Fl 's survived the 
infection. Fl (B6B 10xB10) mice were back-crossed to MHC-II-Aa_
1
_ (B6B 10) mice, and 
N2 (B6B 10xB6810 .CBA) progenies produced were: 25% homozygous for unknown 
mutation and homozygous for MHCII-Aa defect, 25% homozygous for unknown 
mutation and heterozygous for MHCII-Aa defect, 25% heterozygous for unknown 
mutation and homozygous for MHCII-Aa defect, 25% heterozygous for unknown 
mutation and heterozygous for MHCII-Aa defect. 
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Table 7.4 Susceptibility of F1 and vanous control mouse strains to 
WNVKuN infection. 
B/6 
CBA 
MHCII-Aa-1-
Fl 
Mortalityb 
0% (0/5) 
0% (0/5) 
100% (5/5)*** 
0% (0/6) 
ATD 
10.2 + 0.45 
a Eight-week-old mice were challenged sc with 1x10
3 PFU of WNVKuN- Morbidity and mortality 
were recorded for 30 days. 
b Statistical significance is computed in comparison with B/6 mice control. Asterisks de
note 
significant difference (***, p < 0.001 ). 
Table 7.5 Susceptibility of N2 (MHCII-Aa _,_ x F1) to WNVKuN infection. 
MHCII genotype Number (percentage) of Number(percentage)of Total 
affected unaffected mice 
MHCII-Aa-1- 7 (29%) 5 (25%) 12 (50%) 
MHCII-Aa+i- 6 (21 %) 6 (25%) 12 (50%) 
Total 13 (54%) 11 (46%) 24 (100%) 
Twenty-four 8-week-old N2 mice were challenged sc with 1x10
3 PFU of WNVKuN via fp , and 
observed for 28 days to record mortality. All mice were genotyped by PCR for MHC-I
I-Aa 
mutation as described in materials and methods. 
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Figure 7.8 Amplifluor SNPs genotyping of pooled DNA samples. Pooled 
DNA from affected (red square) and unaffected (yellow square) N2 generation mice 
groups were analysed with the use of ~ 110 SNPs genetic markers that can distinguish 
CBA (green fluorescence) against B6 or B 10 (red fluorescence) as described in 
materials and methods. DNA from tail samples of B/6 (red circle), CBA (green circle), 
and B/6xCBA (yellow circle) mice, and sample buffer without DNA (x) were used as 
controls. The selected example graphs represent 4 SNPs genomic markers located 
between 11.88 Mb and 191.15 Mb of chromosome 1, with best approximation and 
localization of the unknown mutation at Chrl :39.91 Mb. 
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Figure 7.9 Localization of unknown mouse resistance gene. Diagrammatic representation of unidentified mouse resistance gene 
localized within chromosome 1 at NCBI genome build 37 positions 29.81 to 79.30 Mb. Mouse chromosome idiograms was derived from 
Larry.Pathology.Washington.Edu 70, a server maintained by Dr David Adler. 
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Figure 7.10 Amplifluor SNPs genotyping of individual DNA samples. Individual DNA from representative 7 affected (red squares) and 7 
unaffected (yellow squares) N2 generation mice groups were analysed by amplifluor SNPs genotyping, with the use of SNPs genetic markers that can 
distinguish CBA (green fluorescence) against B6 or B 10 (red fluorescence) as described in materials and methods. DNA from tail samples of B/6 (red 
circle), CBA (green circle), and B/6xCBA (yellow circle) mice, and sample buffer without DNA (x) were used as controls. The example graphs 
represent SNP genomic location 11.88 Mb and 36.92 Mb of chromosome 1, with best approximation and localization of unknown mutation at 
Chrl :36.92 Mb. 
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Figure 7.11 Mapping of the unknown virus susceptibility allele to an -7 Mb region on chromosome 1. Informative haplotypes 
corresponding to 12 affected (Aff) and 12 unaffected (Un) N2 mice are presented. SNP markers that discriminate between B6 against BIO and CBA, 
chromosomal location and virus susceptibility phenotypes are shown. "Het'' (in light shade background) refers to heterozygous B6Bio and CBA 
genotypes in an indicated region, while "B6" (in darker shade background) corresponds to homozygous B6B10 genotype, but excludes the CBA 
genotype. The unknown virus susceptibility allele was mapped to a -50 Mb region of chromosome one (NCBI Build 37.1 position 29,807,982 and 
79,303,391 as enclosed by outer bold borders), and narrowed to a -6.86 Mb region of chromosome 1 (NCBI Build 37.1 position 39,913,715 and 
43,799,240 as enclosed by inner bold borders). Mice that succumbed to WNVKUN infection (103 PFU injected into the footpad) were classified as 
affected, while mice that were resistant to infection were classified as unaffected. 
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Figure 7 .12 List of genes localized within NCBI mouse genome build 37 .1 position 39,913,715 and 43,799,240 of chromosome 
1. Summary of genes identified within the ~ 7 Mb localized region of interest in chromosome 1 using the Esembl genome browser. Genes with known 
immunologic functions were highlighted with yellow-bordered boxes. 
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Table 7 .6 List of mouse orthologs of 22 human genes identified by RNA 
interference as important for resistance against WNV infection. 
Gene Gene name NCBI reference Mouse ortholog 
ACRC acidic repeat containing NM 052957 no ortholog 
AMELY amelogenin, Y-linked NM 001143 no ortholog 
acidic (leucine-rich) nuclear Chr4:4646377 4-
ANP328 phosphoprotein 32 family, member NM 006401 46485529 B 
ATCAY ataxia, cerebellar, Cayman type NM 033064 
Chr10:80667253-
(caytaxin) 80693578 
DEFA3 defensin, alpha 3, neutrophil- NM 005217 
Chr8:22427088-
specific 22428056 
DHRS10 hydroxysteroid (17-beta) NM 016246 Chr7:52810263-dehydrogenase 14;HSD17814 52822688 
DOCK4 dedicator of cytokinesis 4 NM 014705 
Chr12:41172640-
41573073 
FAM106A family with sequence similarity 106, NM 024974 no ortholog 
member A;FAM106A 
FK8P1B FK506 binding protein 18, 12.6 kDa NM 004116 
Chr12:4839981-
4848401 
IRF3 interferon regulatory factor 3 NM 001571 
Chr7:52253018-
52258218 
KBT8O8 kelch repeat and 8T8 (POZ) NM 032505 Chr6:95067234-domain containing 8 95079712 
KIAA0753 KIAA0753 XM 375397 
Chr11 :71967431-
- 72020961 
LPGAT1 lysophosphatidylglycerol XM 375837 
Chr1: 193541713-
acyltransferase 1 193608134 
MSM8 microseminoprotein, beta NM 002443 
Chr14:32955212-
- 32971556 
NFS1 NFS 1 nitrogen fixation 1 homolog NM 021100 
Chr2: 155904665-
(S. cerevisiae) 155969922 
NPIP nuclear pore complex interac
tjng NM 006985 no ortholog 
protein 
NPM3 nucleophosmin/nucleoplasmin , 3 NM 006993 
Chr19:45822224-
45824081 
SCGB2A1 secretoglobin , family 2A, member 1 NM 002407 no ortholog 
SERPINB7 serpin peptidase inhibitor, clade 8 NM 003784 
Chr1: 109296232-
(ovalbumin) , member 7 109349266 
SLC16A4 solute carrier family 16, member 4 NM 004696 
Chr3: 107094148-
(monocarboxylic acid transporter 5) 107115033 
SPT8N4 spectrin , beta , non-erythrocytic 4 NM 020971 
Chr7:28141402-
28232705 
TMEM146 transmembrane protein 146 NM 152784 
Chr17:56767566-
56803879 
Original data derived from Krishnan et al. (2008) . 
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Figure 7.13 Susceptibility of B/6 wt and MyD88_,_ mice to flavivirus 
-, 
infection. Groups of 12-week-old mice were infected sc via the footpad with 10_) PFU 
of JEV. Morbidity and mortality were recorded daily, and surviving mice were 
1nonitored for 28 days. The data shown were constructed frorn two independent 
experiments. 
207 
7 .2.5 The tuara mouse: breeding the recessive susceptibility allele to 
homozygocity on a background of wt MHC-11. Interpretation of the contribution 
of the spontaneous mutation identified in MHCII-Aa-1- mice to the phenotype of 
increased susceptibility to viral infection is complicated by the presence of the MHC-II 
defect. A new mouse strain that is homozygous for the virus susceptibility trait and wt 
at the MHC-II locus was then generated. Two methodologies were used to allow the 
segregation of the spontaneous mutation from the Aa gene knockout. N2 mice were 
screened for the MHC-II genotype by conventional PCR, and for the viral susceptibility 
allele by a genome screen using flanking SNPs markers at the area of interest in 
chromosome one. Mice that were homozygous for the virus susceptibility allele 
( expected "affected" phenotype) and heterozygous at the Aa gene locus were 
intercrossed to produce N3 progeny (Fig. 7.14). All progeny N3 mice were expected to 
be carrying the viral susceptibility allele, whereas only 25% were wt for the Aa gene. 
N3 mice that were identified by conventional PCR as wt for the Aa gene were 
intercrossed to produce N4 progeny mice. As expected, all N4 mice were homozygous 
for the virus susceptibility trait and wt at the MHC-II locus. These mice were 
established as a new strain, designated as the tuara mice strain. Tuara mice are on 
B6810xCBA genetic background (-75% B6B10 and -25% CBA), and future work may 
require that the mice be backcrossed onto the B/6 background. However, given the 
strong susceptibility phenotype of tuara mice to virus infections in comparison to B/6 
and CBA wt control mice, backcrossing to B/6 was not considered necessary for 
functional studies of the unknown susceptibility allele in host resistance to infection. 
The exquisite susceptibility of tuara mice was confirmed when challenged with either 
WNVKUN or JEV (Fig. 7.15A,B). All tuara mice succumbed to either WNVKUN or JEV 
infection with a fulminant phenotype similar to that of MHCII-Aa_1_ mice. 
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N3 mice (N2xN2) 
100% of mice carry the unknown mutation 
50% of mice are homozygous for MHCII-Aa mutation and 
heterozyous for unknown mutation 
25% of mice are homozygous for MHCII-Aa mutation and 
homozygous for unknown mutation 
25% of mice are homozygous for MHCII-Aa wild-type and 
homozygous for unknown mutation 
~0000 
---===-' -------===---
N4 mice (N3xN3) 
100% of mice are homozygous for MHCII-Aa wild-type and 
homozygous for unknown mutation 
Figure 7 .14 Generation of the tuara mouse strain. A) N2 (B6B 10xB68 10CBA) 
mice identified as MHCII+'- by genotyping and carrying the unknown mutation based on 
SNP marker detection were crossed. All N3 progenies carry the unknown mutation: 
50% homozygous for unknown mutation and heterozygous for MHCII-Aa defect , 25% 
homozygous for unknown mutation and homozygous for MHCII-Aa defect, 25 % 
homozygous for unknown mutation and wt for MHCII-Aa. B) N3 mice that were 
homozygous for the unknown mutation and wild-wild type for MHCII-Aa were 
i~tercrossed to produce N4 progenies that are I 00% homozygous for the unknown 
mutation and wild-type for MHCII-Aa , which are designated as the tuara mouse strain . 
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Figure 7.15 Susceptibility of tuara mice to challenge with JEV and 
WNVKUN• Groups of 8-week-old mice were infected sc with 103 PFU of JEV (A) or 
WNVKUN (B). Morbidity and mortality were recorded daily, and surviving mice were 
monitored for 28 days. The data shown were constructed from two independent 
experiments. Asterisks denote statistical significance(***, P < 0.001). 
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7.2.6 High viral burden and widespread viral tropism in tuara mice. Tuara 
and B/6 wt mice were infected sc with lxl03 PFU of JEV, and serum and various 
tissues were collected at 2-day-intervals to determine viral load by plaque titration in 
Vero cells. Viral load in serum and spleens of B/6 wt mice were undetectable, whereas 
tuara mice displayed persistent and significantly elevated viremia (Fig. 7. l 5A), and 
persistently detectable virus in spleens with GMT of > 105 PFU/g of tissue all 
throughout the recorded time points (Fig. 7 .16B ). Also, all infected tuara mice 
presented with rapid and uncontrolled virus dissemination into the CNS. Virus was 
initially detectable in brains of tuara mice on day 4 pi, and peaked at day 7 pi with the 
GMT ,__,5 log higher than that in wt mice (Fig. 7. l 6C). In contrast to undetectable virus 
in spinal cords of wt mice, virus dissemination into the spinal cords of tuara mice 
appeared already on day 4 pi, and was significantly elevated on day 7 (Fig. 7 .16D). 
Moreover, tuara mice displayed widespread viral tropism. Va_rious peripheral tissues 
including liver, kidney, muscle, and lungs on day 7 pi had detectable virus with GMT 
levels exceeding > 5xl03 PFU/g of tissue (Fig. 7.16E). This is in contrast to 
undetectable levels in the case of wt control group. Altogether, these data indicate that 
even in the absence of the MHC-II defect, tuara mice presented with a severe disease 
phenotype characterized by persistent viremia, widespread viral tropism, and 
widespread dissemination of the virus into the CNS. 
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Figure 7.16 High viral burden and widespread viral tropism in tuara mice. 
Eight-week-old mice were challenged with 103 PFU of JEV injected into the footpad, 
and sacrificed at indicated time points for serum and tissue collection. Viral load in (A) 
serum (B) spleen (C) brain and (D) spinal cord and (E) other tissues (D7 pi only) was 
measured by plaque titration in Vero cells. Asterisks denote statistical significance (*, P 
, 
< 0.05). 
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7.2.7 Intact adaptive immune responses in tuara mice. Given the rapid, 
fulminating infection observed in tuara mice after exposure to JEV, the putative 
mutation most likely results from disablement of a critical innate virus resistance gene, 
and does not involve the adaptive immune responses. This is supported by the finding 
that, ex vivo, JEV infection of bone marrow-derived macrophages from tuara mice 
resulted in significantly elevated viral load in culture supematants as compared to wt 
mice (-2 logs difference) (Fig. 7 .17). Moreover, antibody and CD8+ T cell immune 
responses in tuara mice remains intact, and were comparable to those in wt mice. The 
serum anti-JEV IgM response displayed similar kinetics between both mice groups, was 
first detectable on D4 pi, and increased to similar levels on D7 pi (Fig. 7 .18A). As 
expected, anti-JEV IgG 1 and IgG2b were comparable but only marginally detectable on 
day 7 pi in both mice groups (Fig. 7 .18C). The functional activity of humoral response, 
as measured by 50% plaque reduction neutralization assay, also_ displayed similar titers 
between tuara and B/6 control mice on D7 pi (Fig. 7 .18C). IFN-y expression of JEV 
NS4B peptides-specific CD8+ T cells was also comparable between tuara and B/6 
control mice on D7 pi (Fig. 7.18D). 
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Figure 7.17 Susceptibility of B/6 and tuara bone marrow-derived 
macrophages to infection with JEV. Bone marrow cells were isolated from lower 
extremity bones of B/6 wt and tuara mice as described in materials and methods, and 
selectively cultured for 7 days towards macrophage differentiation. Mature bone 
marrow-derived macrophages were then infected with JEV at MOI of 1. Virus load in 
culture supematants at 24 pi was later determined by plaque titration in Vero cells. 
Asterisks denote statistical significance(** , P < 0.01). 
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Figure 7.18 Antibody and cos+ T cell responses in JEV-infected B/6 and 
tuara mice. Eight-week-old tuara and wt mice were infected sc with 103 PFU of JEV, 
and serum samples and splenocytes were collected at the indicated time points. Anti-
JEV IgM (A) and IgG (B) isotype antibody titers were determined by ELISA. The data 
presented are reciprocal mean endpoint titers representative of 4 mice per time point 
with the SEM indicated by error bars. (C) Neutralizing antibody titers determined by 
plaque reduction neutralization assay. The data presented are mean PRNTso titers 
representative of 4 mice per time point with the SEM indicated by error bars. (D) 
Splenocytes harvested at day O and 7 pi and stimulated ex vivo with H-2Db -restricted 
JEV NS4B protein-derived peptides, and IFN-y production in CDS+ T cells was 
measured by flow cytometry. Data represent means of 4 mice samples per time point 
with the SEM indicated by error bars. 
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7.2.8 Susceptibility of tuara mice to DNA viruses. To investigate if the 
unknown mutation conferring increased susceptibility to flaviviral infection has a 
broader role in the defense against diverse groups of viruses, tuara and control mice 
(B/6 and CBA) were challenged with a DNA virus. As expected B/6 and CBA mice 
challenged iv with lxl05 PFU of vaccinia virus-Western Reserve strain (VACVWR) did 
not show mortality nor did they present with any signs of disease. In sharp contrast, 
V ACY WR infection of tuara mice resulted in a fulminant disease phenotype, with 100% 
mortality and MST of 4.4 + 0.5 days (Fig. 7.19). 
It should be noted that an earlier study by Chaudhri et al (2006) have showed that 
Ectromelia virus (ECTV) challenge in MHCII-Aa-1- mice used in this work, displayed 
100% mortality. However, >90% of mice succumbed to infection only after 15 days pi. 
A similar challenge with ECTV in the same mouse strain during my time, in contrast, 
revealed a fulminant disease phenotype of complete and rapid lethality, with all mice 
dying by day 5 pi ( data not shown). This suggests that the spontaneous mutation in the 
MHCII-Aa_1_ mice occurred during the past -8 years. 
These findings strongly suggest that the susceptibility allele is pivotal in the genetic 
resistance to a wide range of viral infections, with a possibility of an even broader role 
in host resistance against bacterial and other microbial pathogens. 
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Figure 7.19 Susceptibility of tuara mice to a DNA virus. Groups of 8-week-
old mice were infected ip with 106 PFU of V ACY WR• Morbidity and mortality were 
recorded daily, and surviving mice were monitored for 28 days. The data shown were 
constructed from two independent experiments. Asterisks denote statistical significance 
(***, P < 0.001). 
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7.2.9 The unknown susceptibility allele display partial inactivation of the 
interferon (IFN) antiviral pathway. One viral infection model that could perhaps 
explain the fulminant disease phenotype observed in tuara mice is a defect in the type 1 
IFN pathway. IFN-a-R-/- mice infected with WNVNY99 (Samuel and Diamond, 2005), 
WNVKUN (Daffis et al., 2011), JEV (Lobigs et al., 2009), or VACV (van den Broek et 
al., 1995) display rapid and complete lethality. However, it should be noted that, 
compared to tuara mice, the MST is shorter when IFN-a-R_;_ mice were challenged with 
WNVKUN (9 + 2 days in tuara mice vs. 5 + 0.4 in IFN-a-R_;_ mice) (Daffis et al., 2011; 
Lobigs et al., 2009). A possible contamination with an in-house IFNR-a-R_;_ mouse 
strain to MHCII-Aa-/- mice was also ruled out, since genotyping of MHCII-Aa-1-
revealed that they were wt for the type 1 interferon receptor ( data not shown). While no 
known components of the IFN pathway map to the ~ 7 MB chromosomal region 
putatively encompassing the susceptibility allele, it remained -important to verify an 
intact type I IFN response in the tuara mouse. 
ELISA determination of interferon production in JEV-infected bone marrow-derived 
macrophages from tuara and B/6 control mice was performed (Fig. 7 .20). Macrophages 
from tuara mice secreted high levels of IFN-a following infection with JEV for 24 
hours (>400 pg/ml), which exceeded IFN-a levels in infected B/6 control cultures (Fig. 
7.20A). In addition, serum IFN-a levels during 48 hours of JEV infection were 
comparable in tuara and B/6 control mice (Fig. 7 .20B). To determine the integrity of 
downstream IFN signalling and antiviral activity, bone marrow-derived macrophages 
from tuara and B/6 control mice were treated for 16 hrs with titrated concentrations of 
IFN-a, and later infected with JEV at MOI of 1. Virus growth inhibition was 
subsequently determined by plaque titration in Vero cells. Pre-treatment of bone 
marrow-derived macrophages from tuara and B/6 control mice with 250 or 100 IU IFN-
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a completely abolished growth of JEV, while untreated cells showed> 2 logs difference 
in virus yield at 24 h pi in tuara mouse-derived cells in comparison to that in a control 
culture at 24 h pi (Fig. 7 .21 ). However, pre-treatment of bone marrow-derived 
macrophages from tuara mice with 1 IU of IFN-a only resulted in marginal inhibition 
of virus growth as opposed to almost complete inhibition observed in B/6 mouse-
derived cells. The difference is even more pronounced (> 2 logs difference) when bone 
marrow-derived macrophages were treated with much lower concentration of IFN-a at 
0.1 IU. 
Altogether, these data suggest that the susceptibility allele impacts on type I IFN 
signalling and antiviral responses. The spontaneous mutation may involve a complete 
disruption of an IFN-inducible antiviral effector gene or a partial dysfunction of a key 
intermediate gene involved in signal transduction for IFN responses. 
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Figure 7.20 IFN-a production in JEV-infected tuara and 8/6 mice. Bone 
marrow cells were isolated from lower extremity bones of B/6 wt (black bar) and tuara 
(white bar) mice as described in materials and methods, and selectively cultured for 7 
days towards macrophage differentiation (A). Mature macrophages were infected with 
JEV at MOI of 1. IFN-a levels in culture supematants at indicated time points were 
determined. (B) IFN-a production in serum in JEV-infected B/6 wt and tuara mice at 
indicated time points. Each bar graph represents 3 biological samples 
220 
10 7 ** IB/6 
-
** 
E 10 6 □ Tuara ....._ 
::::> 10 5 * LL 
a. 10 4 0 
T"'" 
C) 10 3 0 
..J 10 2 - ----------------------------
10 1 
Mock 0.1 1 10 100 250 
Figure 7 .21 Inhibition of JEV replication after IFN-a stimulation of bone 
marrow-derived macrophages from B/6 wt and tuara mice. Bone marrow 
cells were isolated from lower extremity bones of B/6 wt (black bar) and tuara (white 
bar) mice as described in materials and methods, and selectively cultured for 7 days 
towards macrophage differentiation. Mature macrophages were treated with 250, 100, 
10, 1, 0.1 IU of IFN-a or mock-treated with tissue culture media for 16 hrs. 
Macrophages were then infected for 24 hrs with JEV at MOI of 1. Viral load in culture 
supernatants were measured by plaque titration in Vero cells. Each bar graph represents 
3-6 samples from two independent experiments. Asterisks denote statistical significance 
(*, P < 0.05; ** , P < 0.01). 
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7 .2.10 Customized sequence capture and re-sequencing identified 
candidate mutations responsible for the fulminant disease phenotype. At 
this point, the candidate gene was successfully segregated from the defective MHC-II 
gene in a new mouse strain, tuara. In summary, tuara mice are homozygous for the 
virus susceptibility trait and wt at the MHC-II locus, and when challenged with JEV, 
displayed a fulminant disease phenotype characterized by i.) complete and rapid 
mortality, ii.) early neuroinvasion, iii.) widespread virus dissemination into the CNS iv.) 
widespread viral tropism. In addition, the fulminant disease phenotype observed in 
tuara mice is most likely attributed to a mutation of a critical innate immune response 
gene, given that tuara mice presented with i.) intact antibody and ii.) CD8+ T cell 
immune responses, and that bone marrow derived-macrophages from tuara mice 
displayed increased susceptibility to JEV infection. Another significant finding was that 
the unidentified gene was not limited to conferring resistance against flavi viral 
infection, but also provided defence against infection with a DNA virus. 
It should also be highlighted that the original MHCII-Aa_;_ mice and/or bone marrow-
derived macrophages from MHCII-Aa-1- mice displayed susceptibility to a low virlunce 
flaviviruses, including WNV KUN, DENV-2, and YFV. A more surprising discovery was 
the finding that ic challenge in parent MHCII-Aa_;_ mice strain with a highly attenuated 
live vaccine , ChimeriVax-JE , resulted in complete lethality. This is remarkable, 
especially when mice deficient in the type 1 interferon receptor (Lobigs et al., 2009) or 
B cells (Chapter 8) tolerated vaccination with ChimeriVax-JE. Accordingly , I 
hypothesized that a combination of crucial innate immune response factor plus 
deficiency in antibody production (as a result of the CD4+ T cell deficiency in MHCII-
Aa-1- mice) has contributed to the lethal phenotype of MHCII-Aa_;_ mice in 
ChimeriVax-JE infections. This was later supported, given that 100% of B cell 
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sufficient and antibody -competent tuara mice, survived ic challenge with ChimeriV ax-
JE ( data not shown). 
To elucidate the remarkable findings described in this chapter, a forward genetics 
approach was employed: starting with an observable phenotype of increased 
susceptibility to viral infection to localization of the susceptibility allele responsible for 
the phenotype. In this hypothesis-free driven exercise, preliminary data was obtained 
with the gene of interest identified and narrowed within a - 7 Mb region of chromosome 
1 at reference positions 36.94 to 43.80 Mb (NCBI mouse genome Build 37.1). 
However, no identifiable gene involved in IFN pathway signalling is located within the 
region. To identify the unknown mutation, two options were available: i.) Targeted 
exome re-sequencing or ii.) customized sequence capture and re-sequencing. The 
former is a robust target-enrichment strategy designed to selectively sequence only the 
exonic regions of the genome, and is based on the assumption that the mutation is 
confined to the coding regions (Bamshad et al., 2011 ). A significant limitation includes 
the exclusion of sequencing non-coding regions that may be responsible for the 
fulminant disease phenotype observed in tuara mice. Although uncommon, genome 
wide association studies have correlated diseases to particular SNV s in the non-coding 
regions of the genome, including intrans and intergenic regions (reviewed in (Manolio, 
2010)). On the other hand, customized sequence capture using the Nimblegen hard-
array and re-sequencing using Illumina HiSeq system, selectively sequences a defined 
region of interest (from 5 to 50 Mb) initially narrowed by chromosomal linkage analysis 
(Sulonen et al., 2011). An advantage of customized sequence capture is that it 
sequences all genomic regions including exons, intrans, UTRs, and intergenic regions. 
Additionally, the high depth coverage (more thc:tn 50 times) provided by the subsequent 
second generation sequencing (Illumina HiSeq) gives the greater likelihood of detecting 
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large insertions or deletions. Hence, a decision to proceed with customized sequence 
capture and re-sequencing was made. 
However, as earlier discussed, it should be highlighted that the gene of interest is not at 
full certainty located in the initially identified 7 Mb genomic region. Given that there 
were variants outside of the expected outcome in the individual SNP genotyping of the 
N2 mice during genome mapping, a customized sequence capture array was designed to 
include a wide genomic area (from 29 Mb to 79 Mb of chromosome 1) to provide a 
greater degree of confidence in detecting the mutation. 
Pure quality genomic DNA samples (> 500µg/sample, concentration of> 1 µg/µl) from 
tails of three tuara mice were prepared by the Animal Phenomics Facility (APF). 
Customized sequence capture bait/primer design was provided by the Nimblegen 
bioinformatics team. Sequence capture by Nimblegen hard array hybridization and re-
sequencing by Illumina HiSeq systems were performed by the next generation 
sequencing team of the Australian Genomics Resource Facility (AGRF) in Melbourne, 
Australia. Bioinformatics teams from AGRF and APF independently provided analysis 
of the raw sequence data generated from Illumina HiSeq re-sequencing. The analysis 
revealed that, due to reasons not yet clear, only 2 out of 3 samples were successful 
during the sequence capture step. The analysed sequence data, provided by the 2 
samples that were successfully captured and sequenced, revealed 3 candidate protein-
coding gene mutations that can be responsible for the observed fulminant disease 
phenotype: Prss40 (Protease, Serine, 40), Cyp20al (cytochrome P450, family 20, 
subfamily a, polypeptide 1), and STATl (Signal Transducers and Activators of 
Transcription) (Table 7 .7-8). 
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The Prss40 gene is localized at position 34,600,820-34,617 ,788 bp of chromosome 1. 
The protein product is known to have proteolytic action for an undefined cellular 
function (Mouse Genome Informatics). It is largely expressed in testicular tissue, and 
limitedly expressed in all other tissues (Fig. 7 .22). The mutation identified is a G>A 
transition at genomic coordinate 34,616,619 of chromosome 1, and results in arginine to 
tryptophan substitution at amino acid position 79 of the Prss40 protein. The second 
candidate gene , Cyp20al, is localized at position 60,400, 167-60,444,904 bp of 
chromosome 1. As a cytochrome P450 enzyme, it is involved in oxidation-reduction 
biological processes for yet undefined cellular function (Mouse Genome Informatics). 
Notably, it is highly expressed in cells of monocytic lineage (Fig 7 .23). The mutation is 
a 6-nucleotide deletion at a splice site region of the gene at genomic coordinates 
60 ,409 ,744 to 60,409 ,749 of chromosome 1. Lastly, the ST AT 1 gene , is localized at 
position 52,176,282-52,218,704 bp of chromosome 1. It has a _protein product that is 
involved in diverse cellular processes with well-defined functions (Mouse Genome 
Informatics). Most importantly , it is a key intermediate protein important for type 1 IFN 
signalling (reviewed in (Sadler et al. , 2008)). The G>T transversion at reference 
position 52,179,547 bp of ST AT 1 gene results in a nonsynonymous mutation, with a 
Tryptophan to Leucine substitution at amino acid position 3 7 of the ST AT 1 protein. It 
has been previously shown that STA Tl-/- mice displayed significantly increased 
susceptibility to infection with diverse group of viruses (Muller et al. , 1994) Although 
tuara mice presented with less severe disease outcome relative to STA Tl-/- mice in 
terms of survival times, it may be that the ST AT 1 mutation in tuara mice only resulted 
in partial dysfunction of ST AT 1 protein. Treatment with lower concentrations IF -a of 
bone-marrow-derived macrophages from tuara mice, relative to B/6 wt mice, only 
resulted in partial antiviral activity, supporting a probable partial dysfunction of the 
STATl protein. Given its predominant role in antiviral signalling pathways, it is most 
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likely that the susceptibility allele 1s a result of partial dysfunction of the ST A Tl 
protein. 
Further experiments are needed to confirm STA Tl, and rule out Prss40 and Cyp20al, as 
the causal gene mutation for the fulminant disease phenotype. Thus, the initial 
comprehensive work done in this chapter leads to a likely identification and 
confirmation of a partial loss-of-function ST AT 1 mutation with profound biological 
consequences. The STATl mutation in tuara mice is a distinct mutation when 
compared to the 10 characterized STAT1 -1- mice (3 chemically induced and 7 targeted 
mutations) listed on the Mouse Genome Informatics database, given the unique locus of 
the mutation.(Table 7 .9). In terms of clinical relevance, particular mutations in the 
human ST A Tl gene had been associated with increased susceptibility to microbial 
infections and, at certain times, autoimmunity (Figure 7 .24 and Table 7.10). Since the 
initial discovery of human STATl mutation in 2001 (Dupuis et al., 2001), an increasing 
number had been identified for the past years, and was recently classified by Boisson-
Dupuis et al., (2012) into 4 subclasses: i.) autosomal recessive with partial STATl 
deficiency, ii.) autosomal recessive with complete STATl deficiency, iii.) autosomal 
dominant with loss-of-function ST A Tl deficiency, and iv.) autosomal dominant with 
gain-of-function STA Tl disorder (Table 7 .10). 
Lastly , this chapter also highlights the issue of frequency of spontaneous mutations 
generated in inbred wt or knockout mouse strains. With 30,000 mouse structural genes 
and average mutation frequency per gamete per locus of 1 o-s, it is though that the 
mutation rate in an inbred mouse is 0.3 per gamete (Bailey, 1978). Subline divergence 
of inbred mouse strains due to spontaneous mutations has been reported in multiple 
studies (Acton et al., 1973; Crusio et al, 1991 ; Grewal , 1962, Keightley , 1998; 
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Whitmore and Whitmore, 1985; van Abeleen and Hughes, 1986 ). The advantage of the 
mutation discovered in this chapter is that the phenotype is patently observ
able. 
Problems can arise when a spontaneous mutation generated produces a s
ubtle 
phenotypic effect, which can affect the observational outcome, and bring 
about 
unwarranted and incorrect conclusions derived from experimental findings. This 
may, 
in part, explain reported variability in outcomes or published results produce
d by 
different laboratories, using a similar wt or knockout mouse strain maintained in
 their 
respective facilities. Certain recommendations were put forward to avoid su
bline 
divergence, and one is regular restocking of mouse colonies from common interna
tional 
frozen embryo source (Bailey, 1978). As full genome sequencing becomes substantially 
less expensive, it may be best that, in the future, complete genome sequences 
of all 
mouse strains used in any study be performed before publication. 
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Table 7.7 
Nlu-taUon 
Deletion 
Insertion 
List of candidate lndel mutations 
Start- ·• ' End- , ··, Variant 
' 
coordinate . coordinate Length 
60409744 ;:-· --· 60409749 --- -6 
~ 
- -
--•-
74606950 74606952 -3 
40081149 40081150 -4 
90108571 90108572 -2 
90163100 90163100 +1 
G•ene 
CYP20A1 
PLCD4 
MAP4K4 
UGT1A5 
HJURP 
Note: Highlighted gene indicates mutation identified in 2 out of 2 samples. 
Table 7.8 List of candidate SNV mutations 
SNP Gene - Reference Variant Gene 
genoty~e • coordinate base base 
Homozygous 
34616691 G · A . PRSS40 
52179547 G T STAT1 
Heterozygous 
151677280 G T PLA2G4A 
171966128 C T DDR2 
Note: Highlighted gene indicates mutation identified in 2 out of 2 samples. 
Gene desccription 
cytochrome P450, family 20, subfamily A, polypeptide 1 
[Source:MGI Sy_mbol;Acc:MGl:1 ~25201] 
phospholipase C, delta 4 
[Source:MGI Symbol;Acc:MGl:107469] 
mitogen-activated protein kinase kinase kinase kinase 4 
[Source :MGI Symbol;Acc:MGI: 1349394] 
UDP glucuronosyltransferase 1 family, polypeptide AS 
[Source:MGI Symbol;Acc:MGl:3032634] 
Holliday junction recognition protein 
[Source:MGI Symbol;Acc:MGl:2685821] 
Gene description 
pro~ease, serine, 40 
[Source:MGI Symbol;Acc:MGl:1270857] 
signal transducer and activator of transcription 1 
[Source:MGI Symbol;Acc:MGI: 103063] 
phospholipase A2, group IVA (cytosolic, calcium-dependent) 
[Source:MGI Symbol;Acc:MGI: 1195256] 
discoidin domain receptor family, member 2 
[Source:MGI Symbol;Acc:MGl:1345277] 
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Figure 7 .22 Expression profile of Prss40 gene. 
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Figure 7 .23 Expression profile of Cyp20a1 gene. High-throughput gene 
expression profiling of Cyp20a 1 gene using the gene annotation portal www. 
bioGPS.org. 
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Table 7.9 List of STAT1 knockout mice 
~ouse4 
Chemically-induced (ENU) 
Stat1tae 
Stat1 m1 Btlr 
Stat1 m2Btlr 
Targeted Knockout 
Stat1tm1.1Mmul 
Stat1 tm1 .2Mmul 
Stat1 tm1 rnv 
Stat1tm1Mam 
Mu~ati~·o -~e~.cription 
T-to-A transversion at nucleotide position 2263, M654K 
T-to-A tra nsversion in exon 11, V319 E 
T-to-A transversion at nucleotide position 31788; frameshift occurs after codon 544 that 
introduces a premature stop codon following codon 561 
A loxP site was inserted upstream of exon 6. A flexed neo cassette was inserted 
downstream of exon 10. ere-mediated recombination removed the neo cassette and left 
exons 6 through 10 flexed . 
ere-mediated recombination removed exons 6 through 10 and the neo cassette. 
A neomycin resistance cassette rep·laced 5. 7 kb of sequence, including 3 exons and a 
portion of a fourth encoding amino acids 221-365 
A targeting vector was designed to place a loxP flanked neomycin resistance gene 
upstream of the first untranslated exon followed by a loxP site downstream of the first 
translated exon. The neo cassette was removed by germ-line ere-mediated 
resombination leaving loxP sites flanking the first two untranslated exons and the first 
translated exon. 
Stat1tm,Rds A neomycin resistance cassette replaced the first three coding exons and 0. 7kb of 5' 
upstream flanking sequence. 
Stat1tm1Tdec Exon 22 and 23a were replaced with a segment containing exon 22, a flexed neo 
cassette and exon 23 containing a nucleotide substitution that results in an amino acid 
substitution of an alanine for a serine at position 727 (S272A), a site within the 
transactivation domain. The neo cassette was removed by germ-line, ere-mediated 
recombination. 
Statfm,uvin Nucleotide substitution(s) results in the amino acid substitution of glutamine for 
glutamic acid at position 705 (E705Q) that abolishes SUMO conjugation. 
Knockout mouse list and mutation description adapted from Mouse Genome Informatics website (www.informatics .jax.org). 
Reference 
Yates et al., 2006 
Crozat et al. , 2006 
Whitley et al., 2008 
Wallner et al., 2012 
Wallner et al., 2012 
Durbin et al., 1996 
Klaver et al. , 2010 
Meraz et al., 1996 
Varinou et al., 2003 
Begitt et al., 2007 
231 
6 
A46T K201 N K211 R P696S 
I 
STAT1 a c17~9 A267~ 1 288A 
Y170N K2861 L600P 
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COOH 
134 cc 317 DNA-8 488 L 576 SH2 683 TS 708 TA 75 0 
O123H 1758_ 1759delAG 1928insA 
Figure 7.24 Identified pathogenic mutations in human STAT1 gene. Schematic diagram of human STAT1 gene with representative regions 
coding for domains 111-XXV of the protein, or regions coding for the coiled-coil domain (CC), DNA-binding domain (DNA-8), linker domain (L), SH2 domain (SH2), tail 
segment domain (TS), and transactivator domain (TA), with their amino-acid boundaries demarcated by bold lines. Morbid mutations are represented by coloured 
text: green (autosomal dominant with partial STAT1 deficiency), brown (autosomal recessive with complete STAT1 deficiency), blue (autosomal recessive with 
partial STA T1 deficiency) and red (autosomal dominant with gain-of-activity of STA T1 ). Figure Adapted from Soisson-Dupuis et al., (2012). 
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· Table 7.10 Classification of STAT1 mutation in humans 
Ty;pe ,:-"·· ! "4' Affected domain . 
' 
I ~ -- V • ,. 
; .Main cellular phenotype · : .. ' ,Mai11 ~ Hrii~a:I phe:notyp.e . · ¼References 
• 
-
Autosomal recessive with 
complete STA T1 deficiency 
Autosomal recessive with 
partial STAT1 deficiency 
Autosomal dominant with 
loss-of-function STAT1 
deficiency 
Autosomal dominant with 
gain-of-function STAT1 
disorder 
. 
N-terminal domain 
SH2 domain 
N-terminal domain 
Coiled-coil domain 
Tail segment domain 
DNA-binding domain 
SH2 binding domain 
Tail segment domain 
Coiled-coil domain 
No STAT1-dependent response to 
IFN-y, IFN-a/~, IFN-I and IL-27 
Impaired STAT1-dependent 
response to IFN-y, IFN-a/~, IFN-I 
and IL-27 
Impaired STAT1-dependent 
response to IFN-y and IL-27 
Enhanced STA T1-dependent 
response to at least IFN-y, IFN-
a/~, IL-27, IL-6 and IL-21. 
Impaired IL-17 T-cell immunity 
Lethal intracellular bacteria 
(mainly mycobacteria) and 
viral (mainly herpes) diseases 
Curable intracellular bacteria 
(mainly mycobacteria) and 
viral (mainly herpes) diseases 
Mycobacterial diseases 
To date, incomplete clinical 
penetrance is oberved 
Chronic mucocutaneous 
caindidiasis and autoimmunity 
IFN - lnteferon; IL - Interleukin. Table adapted, with some modifications, from Soisson-Dupuis et al., (2012). 
Dupuis et al., 2003 
Chapgier et al., 2006a 
Vairo et al., 2011 
Chapgier et al., 2009b 
Kong et al., 2010 
Kistensen et al., 2011 
Chapgier et al., 2006a 
Dupuis et al., 2001 
Tsumura et al., 2012 
Sampaia et al., 2012 
Hirata et al., in preparation 
Liu eta/., 2011 
van de Veerdnok et al., 2011 
Smeekens et al., 2011 
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ChapterB 
Protective role of memory B cells in vaccination 
against JEV and related flaviviruses 
8.1 Introduction 
Vaccination is the most cost-effective intervention to prevent Japanese encephalitis (JE) 
(Ding et al., 2003; Siraprapasiri et al., 2006; Surratdecha et al., 2006). The public health 
impact of incorporating JE vaccines into the national immunization program in Japan 
cannot be underestimated; since the introduction of formalin-inactivated mouse brain-
derived JE vaccine (globally marketed by Sanofi-Pasteur as JE-V AX), the annual 
incidence of JE cases dropped from more than 1,000 per year in the late 1960's, to less 
than 100 from 1982 to 1991, and then to less than 10 from 1992 to 2004 (Matsunaga et 
al., 1999; Arai et al., 2008). However, due to perceived issues of safety, the Japanese 
authorities have recently recommended the suspension of its use (reviewed in (Halstead 
and Thomas, 2011)). Hence, the production of JE-V AX, the only internationally 
licensed JE vaccine at that time, was ceased in 2005. The policy was also implemented 
in anticipation of the replacement of JE-V AX with new-generation JE vaccines, such as, 
ChimeriVax-JE and inactivated Vero-cell culture derived (ccJE) vaccines. 
ChimeriVax-JE is a recently licensed live-attenuated JE vaccine, that was designed via a 
construct composed of genes encoding for envelope and premembrane proteins of JEV 
SA 14-14-4 strain and non-structural proteins of Yellow Fever 17D (Chambers et al., 
1999; Guy et al., 2012). A series of studies revealed that ChimeriVax-JE is a promising 
vaccine with an impressive safety and efficacy profile (Chokephaibulkit et al., 201 O; 
Monath et al., 2002; Monath et al., 2003; Nasveld et al., 2010; Torresi et al., 2010). On 
the other hand, Advax-adjuvanted ccJE (JE-ADV AX™) is another promising new-
generation JE vaccine, which was shown to elicit robust humoral immune response 
against JEV, with antibody titres comparable to that induced with ChimeriVax-JE, and 
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superior to that elicited with non-adjuvanted JE-V AX or alum-adjuvanted JEV vaccine 
(Jespect; Novartis) (Lobigs et al., 2010). 
In spite of increasingly available list of licensed and candidate JE vaccines, a profound 
understanding on the immunological correlates underlying vaccine-mediated protection 
remains not completely defined (reviewed in (Lobigs and Diamond, 2012)). A robust 
humoral immune response was deemed crucial in vaccine-mediated homologous 
protection against JE. Neutralizing antibodies against flaviviral E protein produced after 
immunization provided complete protection from lethal encephalitis, whereas CD8+ T 
cells was documented to be less substantial, and at best provided only limited protective 
contribution (Konishi et al., 2003; Konishi et al., 1998b; Pan et al., 2003). Furthermore, 
the cross-protective efficacy of flaviviral vaccines, such as Advax-adjuvanted ccJE, 
prM/E protein chimeric flaviviruses, and prM/E protein-based _DNA vaccination are 
thougth to largely depend on competent humoral immune responses (Bosco-Lauth et al., 
2011; Lo bigs et al., 2009; Lo bigs et al., 2003c, Lo bigs et al., 2011 ). 
The earlier chapters delved on the basic immunobiology of Japanese encephalitis, in the 
aim of using the insights in defining the immunological correlates of protection of 
rationally designed JE vaccines. Notably, a robust humoral immune response is 
critically important against primary infection with JEV (Chapter 3). While CD4+ T cells 
_j__ 
provide essential help in enhancing antibody responses, CD8 ' T cells are, at best, 
marginal in providing contribution in disease amelioration. In this chapter, I extend my 
inyestigation on establishing the mechanism of vaccine-mediated protection against 
homologous and heterologous flavivirus infections. 
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8.2 Results and Discussion 
8.2.1 Absolute requirement for B cells in vaccine-mediated immune 
response. B cells but not CD8+ T cells are instrumental in recovery from primary 
infection with JEV (Chapter 3). Here I investigated whether a similar pivotal role of B 
cells exists in vaccine-mediated protection against JE. Groups of 8-week-old µMT_;_ 
mice were immunized subcutaeneously (sc) with lx105 PFU of ChimeriVax-JE or 2 
doses, given 2 weeks apart, of 1 µg of ccJE + Advax (Table 8.1 ). Another mice group, 
that did not receive any immunization, served as control. A month after completion of 
vaccine regimen, mice were challenged via the footpad (fp) with 103 PFU of JEV. All 
immunized and control mice succumbed to disease on or before D 12 post-infection (pi). 
This data clearly demonstrate the absolute requirement for antibodies in vaccine-
mediated homologous protection against JE. 
To determine the role of CD4+ T cells in vaccine-mediated immune responses , groups 
of 8-week-old MHCII-Aa~-/- mice were immunized sc with lxl 0
5 PFU of ChimeriVax-
JE, or left unimmunised (Table 8.1 ). A month after immunization, mice were 
challenged via the fp with 103 PFU of JEV. Control mice displayed complete mortality 
with mean survival time (MST) of 12.2 + 0.4 days. On the other hand 60% of 
immunized succumbed to infection, with delayed MST of 14.2 + 3 .2 days. Although the 
difference was not statistically significant, this data, together with the findings in 
Chapter 3, clearly reflect the essential helper function of CD4+ T cells in inducing 
protective humoral immune responses after a primary infection or immunization. 
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Table 8.1 Contribution of vaccine-mediated humeral and CD4+ T cell 
immune responses against challenge with JEV. 
Mice and lmmunogena 
Naive 
ChimerVax-JE 
ccJ E 1 µg + Advax 
Mortality (no. of 
deaths/total} 
100% (4/4) 
100% (4/4) 
100% (5/5) 
---
---
---
--~---
--~---
--
M HCI I-Aaf3_,_ 
Naive 100% (5/5) 
ChimerVax-JE 67% (4/6) 
P valueb 
11.8 ± 1.0 
11.0 ± 0.0 0.21 
11.2 ± 1.1 0.44 
·------
---
~- -------
----
-
----
----
-- ,---- - - --
----
, 
12.2 ± 0.4 
----
----
- ---
-----
--- --
-- --
14.2 ± 3.2 0.29 
a Eight-week-old µMT_,_ or MHCII-Aa~-t- mice were immunized sc with 1x10
5 of ChimeriVax JE or 
2 doses, given 2 weeks apart, of 1 µg of ccJE + Advax. Na"fve control mice did no
t received any 
immunization. A month after completion of vaccination schedule, mice were cha
llenged via the 
fp with 103 PFU of JEV. 
b Statistical significance was computed in comparison with naive control . 
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8.2.2 ~2m_,_ mice are highly susceptible to JEV infection and provide a 
model for evaluating B cell memory responses following vaccination. For 
the purpose of evaluating memory B cell responses after vaccination, I established a 
mouse model characterized by deficiency in CD8+ T cells and persistent antibody, 
thereby uncovering protective B cell immunity following vaccination. ~2m_1_ mice 
exhibit a congenital deficiency in CD8+ T cells due to a defect in MHC-I assembly, cell 
surface transport and antigen presentation (Koller et al., 1990). In addition, the mice 
also lack long-lived IgG as a result of a deficiency of neonatal Fe receptor (FcRn) 
(Brambell, 1970; Junghans and Anderson, 1996; Ghetie et al., 1997; Suzuki et al., 
2010). FcRn has a MHC-I-like molecular structure, with ~2m protein incorporated as 
the light chain (Simister and Mostov, 1989; West and Bjorkman, 2000). Along with 
other proteins, IgG is taken up by various cells in the body by fluid-phase endocytosis, 
is transported to an endosomal compartment, and, at low pH, is bounded to F cRn with 
high affinity (reviewed in (Junghans, 1997; Ghetie and Ward, 2000) ). The strong 
binding of IgG with FcRn, diverts and prevents its catabolic degradation within 
lysosomes, and recycles it back extracellularly upon neutral-pH induced dissociation 
with FcRn (reviewed in (Rojas and Apodaca, 2002)). 
To test the impact of ~2m deficiency on susceptibility to JEV infection, 8-week-
old ~2m_1_ and B/6 wt control mice were inoculated iv with 103 PFU of JEV (Fig. 8. lA). 
Relative to wt control, ~2m_1_ mice displayed significantly increased mortality ( 100% 
vs. 75%, respectively), and shorter MST (12.0 ± 2.3 vs. 13 ± 1.4 days, respectively). 
Subcutaneous challenge of 8 or 12-week-old ~2m_1_ mice with 103 PFU of JEV similarly 
presented with increased mortality (95% and 94%, respectively) in comparison to wt 
controls (65% and 55%, respectively) (Fig. 8. lB,C). 
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To determine whether the increased mortality rates observed in B2m_1_ mice were 
attributed to defective viral clearance, groups of 8-week-old B2m_1_ and B/6 wt mice 
were inoculated with 103 PFU of JEV, and sacrificed at 2-day-interval time points for 
serum and tissue collection. Viral load was determined in serum and spleens by real 
time RT-PCR, and in brains and spinal cords by plaque titration in Vero cells. Serum 
viral load in B2m_1_ mice presented with similar kinetics and magnitude relative to wt 
mice (Fig. 8.2A). Peak viremia appeared on D2 post-infection (pi), with geometric 
mean titres (GMT) decreasing afterwards. Likewise, viral load in spleen of B2m _1_ mice 
was similar to that of wt controls, with peak titres on D4 pi (Fig. 8.2B). On the contrary, 
viral load in brains and viral dissemination into the spinal cord were significantly 
elevated in B2m_1_ mice than wt controls. Virus in brains of B2m_1_ mice was initially 
detected on day 6 pi, and relative to wt mice, GMT was -100-fold and -1,000-fold 
higher on days 8 and 10 pi, respectively (Fig. 8.2C). Furthermore, viral dissemination 
into the spinal cord was more pronounced in B2m_1_ mice relative to wt mice (- 3 logs 
GMT difference on D 10 pi) (Fig. 8.2D). 
As earlier described, B2m_1_ mice exhibited short-lived IgG isotype antibodies brought 
about by absence of B2m protein-dependent protection of serum IgG from catabolism 
(reviewed in (Rojas and Apodaca, 2002)). To determine whether this phenomenon is 
similarly observed in JEV-infected B2m_1_ mice, serum antibody titres were determined 
by ELISA in comparison to wt controls. The kinetics and magnitude of anti-JEV IgM 
antibodies was similar in both groups, initially detected on D4 pi, and peaked on D8 pi 
(Fig. 8.3A). Anti-JEV IgG 1 and IgG2b antibodies in wt mice were initially detected on 
D8 pi, and increased on D 10 pi (Fig. 8.3B). This is in contrast to what was observed in 
B2m _1_ mice, where IgG 1 and IgG2b levels were significantly lower on D 10 pi, and were 
threefold and twofold lower than the levels found in wt controls. In spite of less than 
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optimal IgG responses in B2m-1-, the functional activity of antibodies, as measured by 
50% plaque reduction and neutralization assay (PRNT 50), was comparable to wt 
controls (Fig. 8.3C). However, it should be noted that, in addition to direct 
neutralization measured by in vitro assays, alternative in vivo mechanisms of viral 
clearance by antibodies such as Fe-portion interaction with complement and Fe 
receptors on cells of monocytic lineage should not be discounted (Chung et al., 2005; 
Hofmeister et al., 2011; Oliphant et al., 2005; Oliphant et al., 2006). Fe-mediated 
clearance of viruses has been suggested to play critical protective role in human 
infections with WNV (Hofmeister et al., 2022). 
In addition to blunted IgG antibody responses, B2m_1_ mice were also documented to 
possess dysfunctional NK cell responses (Alsharifi et al., 1996; Muller et al., 1995; Tay 
et al., 1995). To investigate whether NK cell response remains intact after exposure to 
JEV, B2m_1_ and B/6 wt control mice were inoculated iv with 103 PFU of JEV, 
splenocytes isolated at indicated time points, and NK cell responses were measured by 
chromium release assay (Fig. 8.3D). On D3 pi, NK cell activity in B2m_1_ was 
approximately threefold lower to that of B/6 wt mice. This was reversed on D7 pi, 
where NK cell activity in B2m_1_ mice increased, and was higher than in wt mice. This 
data represented a similar observation found in previous studies, where B2m_1_ mice 
exhibited delayed NK cell responses after viral infection. However, given that NK cell 
depletion did not alter susceptibility of mice to JEV infection (Chapter 5), dysfunctional 
NK cell responses may be of little probative value in increasing the susceptibility of 
B2m_1_ to challenge with JEV. 
A less explored factor, that may explain the increased susceptibility to JEV infection, is 
the failure to induce an optimal IFN-y response in ~2m_1_ mice. Previous studies have 
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suggested the role of B2m protein in the efficient production of IFN-y (Antonelli et al., 
1988; Klingel et al., 2003). This is especially important, given the data I presented in 
chapter 5 that IFN-y plays an essential protective role against lethal JE. However, my 
initial investigation revealed comparable kinetics and magnitude in serum IFN-y levels 
in both JEV-infected B/6 wt and B2m_1_ mice (data not shown). Lastly, another 
unexplored factor is the documented presence of hereditary hemochromatosis in B2m_1_ 
mice. Hepatic iron overload in B2m _1_ mice is well documented, and is attributed to the 
absence of B2m-interacting protein important for iron homeostasis (Feder et al., 1997; 
Santos et al., 1996; Santos et al., 2000, Rothenberg and Voland, 1996; Waheed et al., 
2002). It can be speculated that a slow but progressive liver disease (Rodrigues et al., 
2006; Khan et al., 2007) can impact on the distinct immunologic functions of the liver. 
Hence, an impairment on hepatic metabolism of Vitamin D, and hepatic synthesis of 
Vitamin D binding protein, C-reactive protein, and all complement proteins can be 
expected (reviewed in (Baeke et al., 201 0; Crisp, 2009; Gao et al., 2008)). The latter of 
which is known to be critical for protection against lethal West Nile encephalitis 
(Mehlhop et al., 2005). 
In summary, B2m _1_ mice displayed high mortality, high brain viral load, and widespread 
dissemination of virus into the CNS. The exquisite susceptibility of B2m_1_ mice to JEV 
challenge is not only attributed to CD8+ T cell deficiency, but also credited to myriad of 
factors contributing to severe immunodeficiency. As such, B2m_1_ mice were identified 
as a suitable stringent challenge model for preclinical evaluation of vaccines against 
JEV. 
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Figure 8.1 Susceptibility of ~2m_,_ mice to low-dose challenge with JEV. 
Intravenous inoculation of 8-week-old (A) or sc inoculation of 8-week-old (B) and 12-
week-old (C) ~2m_1_ and B/6 wt control mice with 103 PFU of JEV. Morbidity and 
mortality were recorded daily, and surviving mice were monitored for 28 days. The data 
shown were constructed from three independent experiments. Asterisks denote 
statistical significance(**, P < 0.01; ***, P < 0.001). 
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Figure 8.2 Viral burdens in 8/6 wt and ~2m_,_ mice after exposure to JEV. 
Eight-week-old mice were challenged sc with 103 PFU of JEV, and sacrificed at 2-day 
interval time points for serum and tissue collection. Viremia was measured in RNA 
copies/ml by qRT-PCR; viral load in brain and spinal cord was measured by plaque 
titration in Vero cells. The lower limit of virus detection was 1x10
3 PFU/g of tissue, and 
is indicated by a dotted line. The data shown were constructed from two independent 
experiments. Asterisks denote statistical significance (*, P < 0.05). 
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Figure 8.3 Antibody and NK cell responses in JEV-infected B/6 wt and 
~2m-1- mice. Eight-week-old B/6 wt and ~2m_1_ mice were infected sc with 103 PFU of 
JEV, and sacrificed at indicated time points for serum and tissue collection. Anti-JEV 
IgM (A) or IgG (B) isotype antibody titres were determined by ELISA. The data 
presented are reciprocal mean endpoint titres representative of 4-5 mice per time point 
with the SEM indicated by error bars. (C) Neutralizing antibody titres were determined 
by plaque reduction neutralization assay. The data presented are mean PRNTso titres 
representative of 4-5 mice per time point with the SEM indicated by error bars. (D) 
Splenocytes harvested at indicated time points, and NK cell activity determined by 
chromium release assay as described in materials and methods. Data represent means of 
4 mice samples per time point with the SEM indicated by error bars. Asterisks denote 
statistical significance (* , P < 0.05). 
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8.2.3 Inactivated JE vaccines protect ~2m_,_ mice from sc challenge with 
JEV. Given the exquisite susceptibility of B2m_1_ mice to challenge with JEV, I have 
used it as a stringent challenge model to evaluate the protective value of JE vaccines. 
Two Vero cell-grown inactivated JE vaccines (JESPECT®, which is adjuvanted with 
alum, and JE-ADV AX™, which contains the polysaccheride adjuvant, inulin, in two 
different formulations either as standard or as supermix) and ChimeriVax-JE were used 
to immunise groups of B2m_1_ mice. The immunisation schedule was with 2 doses given 
at 2 weeks apart, with the following treatment groups: PBS alone (as negative control), 
low (0.05 µg) and high (0.5 µg) doses Jespect (as positive control), low and high doses 
of ccJE alone, low and high doses of ccJE adjuvanted with Advax supermix, and low 
dose ccJE adjuvanted with Advax (Table 8.2). Another group of mice received sc lxl05 
PFU of ChimeriVax-JE. A month after completion of immunization schedule, mice 
were challenged sc with 103 PFU of JEV, and mortality recerded over a 28-day-
observation period. As expected, control B2m_1_ mice immunized with PBS alone 
displayed high mortality rate after JEV challenge (87%) (Table 8.2). In contrast, control 
B2m_1_ mice groups immunized with either low or high dose Jespect vaccine displayed 
complete resistance from lethal Japanese encephalitis. Also, 100% survival rate was 
observed in mice receiving ChimeriVax-JE, and in mice groups receiving high dose 
ccJE adjuvanted with either Advax supermix or Advax. Even in the absence of 
adjuvant, immunization with high dose ccJE alone similarly provided significant 
protection from JEV infection (mortality of 1 out of 10), while immunization with low 
dose ccJE alone only provided limited protection (mortality rate of 53%). The efficacy 
of -low dose ccJE vaccine was significantly improved when it was adjuvanted with 
either Advax supermix or Advax (mortality of 0% and 10%, respectively (Table 8.2). 
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It is well documented that humoral immunity is crucial for vaccine-mediated protection 
against lethal Japanese encephalitis (reviewed in (Lobigs and Diamond, 2012)). As a 
standard for clinical efficacy for JE vaccines, the established correlate of protection is 
neutralizing titres of at least 1/10 of serum dilution. However, as earlier presented, p2m-
/- mice exhibited dysfunctional IgG antibody responses after live JEV infection. JEV-
specific IgG responses in p2m-1- and B/6 wt mice immunized with low-dose ccJE + 
Advax or low-dose ccJE alone were then determined. IgG 1 and IgG2b antibody 
responses in all mice groups were initially detected at low levels on D8 post-vaccination 
(Table 8.3). On D18 pi, B/6 wt mice immunized with ccJE + Advax expectedly 
presented with higher IgG 1 and IgG2b antibody responses relative to B/6 wt mice 
immunized with ccJE only, and this difference was maintained until D28 pi. p2m-1- mice 
immunized with ccJE alone presented with low to undetectable titres on days 18 and 28 
pi. Interestingly, p2m-1- mice immunized with ccJE + Advax similarly presented with 
markedly low IgG antibody responses on days 18 and 30 pi, with titres ranging from 
undetectable to 200. This consistently reflected a dysfunctional IgG response uniquely 
found in mice with deficiency in P2m protein. 
Measurement of pre-challenge neutralizing titres revealed that P2m_1_ mice immunized 
with ccJE + Advax was markedly lo,v compared to its counterpart B/6 controls (mean 
PRNT 50 titre of< 10 vs. 116, respectively) (Table 8 .4 ). This finding is paradoxical to the 
notion that pre-challenge neutralizing titres serve as the main correlate of protection 
against lethal Japanese encephalitis, since almost all p2m-/-mice immunized with ccJE + 
Advax survived the challenge with JEV. It was then speculated that in spite of failure to 
maintain detectable levels of post-immunization neutralizing IgG antibodies, P2m_1_ 
mice are still capable of memory B cell development, that are readily inducible to 
produce protective antibodies in time of viral challenge. Interestingly, on days 5 and 10 
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pi, B2m_1_ mice immunized with ccJE + Advax presented with neutralizing titres higher 
than B2m_1_ mice immunized with ccJE alone (D5 pi: 38 vs. 14, respectively; D10 pi: 
672 vs. 385, respectively). Indeed, post-infection neutralizing titre levels in immunized 
B2m_1_ mice correlated well with the outcome observed in earlier mice challenge 
experiments. This data reflected that B2m_1_ mice are capable of inducing memory 
immune responses vital for protection against JEV infection. 
The phenomenon of vaccine-mediated protection 1n B2m_1_ might help explain the 
disparity in established vaccine efficacy and clinical effectiveness of mouse brain-
derived formalin-inactivated JE vaccine, JE-V AX. It has been noted that the annual 
incidence of JE in Japan was significantly declining in the past decades, despite more 
than 50% of a representative cohort population aged 20-59 years old had undetectable 
post-immunization neutralizing antibodies (Kitano, 1993; Konishi and Suzuki, 2002). A 
three-dose vaccination regimen of JE-V AX afforded an overall time-limited efficacy of 
91 % for only up to two years (Hoke et al., 1988), and yet based on crude evaluation of 
clinical effectiveness, vaccinated individuals had 2,000 to 80,000 times greater ratio of 
subclinical to clinical infections than unvaccinated population (Konishi and Suzuki, 
2002). It is hypothesized that majority of the individuals exposed to JEV were protected 
by vaccination received during childhood. The discrepancy in vaccine efficacy and 
clinical effectiveness might be explained by rapidly induced anamnestic antibody 
response in vaccinated individuals with undetectable levels of pre-exposure neutralizing 
antibodies. This essentially reflected immunized B2m_1_ mice, which were primed for the 
development of durable memory B cells that are readily and rapidly inducible to 
produce neutralizing antibodies at the time of JEV challenge. This phenomemon was 
similarly observed in a previous study, where wild-type mice immunized with a plasmid 
vaccine encoding prM and E genes of JEV displayed low to undetectable levels of post-
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immunization neutralizing titres (Konishi et al. , 1999). However, upon live JEV 
challenge, mice rapidly induced neutralizing antibodies, and were completely protected. 
In summary, this section confirmed the suitability of ~2m_1_ mice as a stringent 
challenge model for evaluating protective value of JE vaccines. This novel mice model 
have demonstrated that memory B cells, induced by either ChimeriVax-JE or JE-
ADV AX™ immunization, were adequate and capable to protect mice from lethal JE. 
This significant protection was afforded in the absence of CD8+ T cells and long-Ii ved 
IgG response. 
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Table 8.2 Protective value of Advax-adjuvanted ccJE vaccine. 
~mmunogena Mortality (no. of · MST± SD, P valueb P valuec 
--
de_aths/tot~!) ·days 
PBS 87% (13/15) 16.2 ± 4.9 
ChimeriVax-JE 0% (0/5) 0.0029 
-, 
JE-spect 0.5 µg 0% (0/5) 0.0029 
JE-spect 0.05 µg 0% (0/8) 0.0029 
·- -- --- --· ----; 
ccJE 0.5 µg 6% (1/16) 16 0.0029 
--, 
ccJE 0.5 µg + Advax supermix 0% (0/10) 0.0029 
ccJE 0.05 µg 53% (8/15) 17.9 ± 5.8 0.03 
-;-
ccJE 0.05 µg + Advax supermix 0% (0/10) <0.0001 0.007 
------, 
ccJE 0.05 µg + Advax 10% (1/10) 13 0.0004 0.04 
a Eight-week-old ~2m_1_ mice were immunized with 2 doses of PBS (control) or indicated vaccine 
formulations. A month after completion of vaccination schedule, mice were challenged sc via 
footpad with 103 PFU of JEV. 
b Statistical significance was computed in comparison with PBS only control. 
c Statistical significance was computed In _comparison with 0.05 µg ccJE only vaccine 
formulation. 
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Table 8.3 JEV-specific lgG isotype antibody responses after Advax-adjuvanted ccJE immunization. 
lgG1i; Mouse strain and 
, lgG2bi; 
. 
. 
'· 
. 
UDmunoge,na ca ,,,,, D18 '028 . . 08·· D18 r · ,• ' 0'28 I 
'· 
I. •' 
B/6wt 
ccJE 0.05 µg <2.0 (<2.0-2 .0) 2 .5 (2 .0-2 .9) 2.4 (2.0-2.6) <2.0 (<2.0-2.0) 2.3 (2 .0-2.6) 2.1 (<2.0-2.6) 
ccJE 0.05 µg + Advax 2.4 (2.0-2.6) >4.1 (>4.1) >4.1 (3 .8->4 .1) 2.3 (2.0-2.6) >4.1 (>4.1) >4.1 (>4.1) 
~2m_,_ 
ccJE 0.05 µg <2.0 (<2.0-2.3) 2.1 (<2.0-2.3) <2.0 (<2.0) <2.0 (<2 .0-2.3) <2.0 (<2 .0-2.0) <2.0 (<2.0-2 .0) 
ccJE 0.05 µg + Advax <2.0 (<2.0-2.0) 2 .2 (<2 .0-2 .3) 2.0 (<2 .0-2.3) 2.2 (<2.0-2.3) 2.0 (<2.0-2.3) <2.0 (<2 .0) 
a Groups of 8-week-old B/6 wt or ~2m_,_ mice were immunized with 2 doses, given 2 week apart, with 0.05 ccJE + Advax or 0.05 ccJE alone. Sera were collected on 
days 8, 18, and 28 post-immunization for lgG1 and lgG2b isotype antibody determination. 
b ELISA endpoint titres of individual test sera were determined as described in the Materials and Methods section ; mean titres (n = 4/ group) and range are given. 
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Table 8.4 Post-i'mmunization and post-challenge JEV-specific neutralizing antibody titres against JEV 
Mouse strain and 
lmmunogena 
B/6 wt 
PBS 
ccJE 0.05 µg 
ccJE 0.05 µg + Advax 
f32m·'-
PBS 
ccJE 0.05 µg 
ccJE 0.05 µg + Advax 
Day post-irnmuniza_tion 
DB 
< 10 ( < 10-10) 
32 (10-80) 
<10 (<10-10) 
16 (<10-40) 
D28 
< 1 0 ( < 1 0-1 0) 
116 (10-320) 
<10 (<10) 
< 1 0 ( < 1 0-1 0) 
D5 
21 (<10-40) 
27 (<10-80) 
232 (40-640) 
10 (<10-20) 
14 (<10-40) 
38(10-80) 
Day post-challengeb 
D10 
388 (20-640) 
424 (40-640) 
736 (160->1280) 
320 (<10-1280) 
385 (<10-640) 
672 (80-1280) 
a Groups of 8-week-old B/6 wt or ~2m·1· mice immunized with 2 doses of 0.05 ccJE + Advax, 0.05 ccJE alone, or PBS control, given 2 weeks apart. Serum was 
collected at days 8 and 28 post-immunization, and days 5 and 10 post-infection with 10
3 PFU of JEV. 
b Plaque reduction neutralization against JEV was determined as described in the Materials and Methods section; mean titres (n = 4/ group) and range are given. 
252 
8.2.4 JE-ADV AX™ elicits immune B cells that efficiently protect against 
lethal JEV challenge. Given that B2m_1_ mice are deficient in CD8+ T cells, it 
remains to be determined whether B cells or CD4 + T cells are the main cell effector 
population responsible for protection provided by Advax-adjuvanted ccJE vaccine. 
Eight-week-old B2m_1_ donor mice were immunized with 2 doses of 0.5 µg ccJE + 
Advax, and a month later after completion of vaccination schedule, were sacrificed for 
splenocyte isolation (Fig. 8.5). CD4+ T cells were purified via depletion of B cells using 
magnetic beads, while B cells were purified via complement-mediated lysis of CD4 + T 
cells. Purified immune CD4+ T or B cells were then injected iv into 10 to 12-week-old 
B2m_1_ mice. A day after transfer, recipient and naive control mice (B2m_1_ mice group 
receiving naive total splenocytes) were challenged sc with 103 PFU of JEV. Relative to 
naive control group, immune CD4+ T cell-recipient mice displayed decreased, but not 
statistically significant, mortality rates (67% vs. 89%, respectively), and longer MST 
(13.3 ± 2.0 vs. 11.9 ± 1.4 days, respectively). On the other hand, mice recipients of 
immune B cells presented with significantly lower mortality rate relative to naive 
control group ( 10% vs. 89%, respectively). The substantial protection observed in 
immune B cell-recipient mice was correlated with higher serum antibody and 
neutralizing titres on days 5 and 10 pi (Table 8.5). On day 5 pi, immune B cell-recipient 
mice presented with PRNT50 titres of 56 (range: 20-80), levels that are notably higher 
than what was observed in CD4+ T cell recipient-mice [26 (range: 10-40)] or naive 
control group [ < 10 ( range: < 10-20)]. The difference was more pronounced on day 10 pi, 
where immune B cell-recipient mice displayed higher PRNT5o titres of 832 (range: 320-
1280), compared to 528 (80-1280) in CD4+ T cell recipient-mice or 452 (20-640) in 
naive control group. 
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Figure 8.5 Immune B cells mediate protection of Advax-adjuvanted ccJE 
against homologous challenge with JEV. Eight-week-old B2m_1_ donor mice 
were immunized with two doses of 0.5 µg of ccJE + Advax, delivered 2 weeks apart, 
lxl07 B cells and CD4+ T cells purified at 1 month after completion of the vaccination 
schedule, and adoptively transferred (lxl07 cells/mouse) into 8-week-old B2m_1_ mice 
recipients. Another group of B2m_1_ mice received naive total splenocytes, and served as 
control. At one-day post-transfer, mice were challenged sc with 103 PFU of JEV. Mice 
were monitored twice daily for morbidity and mortality over a 21-day-observation 
period. Asterisks denote statistical significance(***, P < 0.00 l ). 
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Table 8.5 Post-challenge serum antibody and PRNT so titres 1n ~2m_,_ 
recipient mice groups. 
Mouse strain and Mean Ab titre [10910) (SD)0 Mean PRNT so titre (range)c 
lmmuno·ge·n3 D5 D10 D5 D10 
Naive 2.4 (2 .0-2.3) 2.5 (2.0-2.9) <10(<10-20) 452 (20-640) 
B cell >4.1 (3.8->4.1) >4.1 (3.2->4.1) 56 (20-80) 832 (320-1280) 
CD4+ T cell 2.8 (2.0-3.2) 3.8(3.2->4.1) 26 (<10-40) 528 (80-1280) 
a Groups of 10 to 12-week-old ~2m_,_ mice recipients of immune B cell or CD4+ T cell
s (from 
~2m_,_ donor mice vaccinated with 2 doses of 0.5 µg ccJE + Advax, given 2 weeks apart). Naive 
control mice group received naive total splenocytes. 
b ELISA endpoint titres of individual test sera were determined as described in the Mater
ials and 
Methods section ; mean titres (n = 4/group) and range are given. 
c Plaque reduction neutralization by individual sera against JEV was determined as desc
ribed in 
the Materials and Methods section; mean titres (n = 4/group) and range are given. 
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8.2.5 Durability of protection with JE-ADVAX™ To determine whether the 
protective value of Advax-adjuvanted ccJE vaccine is long-lived, groups of 6-week-old 
~2m_1_ were immunized with 2 doses of 0.05 µg ccJE + Advax or with PBS ( control) 
(Fig. 8.6). Six months after completion of the vaccination schedule, mice were 
inoculated sc with 103 PFU of JEV, and mortality recorded over a 28-day-observation 
period. Relative to PBS control group, ~2m_1_ mice immunized with low dose ccJE + 
Advax exhibited complete protection against JEV. As expected, the pre-challenge 
antibody ELISA and PRNT so titers were undetectable in both groups (Table 8.6). 
However, on day 5 pi, antibody and neutralizing titers were threefold and fourfold 
higher in low dose ccJE + Advax-immunized mice than in control group. This indicates 
that although ~2m_1_ mice are unable to maintain long-lived antibody levels due to 
defects in antibody metabolism (reviewed in (Rojas and Apodaca, 2002)), these are able 
to produce durable B cell memory that is readily responsive upon homologous 
challenge even at 6 months post-immunization. 
To support the finding that ccJE + Advax immunization induces the development of 
long-lived protective memory B cell response, an immune B cell splenocyte transfer 
experiment was done. Eight-week-old B/6 wt donor mice were immunized with two 
doses of 0.5 µg of ccJE + Advax, delivered 2 weeks apart (Fig. 8. 7 A). Splenocytes were 
isolated at 3 months post-completion of vaccination schedule, and B cell were purified 
via complement-mediated lysis of CDS+ and CD4+ T cells. Naive B cells purified from 
unvaccinated mice served as control. Immune and naive B cells were then transferred iv 
into B/6 w/t recipient mice. A day after transfer, recipient mice were challenged sc with 
103 PFU of JEV, and mortality was recorded over 28-day-observation period. Mice 
group receiving immune B cells displayed significantly improved outcome relative to 
control mice group (mortality rate of 20% vs . 80%, respectively). A second experiment 
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was done, wherein immune B cells were collected and purified from donor mice 
immunized for 6 months with the same vaccine regimen (Fig. 8. 7B). Again, naive B 
cells purified from unvaccinated mice served as control. Similarly, immune B cell-
recipient mice group displayed significantly lower mortality rate relative to nai"ve B 
cell-recipient mice group ( 40% vs. 90%, respectively). Relative to control group, the 
improved survival outcome in mice recipient of immune B cells was correlated with 
higher serum antibody and neutralizing titres on D5 pi (Table 8.7). Mice recipient of 
immune B cells isolated from 3 months post-vaccinated donor mice had sixfold and 
eightfold higher antibody and PRNT 50 titres, respectively; while mice recipient of 
immune B cells isolated from 6 months post-vaccinated donor mice had threefold and 
fourfold higher antibody and PRNT 50 titres, respectively. 
Altogether, these data strongly suggest that immunizatio~ of mice with Advax-
adjuvanted ccJE confers long-lasting B cell-mediated immunity that is substantially 
protective against homologous challenge with JEV. 
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Figure 8.6 Low dose Advax-adjuvanted ccJE vaccine exerts long-term 
protection against challenge with JEV. Six-week-old ~2m_1_ mice were 
immunized with two doses of 0.05 µg of ccJE + Advax or PBS control at 2 weeks apart. 
Six months after the last dose, mice were challenged sc with 103 PFU of JEV. Mice 
were monitored twice daily for morbidity and mortality over a 28-day-observation 
period. Asterisks denote statistical significance (*, P < 0.05). -
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Table 8.6 
mice. 
Post-challenge serum antibody and PRNT 50 titres 1n B2m_,_ 
Treatment8 Mean Ab titre [log 10] (SD)b 
Pre-challenge 
PBS < 2 (< 2) 
0.05 µg ccJE + Advax < 2 (< 2) 
Post-challenge 
2.5(2.0-2.9) 
3.1(2.3-3.5) 
Mean P.RNTso titre (range( 
Pre-challenge - Post-challenge 
< 10 (<10) 
< 10 (<10) 
28 (10-80) 
108 (20-320) 
a Groups of 8-week-old ~2m_,_ immunized with PBS control or 2 doses of 0.05 µg ccJE + Advax, 
given 2 weeks apart, and challenged with 6 months later 103 PFU of JEV. Sera were collected 
at day 5 pi for serologic examination. 
b ELISA endpoint titres of individual test sera were determined as described in the Materials and 
Methods section; mean titres (n = 4/group) and SD are given . 
c Plaque reduction neutralization by individual sera against JEV was determined as described in 
the Materials and Methods section; mean titres (n = 4/ group) and range are given. 
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Figure 8.7 Advax-adjuvanted ccJE vaccine induces durable and 
protective B cell response. Eight-week-old B/6 wt donor mice were immunized 
with two doses of 0.5 µg of ccJE + Advax, delivered 2 weeks apart, B cells purified at 3 
(A) or 6 (B) months after completion of the vaccination schedule, and adoptively 
transferred (lxl07 cells/mouse) into 8-week-old B/6 mice recipients. A control group of 
B/6 mice received naive B cells purified from unvaccinated niice. A day after transfer, 
mice were challenged sc with 103 PFU of JEV. Mice were monitored twice daily for 
morbidity and mortality over a 28-day-observation period. Asterisks denote statistical 
significance(* , P < 0.05). 
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Table 8. 7 Post-challenge serum antibody and PRNT 50 titres 1n B/6 wt 
recipient mice groups. 
Treatment8 
3 months 
Naive B cell 
Immune B cell 
6 months 
Naive B cell 
Immune B cell 
Mean Ab titre [log10] (rangel Mean PRNTso titre (ranget 
2.4 (<2.0-2.6) 
3.2 (2 .0-3.5) 
2.7 (2 .0-2.9) 
3.0 (2 .6-3.5) 
12 (<10-20) 
98 (10-320) 
21 (<10-40) 
84 (20-160) 
a Groups of 8-week-old B/6 mice recipients of naive or immune B cells (mice groups were 
derived from Figure 8.7). Immune B cells were from B/6 wt donor mice immunized (2 doses of 
0.5 µg ccJE + Advax, given 2 weeks apart) for 3 or 6 months, and naive B cells were from 
unvaccinated B/6 wt donor mice. A day after transfer, all recipient mice were challenged sc with 
1x103 PFU of JEV, and sera collected at 05 pi for serology. 
b ELISA endpoint titres of individual test sera were determined as described in the Materials and 
Methods section; mean titres (n = 4/group) and range are given . 
c Plaque reduction neutralization by individual sera against JEV was determined as described in 
the Materials and Methods section; mean titres (n = 4/ group) and range are given . 
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8.2.6 Cross-protection against highly virulent WNVNv99 challenge with JE-
ADV AX™ in the absence of CDS+ T cells. Previous studies have shown that 
vaccination against encephalitic flaviviruses can be associated with either cross-
protective immunity or disease-potentiating immunity (reviewed 1n (Lobigs and 
Diamond, 2012)). Enhancement of disease post-vaccination was attributed to an 
antibody-dependent phenomenon, a mechanism similarly hypothesized to be the basis 
of severe dengue hemorrhagic fever after secondary dengue virus infection (reviewed in 
(Murphy et al., 2011 )). This is especially important, given that antigenically closely 
related flaviviruses under JE-serocomplex can co-exist within a particular geographical 
area, for instance, WNV and JEV in India, or WNV and MVEV in the Australasian 
region (reviewed in (Mackenzie et al., 2004; van de Hurk et al. , 2009)). Establishing the 
feasibility of a broadly cross-protective flaviviral vaccine is also important given that, 
up to this date, there is no currently available WNV vaccin_e, and the likelihood of 
developing a vaccine against low endemicity MVEV is seen as economically unviable. 
To further extend the investigation on whether Advax-adjuvanted ccJE vaccine exhibits 
cross-protective value against a closely-related flavivirus , 8-week-old ~2m_1_ mice were 
immunized with two doses of 0.5 µg ccJE + Advax vaccine preparation, and challenged 
sc with 1x103 PFU of WNV NY99 a month after completion of vaccination schedule (Fig. 
8.8). All ~2m_1_ control mice immunized with PBS only succumbed to WNVNY99 
challenge, with MST of 11.5 ± 1.4 days. In contrast, ~2m_1_ mice immunized with 
Advax-adjuvanted ccJE had significantly lower mortality rate (15%) and longer MST 
(12.5 ± 0.7 days). This data clearly demonstrate that Advax-adjuvanted ccJE vaccine 
provides substantial cross-protection against lethal West Nile encephalitis. 
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To determine the cell population mainly responsible for cross-protection of Advax-
adjuvanted ccJE vaccine against WNVNY99 infection, an immune splenocyte transfer 
experiment was done (Fig. 8.9). Eight-week-old B/6 wt donor mice were immunized 
with 2 doses of 0.5 µg ccJE + Advax vaccine preparation, and sacrificed 3 weeks later 
after the last vaccine dose for splenocyte isolation. CD4+ T cells were purified by B cell 
depletion via magnetic beads and subsequent CD8+ T cell depletion via complement-
mediated lysis, while B cells were purified via complement-mediated lysis of both 
CD4+ and CD8+ T cells. Purified immune CD4+ Tor B cells were then injected iv into 
8-week-old B/6 mice. A day after transfer, recipient and naive control mice were 
challenged sc with 104 PFU of WNVNY99 . Relative to the naive control group, immune 
CD4+ T cell recipient mice group displayed lower, but not significantly different, 
mortality rates (33% and 50%, respectively). On the contrary, immune B cell recipient 
mice group displayed significantly improved outcome after ~VNY99 infection, with a 
13% mortality rate. This data clearly demonstrate that memory B cells play a 
predominant role in Advax-adjuvanted ccJE vaccine-mediated heterologous protection 
against WNV NY99 infection. 
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Figure 8.8 Cross-protective value of Advax-adjuvanted ccJE vaccine 
against challenge with WNVNY99· Groups of 8-week-old ~2m_1_ mice were 
immunized with two doses of 0.5 µg of ccJE + Advax or PBS control, delivered 2 
weeks apart. Six weeks after completion of the vaccination schedule, mice were 
inoculated sc with 103 PFU of WNVNy99. Morbidity and mortality were recorded daily, 
and surviving mice were monitored for 21 days. The data shown were constructed from 
two independent experiments. Viral challenge was performed by Dr Natalie Prow at a 
PC3 facility in University of Queensland. Asterisks denote statistical significance (* * *, 
P<0.001). 
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Figure 8.9 Advax-adjuvanted ccJE vaccine provides B cell-mediated 
cross-protection against WNVNv99 challenge. Eight-week-old B6/wt donor mice 
were immunized with two doses of 0.5 µg of ccJE + Advax, delivered 2 weeks apart, B 
cells and CD4+ T cells purified at 3 weeks after completion of the vaccination schedule, 
and adoptively transferred (lx107 cells/mouse) into 6-week-old B/6 wt mice recipients. 
Another group of B/6 wt mice did not received any cells, and served as naive control. A 
day after splenocyte transfer, mice were challenged sc with 10
4 PFU of WNVNY99 . Mice 
were monitored twice daily for morbidity and mortality over a 21-day-observation 
period. Experiment was performed, together with Dr Natalie Prow, at a PC3 facility in 
University of Queensland. Asterisks denote statistical significance(*, P < 0.05). 
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8.2.7 Cross-protection with MVE. Previously, Licon Luna et al. (2002) 
demonstrated that mice deficient in CD8+ T cell effector pathways are less susceptible 
to challenge with MVEV. In support of the aforementioned finding, B2m _1_ mice had 
better survival outcome relative to B/6 wt control when challenged with MVEV 
(unpublished data). Given the relative resistance to MVEV challenge (mortality rate of 
< 30%), B2m_1_ mice is not a suitable model for a vaccine protection experiment. 
Alternatively, to address the question whether Advax-adjuvanted ccJE vaccine also 
exerts cross-protection against MVEV challenge, an immune B cell transfer to weanling 
mice was performed (Fig. 8 .10). Weanling mice are highly susceptible to MVEV, and 
provide a standard virulence model. Eight-week-old B/6 wt donor mice were 
immunized with 2 doses of 0.5 µg ccJE + Advax. Six weeks after the last dose, donor 
mice were sacrificed, splenocytes were isolated, and immune B cells were purified via 
complement-mediated lysis of CD4+ and CD8+ T cells. Purified immune and naive B 
cells (isolated from unvaccinated mice) were then injected ip into 4-week-old B/6 mice. 
A day after transfer, recipient mice were challenged iv with 10
5 PFU of MVEV. 
Relative to naive B cell recipient control mice group, immune B cell recipient mice 
displayed lower mortality rate ( 40% vs. 80%, respectively), and longer MST ( 12.8 ± 1.5 
vs. 11.3 ± 1.3 days, respectively). This data demonstrate that memory B cell cells , 
induced by Advax-adjuvanted ccJE vaccine, provides significant cross-protection 
against Murray Valley encephalitis. 
As a supplementary contribution to an earlier publication (Lobigs et al ., 2009), I also 
investigated on the cross-protective value of ChimeriVax-JE against MVEV, with the 
use of another stringent mice model. Groups of 6-week-old IFN-aR_;_ mice were 
immunized ip with lx105 PFU of ChimeriVax-JE, or left unimmunised (Table 8.8). A 
month later after immunization, mice were inoculated iv or via the fp with 1 x I 0
2 PFU 
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of MVEV. All unimmunised mice succumbed to the disease, with MST delayed by ,..., 1 
day in mice challenged via the fp in comparison to that following iv challenge. All 
immunized mice were completely protected from infection. Next, I investigated on the 
mechanism of cross-protection of ChimeriVax JE against MVEV, through splenocyte 
transfer experiments. ChimeriVax-JE immune splenocytes were transferred to naive 
mice with or without the additional transfer of immune serum (Table 8.8). Recipient 
mice were challenged with MVEV (102 PFU) by the iv or sc route. Transfer of 
ChimeriVax-JE immune splenocytes (1 x 107 or 5 x 107 cells) did not provide 
protection from lethal challenge by either of the two routes but significantly prolonged 
survival by 1 to 2 days in the recipient groups relative to untreated mice (Table 8.8). 
Naive splenocyte transfer did not alter MST and mortality. Immune serum transfer (300 
µl total given at intervals pre- and post-challenge [Table 8 .8]) also failed to protect 
animals fro1n lethal MVEV infection but delayed the MST by ,...,3 days in comparison to 
that seen in the untreated controls. PRNT 50 titers of pooled immune sera used in the 
transfer experiments were in the ranges of 320 to 640 against JEV and 20 to 40 against 
MVEV. Mice were partially protected against lethal MVEV challenge following 
transfer of immune serum plus splenocytes, demonstrating the partial contribution of 
cell-mediated immunity elicited with ChimeriVax-JE in heterotypic protection. This 
was at least in part mediated by T cells, given that B-cell-depleted splenocytes 
maintained some protective value when transferred in the presence of immune serum, 
although this effect was marginal. 
Altogether, this final section further supports the feasibility of using cross-protective 
vaccines against closely-related flaviviruses. Both Advax-adjuvanted ccJE and 
ChimeriVax-JE provided significant cross-protection against challenge with MVEV, 
and this protection is largely mediated by a durable humoral immune response. 
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Figure 8.10 Advax-adjuvanted ccJE vaccine exerts cross-protection 
against challenge with MVEV. Eight-week-old B/6 wt donor mice were 
immunized with two doses of 0.5 µg of ccJE + Advax, delivered 2 weeks apart. B cells 
were purified at 6 weeks after completion of the vaccination schedule, and adoptively 
transferred ip ( 1x10 7 cells/mouse) into 4-week-old B/6 mice recipients. A control group 
of B/6 mice received naive B cells isolated from unvaccinated mice. A day after 
transfer, mice were challenged iv with 105 PFU of MVEV. Mice were monitored twice 
daily for morbidity and mortality over a 28-day-observation period. Asterisks denote 
statistical significance (* , P < 0.05). 
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Table 8.8 Contribution of immune responses to heterotypic protection 
by ChimeriVax-JE against MVEV 
Challenge route and treatmenta No.of ATD,days survivors/total (P)b 
iv 
-------------
-------------
--·----·--· 
--
None 0/8 5.9 
Immunization (105 PFU ChimeriVax-JE) 5/5 NA 
-- ----
Immune serum (300 µIt 0/4 9.5 (0.003) 
,------------------------ -~ ----- -----
Immune splenocytes (1 x 107 cells) 0/8 7.4 (0.0004) 
-- --- ----
Immune splenocytes (5 x 107 cells) 0/6 7.3 (0.001) 
--------------
-
SC 
None 
Immunization (105 PFU ChimeriVax-JE) 
Immune serum (300 µl)d 
0/5 
11 /11 
0/6 
6.8 
--- -- -- - ---
NA 
---- ---~ 
9.7 (0.006) 
Naive splenocytes (2 x 107 cells) 0/10 6.8 
---------------
---------------
--------
Immune splenocytes (2 x 107 cells) 0/8 7.8 (0.002) 
-----------
------------
Immune serum (300 µl)d plus splenocytes (2 x 107 cells) 
Immune serum (300 µl)d plus T cells (1 x 107 cells) 
-- -
----
Immune serum (300 µl)d plus T cells (5 x 106 cells) 
---------
12.8 (0.0006) 4/10 
2/6 
-- ---- ---- - ---
9.0 (0 .002) 
-- - - -
1/5 7.8 (0.01) 
a Six-week-old IFN-a-R_,_ mice were immunized with 105 PFU of ChimeriVax-JE ip or left 
untreated. These donor mice were sacrificed 4 weeks later, and serum and spleen cells 
were harvested and transferred to 10-week-old I FN-a-R_,_ recipients , which were 
challenged with 102 PFU MVEV iv or by injection into the fp . Age-matched naive and 
ChimeriVax-JE-immunized mice were included as controls . 
b The ATD was analyzed for significance using the Wilcoxon signed-rank test. For mice 
challenged iv , the ATD was compared to that of the naive group . For mice challenged sc , 
the effect of serum transfer only on ATD was compared to that of the na"fve group , while the 
effect of splenocyte transfer with or without immune serum on ATD was compared to that of 
na"fve splenocyte recipient mice. NA, not applicable. 
c Immune serum transfer schedule : 150 µI on day 1 pre-challenge and 150 µI on day 1 
post-challenge. 
d Immune serum transfer schedule: 100 µI on day 1 pre-challenge and 50 µI on days 0, 1, 
3, and 5 post-challenge. 
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Chapter 9 
Concluding Remarks 
A sound understanding on the immunobiology of infectious diseases is essential. 
Fundamental discoveries can generate basic insights that can aid in designing rational 
vaccines and novel therapies. Japanese encephalitis (JE) is the leading cause of viral 
encephalitis in Asia. In terms of incidence and severity of encephalitis in human 
populations, Japanese encephalitis virus (JEV) is the most important member of the JE 
serocomplex, which includes Murray Valley encephalitis virus (MVEV) and West Nile 
virus (WNV). In spite of that, the immunological correlates for recovery from primary 
JEV infection remains poorly defined, in contrast to a more detailed understanding with 
regards to the pathogenesis of West Nile encephalitis. 
In this work, I have established a pathogenesis model for JE. C57BL/6 wild-type (wt) 
mice, inoculated subcutaneously (sc) via the footpad with low-dose virus JEV, 
displayed fatal encephalitis in -60%, and viral burden in th~ central nervous system 
(CNS) (Chapter 3). The disease closely resembles human viral encephalitis, which is 
characterized by seizures, ataxia, postural imbalance, and at times, unilateral hind limb 
paralysis. Wt mice induces a robust immune response to the sc challenge with JEV 
(Figure 9 .1 ), characterized by systemic type I interferon response within the first 48 
hours, NK cell activity that peaks at ~D3-4 post-infection (pi), JEV-specific IgM 
response that is initially detectable on D4, and peaks on D8 pi, JEV-specific IgG 
response that is initially detectable on D8 pi and increases thereafter, gradual splenocyte 
expansion of CD4+ and CD8+ T cells, extensive CD8+ T cell activation (judged by 
upregulation of surface markers CD69 and CD25 and cytokine production after 
stimulation with a JEV NS4B protein-derived H-2Db -binding peptide) peaking on ~D7 
pi, and CCR5-mediated trafficking of leukocytes into the CNS (Chapters 3-7). 
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Figure 9.1 Kinetics of immune response after primary JEV infection. 
Approximate graphical representation of immune response kinetics ( shaded areas under 
solid lines) and viral dissemination (non-solid lines) in wt mice after sc infection with 
low-dose JEV. Data is extrapolated from the following: IFN-a - serum levels 
determined by ELISA, NK cell - cytotoxic assay and intracellular staining of IFN-y, T 
cell - T cell expansion and intracellular cytokine staining by F ACS, Anti-JEV IgM -
serum levels determined by ELISA, and Anti-JEV IgG - serum levels determined by 
ELISA, serum and spleen viral load - real time RT-PCR, CNS viral load - plaque 
titration in Vero cells. 
• 
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I have demonstrated, by in vzvo depletion of NK cells in wt mice, that this innate 
cytolytic effector cell population 1s dispensable for survival, and control of JEV 
infection in the periphery and in the CNS (Summarized in Table 9 .1 ). Using mice 
lacking B cells (µMT_;_ mice) and immune B cell transfer to wild-type mice, I have 
established a critically important role for humoral immunity in preventing virus spread 
to the CNS. CD4+ T cell help plays an essential part in the maintenance of an effective 
antibody response necessary to combat the infection, since mice lacking major 
histocompatibility complex class II (MHCII) display with truncated IgM and blunted 
IgG responses and uniformly high lethality. On the other hand, CD8+ T cells have a 
limited role in recovery from primary infection with JEV. Only a combined transfer of 
immune CD4+ T and CD8+ T cells, and not the transfer of immune CD8+ T cell alone, 
afford protection in JEV-challenged recipient wt mice. Using in vivo depletion of CD8+ 
T cells in wt mice, an increase viral burden in the CNS is observed, however no 
significant effect is seen on the survival phenotype. It remains unclear whether 
immunopathology associated with CD8+ T cell infiltration of the brain or an insufficient 
magnitude of the response, per se, explains why the viral load reduction in the CNS 
mediated by CD8+ T cells do not translate into a survival advantage. Together, these 
data suggest, at best, a marginal contribution of CD8+ T cells in the pathogenesis of JE. 
The relative importance of effector pathways of cytotoxicity in protection from lethal JE 
was examined using knockout mice models (Chapters 3-5). Mice lacking individual key 
effector molecules (Fas receptor, perforin, or granzymes) of cytolytic pathways display 
~ncreased CNS JEV burden, however, present with no impact on survival rate. Only 
mice defective in both granule exocytosis and Fas-Fas ligand pathways display 
increased susceptibility to JEV infection. The two cell contact-dependent cytotoxic 
effector mechanisms act within the CNS to reduce disease severity, and indicate a 
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redundancy in control JEV infection (Chapter 4). The pleiotropic cytokine, IFN-y, is 
critical for protection from severe JE (Chapter 5), through a mechanism that involves 
suppression of virus growth in the CNS. T cells trafficking into the CNS are the main 
source of IFN-y, which promotes non-cytolytic clearance of virus from the CNS. 
In Chapter 6, I have extended the investigation on a key chemokine receptor 
documented as a critical host antiviral factor against JE. The chemokine receptor CCR5 
play a role in activation and chemotaxis of leukocytes after JEV infection. Inoculation 
with JEV in mice deficient in CCR5 significantly displays increased mortality and viral 
burden in the CNS. Hum oral immune responses, which are essential in recovery from 
JEV infection, are of similar magnitude in CCR5 sufficient and deficient mice. 
However, absence of CCR5 results in a multifaceted deficiency of cellular immune 
responses characterized by reduced natural killer and CD8+ T _cell activity, low splenic 
cellularity, and impaired trafficking of leukocytes to the brain. These findings are 
consistent with a mechanism by which CCR5 expression enhances lymphocyte 
activation, and thereby promotes host survival in JE. 
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Table 9.1 Factors affecting outcome of JEV infection 
Factor 
Age 
Route of infection 
Mouse strain background 
Innate Immunity 
Natural Killer cells 
Macrophages 
MyD88 
Interferon-a receptor 
Adaptive Immunity 
Cell effectors 
B cells 
CD4+ T cells 
CDS+ T cells 
Cytolytic Pathways 
Perforin 
Granzyme A/B 
Fas 
Perforin + Granzyme A/B 
Fas+ GzmA/B 
Other Cytokines and Chemokines 
CCRS 
lnterferon-y 
(j) increased, (t) decreased 
Outcome of JEV infection 
j disease severity in younger animals 
intracranial and intranasal = high mortality 
extraneural = t disease severity 
impacts on disease outcome 
129 is more resistant than C57B1/6 
absence = no effect on disease severity 
susceptible to JEV infection 
absence = no effect on disease severity 
absence = j disease severity 
absence = j disease severity 
absence = j disease severity 
absence = j CNS viral burden 
without impact on mortality rate 
absence = no effect on disease severity 
absence = no effect on disease severity 
absence = no effect on disease severity 
absence = no effect on disease severity 
absence = j disease severity 
absence = j disease severity 
absence = j disease severity 
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The above findings highlight some differences in the pathogenesis of JE and closely 
related encephalitic flaviviruses. First, CD8+ T cells display variable and conflicting 
roles in the pathogenesis of flaviviral encephalitis. Whereas the CD8+ T cell response is 
required for virus elimination from the CNS and survival in mouse models of West Nile 
encephalitis (Shrestha and Diamond, 2004; Shrestha et al. , 2006a; Wang et al. , 2003; 
Wang et al., 2004), a disease-potentiating effect of cytotoxic T cells was documented in 
mice infected with MVEV (Licon Luna et al., 2002). In this work, I have presented that 
CD8+ T cells are at best, subsidiary in providing protective contribution against lethal 
JE. Second, mice with genetic deficiency in either FasL-Fas or perforin-dependent 
pathway of cytotoxicity showed greatly increased susceptibility to virulent lineage I 
WNV infection (Shrestha and Diamond, 2007; Shrestha et al., 2006a) but did not differ 
from wt mice in susceptibility to infection with JEV (Chapter 3) or lineage II WNV 
strain Sarafend (Wang et al. , 2004) and were more resistant to infection with MVEV 
(Licon Luna et al. , 2002). Only a combined deficiency in FasL-Fas and perforin-
dependent pathways, increases the susceptibility of mice to severe JE, indicating a 
redundancy in contact-dependent pathways of cytotoxicity. Third, the mechanism of 
increased susceptibility to WNV infection in IFN-{1- mice was mainly attributed to 
failure of early peripheral viral clearance by a potent IFN-y-producing yb T cells 
(Shrestha et al. , 2006b ), whereas in the case of JE, the morbid phenotype in IFN-{
1
-
mice is largely attributed to absence of IFN-y-producing T cell-mediated non-cytolytic 
clearance of virus from the CNS. 
Another extended investigation is the establishment of a novel immunodeficient mouse 
strain, Tuara. Remarkably, the loss-of-function mutation , conferring enhanced 
susceptibility to flavivirus infections, is a spontaneously generated defect found in an 
inbred knockout mouse strain, MHCII-Aa_;_ mice. After series of experiments, the gene 
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of interest have been segregated from the MHCII defect to produce the Tuara mouse, 
for which, after customized sequence capture and re-sequencing, is identified to carry 
candidate mutations within -50 Mb region of Chromosome 1, with the G>T 
transversion at mouse genome reference position 52,179,547 bp of ST AT I gene as the 
most likely causal mutation. This is a unique STATl mutation, with a likely profound 
biologic consequence of clinical relevance. This finding can provide valuable additional 
insights, in relation to the increasing diverse list of ST A Tl deficiencies in humans 
(reviewed in (Boisson-Dupuis et al., 2012)). 
Finally in Chapter 8, in application of the insights gained from the experiments on the 
basic immunobiology of JE, I have investigated on the mechanism of protection of new 
generation JE vaccines (live attenuated ChimeriVax-JE and Advax-adjuvanted 
inactivated Vero cell-derived JE vaccines) against homol_ogous or heterologous 
flaviviral challenge. Using a ~2m_1_ mice challenge model, the crucial role of long-term 
memory B cells in vaccine-mediated protection against JEV and WNV NY99 have been 
established. The significant level of protection has been provided in the absence of 
CD8+ T cells or long-term vaccine-induced neutralizing antibodies. Using splenocyte 
transfer experiments in IFN-a-R_;_ or weanling wt mice, humoral immunity is identified 
as the key survival determinant in JE vaccine-mediated cross-protection against Murray 
valley encephalitis. Altogether, it can be concluded that humoral immunity plays the 
most critical role in both primary and vaccine-mediated immune responses against 
infection with JEV or related flaviviruses. 
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